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Transplant patients at high risk of invasive mold infections receive voriconazole for 
prophylaxis. Low exposure of voriconazole predisposes patients for infection. High 
concentrations are associated with toxicity. Large variability in voriconazole exposure with a 
fixed dosing regimen has been observed in transplant patients. The objectives are to characterize 
the pharmacokinetics of voriconazole in transplant patients, to identify factors associated with 
the variability in the pharmacokinetics, and to develop adequate dosing guidelines for transplant 
patients. 
 
 iv
Liver, lung and pediatric bone marrow transplant (BMT) patients were enrolled. Multiple 
blood samples were collected within one dosing interval (totally 75 full pharmacokinetic 
profiles). Voriconazole plasma concentrations were measured using HPLC. Non-compartmental 
analysis was performed using WinNonlin. Population pharmacokinetic models were developed 
using NONMEM. Covariate models were built using a forward addition and reverse removal 
approach. Precision of parameter estimation was evaluated by bootstrapping. Adequate dosing 
regimens were developed using Monte Carlo simulations. 
 
There was good correlation between AUCo-∞ and trough voriconazole plasma 
concentrations in all patient groups. In liver transplant patients, CL/F and V/F of voriconazole 
significantly decreased with postoperative time, CL/F of voriconazole significantly increased 
with liver function, and CYP2C19*2 allele carriers exhibited significantly higher exposure. 
Donor characteristics had no significant association with pharmacokinetics of voriconazole in 
liver transplant patients. In lung transplant patients the bioavailability of voriconazole was 
substantially lower, but significantly increased with postoperative time, and patients with cystic 
fibrosis (CF) exhibited a significantly lower bioavailability and exposure than non-CF patients. 
Clearance of voriconazole significantly increased with liver function in BMT patients. BMT 
patients had significantly higher clearance and significantly lower volume of distribution 
compared to liver and lung transplant patients, but bioavailability was similar to lung transplant 
patients. 
 
In conclusion, weight-adjusted or fixed dosing regimens resulted in highly variable 
exposure of voriconazole in liver transplant, lung transplant and BMT patients. Given that trough 
 v
voriconazole concentration is a good measure of drug exposure (AUC), voriconazole dose can be 
individualized based on trough concentrations. Population analysis demonstrated inadequacy of 
oral administration of voriconazole and adequacy of intravenous administration during the first 
few post-operative days, followed by oral doses for optimal drug exposure. 
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Chapter I Introduction 
 
1.1 Voriconazole and its use in transplant patients 
 
Due to chronic immunosuppression, infections are common life-threatening complications in 
organ transplant patients (28). Invasive aspergillosis is one of the most dreaded complications in 
transplant patients (77) due to its high mortality rate, which can range up to 88.1% (64). 
Voriconazole (V-Fend®, Pfizer, formerly known as UK-109496), (2R,3S)-2-(2,4-
difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1,2,4-triazol-1-yl)butan-2-ol, is a novel broad-
spectrum triazole systemic antifungal agent and an ideal drug to prevent invasive aspergillosis. 
Compared with other azole antifungal agents, it has potent activity against a broader spectrum of 
clinically significant fungal pathogens, including Aspergillus, Candida, Cryptococcus 
neoformans, and some unusual organisms such as Fusarium and P. boydii (36, 82, 106, 112, 119). 
The primary mode of antifungal action of voriconazole is the inhibition of fungal cytochrome 
P450-dependent ergosterol synthesis (mediated via 14-alpha-sterol demethylase) resulting in a 
loss of ergosterol in the fungal cell wall. 
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Figure 1. Voriconazole chemical structure 
 
 
 
 
Voriconazole is available in intravenous and oral formulation. It is formulated as lyophilized 
powder reconstitution into a solution for intravenous infusion, as well as tablets and powder for 
suspension for oral administration. 
 
1.2 Clinical pharmacokinetic properties of voriconazole 
 
The clinical pharmacokinetic properties of voriconazole have been well characterized in non-
transplant patients in clinical trials during its development (25, 88, 89). In addition, Purkins et al. 
(95-97) investigated the clinical pharmacokinetics of voriconazole in healthy adult volunteers, 
Robatel et al. (102) studied adult patients with end-stage renal disease (ESRD) undergoing 
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hemodialysis, Peng et al. (85) studied adult patients with ESRD undergoing peritoneal dialysis, 
Walsh et al. (130) investigated immunocompromised pediatric patients (2–11 years old), and 
Lazarus et al. (61) studied non-transplant patients at risk of fungal infections. At the time of our 
studies, there was no information available on the pharmacokinetics of voriconazole in transplant 
patients. Population approaches have previously been used to investigate voriconazole 
pharmacokinetics in non-transplant patients (55, 75, 130), but not in transplant patients. There is 
a need to evaluate the pharmacokinetics of voriconazole in transplant patients in order to 
optimize therapy with voriconazole in the patient population. 
 
1.2.1 Absorption 
 
Voriconazole is highly lipophilic and is rapidly absorbed. Its peak concentration after a single 
oral dose is reached within 2 hours. Its bioavailability after oral administration is estimated to be 
96% in non-transplant population based on pooled data from 207 healthy volunteers (88). These 
results indicate that similar exposure of voriconazole is expected with identical intravenous and 
oral doses of voriconazole. 
 
1.2.2 Distribution 
 
Voriconazole is extensively distributed into peripheral tissues, and therefore has a large volume 
of distribution. The steady-state volume of distribution range from approximately 2 L/kg to 4.6 
L/kg (88, 89). The unbound fraction of voriconazole in plasma is 42%, and it is independent on 
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dose and plasma concentration (88, 89). Volume of distribution at steady state is not significantly 
different between the intravenous and oral administration (95), suggesting that the bioavailability 
of voriconazole is close to 100%. These observations suggest that changes in plasma protein 
binding are not expected to markedly alter the pharmacokinetics of voriconazole. 
 
1.2.3 Metabolism and elimination 
 
Voriconazole is extensively metabolized hepatically. Less than 2% of the dose is excreted 
unchanged in the urine. The major metabolite (N-oxide) accounts for 72% of circulating 
radiolabelled metabolites in plasma but exhibits no antifungal activity (88). The metabolites of 
voriconazole are primarily eliminated in the urine, with approximately 80% to 83% of the 
radioactivity being recovered in the urine (25, 88, 89, 103). 
 
Total body clearance of voriconazole ranged from 13 to 36 L/h in healthy volunteers (102). The 
mean elimination half-life (t1/2) of voriconazole is about 6 hours following single and multiple 
oral or intravenous administration (48). Clearance and terminal phase elimination rate constant 
are not significantly different between the intravenous and oral administration (95). 
 
Voriconazole is metabolized primarily by the Cytochrome P450 (CYP) isoenzymes CYP2C19, 
and to a lesser extent by CYP2C9 and CYP3A4 (44, 52, 83, 112) to inactive metabolites. 
Voriconazole is also an inhibitor of these three enzymes (103). CYP2C19 demonstrates genetic 
polymorphism with 3–5% of Caucasians and African Americans populations expected to be poor 
metabolizers, whereas the prevalence is 15–20% amongst Asians (52, 113). Voriconazole 
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concentrations (AUCτ) have been reported to be 4 times higher in poor metabolizers than 
extensive metabolizers (88). This observation indicates that genotype of a patient might 
significantly alter the pharmacokinetics of voriconazole. However, currently there is no 
recommendation for dosing adjustment with regard to the genotype of the patients. 
 
1.2.4 Nonlinear pharmacokinetics 
 
Voriconazole exhibits nonlinear pharmacokinetics. The values of Cmax and area under the 
plasma concentration-vs-time curve during a dosage interval τ (AUCτ) increase 
disproportionately with the dose following multiple doses of both oral or intravenous 
administration (88, 89). For oral administration, a 2-fold increase in dose (from 200 to 400mg 
twice daily) led to a 2.8-fold increase in Cmax (from 1.9 to 5.3 μg/ml) and a 3.9-fold increase in 
AUCτ (from 9.8 to 37.5 μg*h/ml), respectively. For intravenous administration, a 1.7-fold 
increase in dose (from 3 to 5 mg/kg twice daily) led to a 2.4-fold increase in Cmax (from 3 to 7.2 
μg/ml) and a 3.1-fold increase in AUCτ (from 13.9 to 43.4 μg*h/ml), respectively (95). As a 
result of nonlinear pharmacokinetics of voriconazole, the t1/2 is dose dependent and is generally 
greater after multiple oral administrations than after single oral administration due to 
accumulation of voriconazole after multiple dosing (96). Saturation of metabolism is likely to be 
the reason for the nonlinear pharmacokinetics of voriconazole since voriconazole is eliminated 
predominantly by metabolism (103). Therefore changes in dosing should take into account. 
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1.3 Variability in the pharmacokinetics of voriconazole 
 
Large inter- and intra-individual variability in voriconazole plasma concentrations regardless of 
the route of administration or the type of patient population has been documented and discussed 
in the literature (6, 63, 66, 80, 81, 96, 109, 114, 118, 122). Several major factors have been 
demonstrated to be significantly associated with the variability in the pharmacokinetics of 
voriconazole. However, nothing is known about various factors that might alter the 
pharmacokinetics of voriconazole in transplant patients. 
 
1.3.1 Age 
 
Clearance is more rapid in children under the age of 12 years, and therefore higher doses are 
required to achieve similar voriconazole exposure compared to that in adults (48). Plasma 
concentrations of voriconazole at steady-state following intravenous administration twice daily 
have been reported to be similar in children (2–11 years old) receiving 4 mg/kg and in adults 
receiving 3 mg/kg (88). 
 
1.3.2 Hepatic dysfunction 
 
Patients with cirrhosis demonstrated approximately 50% lower clearance of voriconazole 
compared to subjects with normal hepatic function (3.6 vs 6.9 L/h) (48). Therefore significantly 
lower doses of voriconazole should be administered to patients with hepatic dysfunction. 
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1.3.3 Food effect 
 
Single and multiple oral administration of voriconazole (200mg) with food resulted in reduced 
bioavailability of voriconazole by approximately 22% and delayed absorption by a mean of 1.1 
hours in healthy male volunteers in comparison to fasted state (98). Multiple dose administration 
of voriconazole with high fat meals resulted in reduced mean Cmax and AUCτ values by 34% 
and 24%, respectively. This factor must be taken into account when designing and interpreting 
pharmacokinetic studies of voriconazole. 
 
1.3.4 Drug-drug interactions 
 
Voriconazole serum concentrations are significantly reduced by co-administration of rifampin, 
rifabutin, phenytoin and are likely to be reduced by carbamazepine and long-acting barbiturates 
(35, 40, 88). Protease inhibitors (saquinavir, amprenavir and nelfinavir) inhibit the metabolism of 
voriconazole. Non-nucleoside reverse transcriptase inhibitors (NNRTIs) either inhibit (efavirenz 
and delavirdine) or induce (efavirenz and nevirapine) the metabolism of voriconazole (20, 88). 
The potential for interaction of voriconazole with other drugs must be taken into account while 
using voriconazole in patients who are on multiple drug therapy. 
 
1.3.5 Other factors 
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Other factors associated with inter-individual variability of voriconazole exposure include 
alcohol abuse in the past (134), CYP2C19 genetic polymorphisms including poor as well as 
ultra-rapid metabolizers (45, 55, 69, 108, 130, 132, 135), gastrointestinal abnormalities (e.g. 
mucositis or diarrhea) (109) impairing drug absorption, and other factors. 
 
 
1.4 Variability in the pharmacokinetics of voriconazole in transplant patients 
 
Transplant patients are very unique populations with many unique physiological changes that can 
potentially alter the pharmacokinetics of voriconazole. In addition to the factors identified in 
non-transplant population mentioned above, many other factors unique in transplant populations 
could be significantly associated with the variability in the pharmacokinetics of voriconazole. 
 
1.4.1 Variability in absorption 
 
Variability in absorption with oral voriconazole administration may cause the large inter-
individual variability of voriconazole exposure. Firstly, impaired gastrointestinal function after 
transplant surgery is a common physiological change that is unique to this patient population. 
The magnitude of decrease in the gastrointestinal function is quite different from patient to 
patient, and therefore may be a source of between-subject variability and could potentially alter 
the rate of absorption of voriconazole. Secondly, voriconazole is highly lipophilic and therefore 
its absorption is likely dependent on secretion of sufficient bile. Variation in bile flow between 
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patients and variable dissolution of voriconazole in patients may be another source of variability, 
and could potentially lead to altered bioavailability, especially in liver transplant patients. Finally, 
administration of voriconazole with food has significant influence on voriconazole absorption, 
and therefore feeding method is also a source of variability in voriconazole exposure in 
transplant patients. 
 
1.4.2 Variability in elimination 
 
Variability in elimination may be another factor responsible for the large inter-individual 
variability of voriconazole exposure, especially in liver transplant patients. First of all, the most 
relevant physiological factor that can lead to the large variability of voriconazole exposure is 
differences in liver function caused by physiological characteristics unique to liver transplant 
patients, because voriconazole is extensively metabolized in the liver with less than 2% of the 
administered dose being excreted unchanged in urine. There are no clinically relevant effects of 
renal impairment on the pharmacokinetics of oral or intravenous voriconazole (94). Secondly, 
voriconazole has demonstrated nonlinear pharmacokinetics due to saturation of metabolism (89, 
94), and may be an important contributor in patients with decreased liver function. Voriconazole 
metabolism may be saturated in some liver transplant patients. Finally, genetic polymorphism of 
CYP2C19 (major metabolizing enzyme for voriconazole) among patients can result in inter-
individual variability in metabolism (45, 55, 69, 89, 94, 108, 130, 132, 135). 
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1.4.3 Drug-drug interactions 
 
Potential drug-drug interactions may also contribute to the large inter-individual variability of 
voriconazole exposure. The transplant patients simultaneously receive many therapeutic agents 
for treatment and prophylaxis. In vitro studies have shown that voriconazole has the greatest 
affinity for CYP2C19, lower affinity for CYP2C9 and limited affinity for CYP3A4 (94). 
Inhibitors and/or inducers of these enzymes may change the pharmacokinetics of voriconazole 
(88, 89, 94). 
 
1.5 Therapeutic drug monitoring of voriconazole 
 
1.5.1 Adverse events 
 
Pooled analyses of 289 healthy volunteers and 1657 patients with invasive fungal infections (a 
total of 1946 subjects) who received voriconazole and participated in clinical trials or 
compassionate use programs demonstrated that approximately 50% of all voriconazole recipients 
experienced at least one treatment-related adverse event (25). 
 
Transient visual disturbances are the most commonly reported adverse event. Approximately 
30% of patients in the clinical trials experienced altered or enhanced visual perception, blurred 
vision, color vision change and photophobia (88). Enhanced brightness of light and blurred 
vision was also reported more frequently with voriconazole (1, 131). The site of action involved 
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in visual disturbances is thought to be the retina with the exact mechanism remaining to be 
determined (88, 89). 
 
Approximately 13% of patients treated with voriconazole showed abnormalities in liver function 
test (88). Serious adverse events including hepatitis and fulminant hepatic failure have also been 
reported. Approximately 12.4% of the patient (206 of 1655 patients) receiving voriconazole 
showed clinically significant abnormalities in transaminase levels (i.e. >3 × ULN) according to a 
pooled analysis of therapeutic trials (88, 89). Furthermore, pharmacokinetic/pharmacodynamic 
analyses have demonstrated that the incidence of clinically relevant abnormalities in liver 
function laboratory tests is correlated with voriconazole plasma levels (25). 
 
Dermatological reactions (mainly skin rashes) were observed in 6% of subjects receiving 
voriconazole in clinical trials (25, 88, 89). Severe skin reactions including erythema multiforme 
(Steven-Johnson syndrome) (16, 25, 88, 89), toxic epidermal necrolysis (15, 42), photosensitivity 
reactions (105), pseudoporphyria (19, 111, 120) and phototoxic reactions (99, 126) have also 
been reported. It is therefore important to maintain the concentration of voriconazole below a 
threshold to minimize adverse events. 
 
1.5.2 Correlation between voriconazole exposure and efficacy/toxicity 
 
It has been reported that low voriconazole exposure is associated with a poor outcome in patients 
with aspergillosis (17, 33, 80, 93, 109, 114, 123, 125) and ultimately death of the patients, while 
high voriconazole plasma concentrations are correlated with an increased risk for toxicity (6, 46, 
 12
67, 109, 117). For example, based on a longitudinal linear logistic regression analysis of pooled 
data from ten clinical trials (1053 patients), there is a significant correlation between 
voriconazole plasma levels and the incidence of abnormal levels of AST, ALT and bilirubin (67). 
Every 1 μg/ml increase in voriconazole plasma concentration was predicted to result in an 
increase in the odds of an AST, ALT, bilirubin and ALP abnormality of 13%, 7%, 17% and 16%, 
respectively. 
 
1.5.3 Application of correlation between voriconazole exposure and efficacy/toxicity to 
therapeutic drug monitoring 
 
Simple efficacy measure for the treatment molds are not quite available yet, to which patient 
dose can be titrated. So far there have only been data in animals for Candida showing a 
predictive pharmacodynamic parameter (AUC/MIC) and a potential target value (2) with no 
equivalent data for molds. However, there is a simple HPLC/UV assay available to monitor 
voriconazole levels and exposure in patients. 
 
Therapeutic monitoring may be important in optimizing therapy with this drug, and has been 
proposed by several investigators (6, 17, 26, 121). Area under the concentration-vs-time curve 
(AUC) is commonly used to characterize total drug exposure. However, multiple blood samples 
throughout the dosing interval are required to estimate AUC, which is inconvenient, costly and 
not practical in clinical settings. Therefore surrogate marker and limited sampling strategies 
should be developed to estimate AUC accurately and precisely while minimizing the number of 
blood samples required.  
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Despite lack of proof that the trough voriconazole plasma concentration is a good surrogate 
marker for exposure (AUC) of voriconazole, target trough voriconazole plasma concentrations 
have been proposed for therapeutic drug monitoring of voriconazole, such as 2.05ug/ml (114), 
2ug/ml (123), 1ug/ml (80) and 2~6ug/ml (125). Therapeutic drug monitoring of voriconazole is 
currently performed in the routine clinical monitoring program at our institution with an 
intention to keep the trough concentration above 1ug/ml. 
 
1.6 Preliminary data 
 
Based on the 2951 samples collected from the routine therapeutic monitoring program at 
University of Pittsburgh Medical Center, nearly 16% of the patients on recommended doses did 
not have any measurable trough plasma concentration, nearly 29% of the patients had trough 
plasma concentration of less than 0.5ug/ml, and nearly 45% of the patients had trough plasma 
concentration of less than 1ug/ml (Figure 2-4, Table 1). These patients are at higher risk of 
fungal infection. This demonstrated that underexposure is a serious problem in voriconazole use 
in transplant patients. Nearly 5% of the patients have trough plasma concentration of more than 
6ug/ml. These patients are at higher risk of toxicity. This suggests that the current dosing 
regimens developed for non-transplant population may not be adequate for transplant patients, 
and therefore rational dosing regimens need to be developed by a better understanding of the 
pharmacokinetics of voriconazole in transplant patients. 
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Figure 2. Priliminary data (08/2007): frequency distribution of voriconazole exposure in the routine 
therapeutic drug monitoring program. Y-axis: number of samples. 
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Figure 3. Update of priliminary data (06/2010): frequency distribution of voriconazole exposure in the routine therapeutic drug monitoring program 
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Figure 4. Update of priliminary data (06/2010): frequency distribution of voriconazole exposure in the routine therapeutic drug monitoring program 
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Table 1. Update of priliminary data (06/2010): frequency distribution of voriconazole exposure in the routine 
therapeutic drug monitoring program 
 
 
Therapeutic Range 
 
Voriconazole level Percentage Label in Figure 3-4 
 
Undetectable 
 
11.8%  
 
Below assay LLOQ 
 
4.5% 00  Below Therapeutic Range (46.4%) 
 
< 1ug/ml 
 
30.1%  
Within Therapeutic Range (48.6%) 
 
1 ~ 6 ug/ml 
 
48.6%  
Above Therapeutic Range (4.6%) 
 
> 6 ug/ml 
 
4.6%  
Interference (0.4%) 
 
 
 
0.4%  
 
 
 18
 
1.7 Study populations 
 
Voriconazole prophylactic regimen is typically administrated in liver transplant, lung transplant, 
small intestine transplant and pediatric bone marrow transplant patients at our institution. Liver, 
lung and bone marrow transplant patients were studied in this dissertation. 
 
The physiological conditions in transplant patients that may alter the pharmacokinetics of 
voriconazole may be different in different transplant populations. In liver transplant patients, 
liver function and gastrointestinal function are likely to play a major role in the pharmacokinetics 
of voriconazole because liver function and gastrointestinal function may be impaired during the 
transplant surgery but recovered with time. In contrast, liver function may not be a major factor 
in lung transplant patients because the majority of the lung transplant patients have normal liver 
function. Gastrointestinal function is likely to play a major role in the pharmacokinetics of 
voriconazole in lung transplant patients because gastrointestinal function may be impaired during 
the transplant surgery but recovered with time. Pediatric bone marrow transplant patients are a 
unique population, and variable gastrointestinal and hepatic function is likely to be the major 
factor contributing to the large variability in the pharmacokinetics of voriconazole. 
 
1.8 Hypotheses 
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A complete understanding of the pharmacokinetics of voriconazole in transplant patients will 
help in optimizing the use of this drug in transplant patients. We hypothesize that  
1. use of a fixed dosing regimen will lead to a large degree of variability in the exposure of 
voriconazole in transplant patients due to variability in liver function since liver 
dysfunction would alter the pharmacokinetics of voriconazole. 
2. Polymorphism in CYP especially CYP2C19*2 will contribute to the observed variability 
since CYP2C19 is the primary enzyme that metabolizes voriconazole. 
3. The bioavailability of voriconazole will be lower in liver, lung and bone marrow 
transplant patients than that reported in non-transplant population due to 
decreased/variable GI function 
4. Trough voriconazole concentration will be a good measure of drug exposure (AUC), and 
voriconazole dose can be individualized based on trough concentrations measurements. 
This relationship will hold good in liver, lung and bone marrow transplant patients. 
 
We have evaluated the above hypotheses in liver transplant (Chapter III), lung transplant 
(Chapter IV) and pediatric bone marrow transplant (Chapter VI) patients using conventional and 
population pharmacokinetic approaches (Chapter II). 
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Chapter II Methods 
 
2.1 Pharmacokinetic modeling 
 
Pharmacokinetics evaluates the time course of the processes of absorption, distribution, 
metabolism and excretion of drugs. Pharmacokinetic modeling employs various pharmacokinetic 
parameters as descriptors of these processes and mathematically relates the drug concentration in 
biological fluids, typically in blood or plasma to time. Pharmacokinetics and pharmacokinetic 
parameters are useful for understanding response/toxicity over time, and important for 
determination of dose and formulation of the drug to be administrated. Important 
pharmacokinetic parameters include clearance (CL), volume of distribution (Vd), absorption rate 
constant (ka), elimination rate constant (k), half life (T1/2), terminal disposition rate constant 
(λz), area under the curve (AUC), mean residence time (MRT), peak plasma concentrations 
(Cmax), time to reach peak concentration (Tmax), and area under moment curve (AUMC). 
Pharmacokinetic parameters have to be determined by modeling drug concentration versus time 
profiles using either classical or population pharmacokinetic modeling techniques. 
 
In this dissertation, pharmacokinetic modeling was extensively applied to estimate the 
pharmacokinetic parameters and evaluate the association between patient variables and 
pharmacokinetic parameters. Classical and population pharmacokinetic modeling techniques 
were both extensively applied. 
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2.2 Classical pharmacokinetic modeling 
 
Classical modeling approaches normally employ linear and nonlinear regression to estimate 
individual pharmacokinetic parameters for each subject. Non-compartment analysis is the most 
commonly used classical modeling approach. Parameters are often summarized as a mean value 
and standard deviation as a reflection of inter-individual variability. The industry standard 
program to implement the analysis is WinNonlin (Pharsight Corp., Mountain View, CA). Non-
compartment analysis was applied to all the studies in this dissertation using WinNonlin. 
 
2.3 Population pharmacokinetic modeling 
 
2.3.1 General approaches 
 
Nonlinear mixed-effects (a combination of fixed and random effects, or constant and varying 
effects) modeling approaches are also normally employed in the analysis of data. Fixed effects 
include typical population values of pharmacokinetic parameters and covariate parameters. 
Random effects include both intra- and inter-individual variability. The industry standard 
program to implement the analysis is NONMEM (GloboMax, Ellicott City, MD). Nonlinear 
mixed-effects modeling was applied to all the studies in this dissertation using NONMEM. 
 
2.3.2 Model building 
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The first step in the model building process was to identify the structural model or base model 
(model without any covariates): TV(Pj)=θj, where TV(Pj) is the typical value of the jth 
population parameter. 
 
Inter-individual variability was described using various models, including: 
1. exponential model:  P ij = TV(Pj) * EXP( η ij) 
2. proportional model:  P ij = TV(Pj) * (1 + η ij) 
3. additive model:   P ij = TV(Pj) + η ij 
4. other models such as  Log(P ij) = Log(TV(Pj)) + η ij 
where Pij is the ith individual’s estimate of the jth basic pharmacokinetic parameter, TV(Pj) is 
the typical value of the jth population parameter, and η ij is a random variable for the ith 
individual and the jth basic pharmacokinetic parameter distributed with mean zero and variance 
of ωj2. 
 
The residual variability (ε) between the observed and predicted concentrations is all the 
variability that remains unexplained. It could be due to intra-individual pharmacokinetic 
variability, model misspecification, variation in concentration measurement, errors in dosing 
history and sampling time, and other variations. It was also described using various models, for 
example: 
1. additive error model:   Cobs = Cpred + ε 
2. proportional error model:  Cobs = Cpred * (1 + ε) 
3. combined error model:   Cobs = Cpred * (1 + ε) + ε’ 
4. exponential error model:   Cobs = Cpred * EXP(ε) 
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5. other error models such as   Cobs = Cpred + ε * Cpred θ 
where Cobs and Cpred are the observed and predicted concentrations, respectively, and ε and ε’ 
are normal random variables with means of zero and variances of δ2 and δ’2, respectively. 
 
2.3.3 Covariate evaluation 
 
One of the major goals of population pharmacokinetic modeling as well as this dissertation is to 
model sources of inter- and intra-individual variability, which is a key issue not readily 
addressed by classical pharmacokinetic methods. Various covariate screening methods are 
available to select the covariates to be evaluated, such as nonlinear least-squares based method, 
Empirical Bayes Estimates based method, likelihood ratio test, direct covariate screening by 
inclusion of the covariate in the model (most reliable but time-consuming), and others. In this 
dissertation, covariate relationships were initially explored using Empirical Bayes Estimates 
based method, and then confirmed by directly incorporating the covariate into the model. 
 
Then a forward and backward stepwise model building process was used to evaluate the 
association of selected covariates with pharmacokinetic parameters and to build the final 
covariate submodel. In the forward inclusion step, each covariate was included into the base 
model and tested one at a time using various approaches to associate the covariate with the 
parameter, such as linear association, exponential association, and other associations. All the 
covariates that were considered significant (see below for criteria) were then included to obtain 
an intermediate multivariate model (full model). Then in the backwards exclusion step, the 
covariates were removed from the full model one at a time. The tested covariate stayed in the 
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final model if the model without the tested covariate was significantly “worse” than the full 
model. The cut-off range of each covariate for data transformation was selected based on clinical 
considerations. 
 
The significance of a covariate effect and the improvement in the model were assessed under 
five criteria: (1) a significant decrease in the minimum objective function value (OFV) of the 
covariate model compared to base model (the decrease in OFV was referred to the chi-squared 
distribution to assess significance), (2) assessment of the log likelihood ratio test, 3) improved 
Goodness-of-Fit, (4) increased precision of parameter estimation, and (5) reduced inter-
individual and residual variability. 
 
Conclusions of significant or insignificant covariate effects were made cautiously. Several 
reasons could lead to an exclusion of a significant covariate (false negative), for example, the 
covariate submodel may be mis-specified, this covariate may not be variable enough in the 
population studied, or the correct model specification of this covariate is a cut-off model while 
the values of this covariate in the population studied happen to be all below or above that cut-off 
value even though this covariate is very variable. 
 
2.3.4 Model evaluation and validation 
 
Bootstrapping was performed to evaluate the precision of the parameter estimation, stability of 
the model and normality of the distribution of the parameter estimates (78). A series of datasets 
were generated by repeated random sampling with replacement (resampling), which had the 
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same size as the original dataset with a different combination of subjects and their data. 
Parameters were estimated in this series of datasets. As the number of resampling approachesd 
infinity, the standard deviations of the parameters obtained from bootstrapping should approach 
to the ‘true’ standard deviations. Statistics of parameter estimates obtained from bootstrapping 
were compared with those obtained from the original dataset. An appreciable discrepancy 
reduces confidence in the model. 
 
Visual predictive check was used to evaluate the predictive performance of the model. The 95% 
prediction intervals (2.5th and 97.5th percentiles of the simulated concentrations) were computed 
by simulating at least 1000 subjects, and should contain approximately 95% of the observed 
concentrations to conclude a good predictive performance of the model. 
 
The most rigorous validation method is external validation, and it was applied in this dissertation 
whenever possible. Concentrations in the validation dataset that was not used for modeling 
building were predicted using the parameters obtained from the model building dataset (also 
called index dataset) and then compared to the observed concentrations. Bias (mean prediction 
error, MPE) and precision (mean absolute prediction error, MAPE, and root mean square 
prediction error, RMSE) were calculated: 
N
CobsCpred
MPE ∑ −= )( , 
N
CobsCpred
MAPE ∑ −= , 
N
CobsCpred
RMSE ∑ −= 2)(  
where Cpred and Cobs denote the predicted and observed concentrations, respectively. Ideally 
the mean absolute prediction error should be comparable with the residual variability.  
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Chapter III Pharmacokinetics of Voriconazole in Liver Transplant Patients 
 
3.1  Abstract 
 
Objectives: To characterize the pharmacokinetics of voriconazole in liver transplant patients, 
evaluate the potential correlations between pharmacokinetic parameters and patient variables, 
externally validate the model, and explore limited sampling strategies (LSS) using Bayesian 
approaches. 
 
Methods: Multiple blood samples were collected within one dosing interval from 15 patients 
who were initiated on a prophylactic regimen of voriconazole 200 mg enterally (tablets) twice 
daily starting immediately post transplant. Voriconazole plasma concentrations were measured 
using high performance liquid chromatography. Non-compartmental pharmacokinetic analysis 
was performed using WinNonlin. Nonlinear mixed-effects pharmacokinetic models were 
developed using NONMEM. The final model was internally evaluated using bootstrapping and 
visual predictive check (VPC), and externally validated by predicting additional samples from 
different patients that were not used for model-building. Maximum a posteriori Bayesian 
estimators were developed to predict AUC with limited samples (LSS). Mean prediction error 
(MPE) and mean absolute prediction error (MAPE) were calculated for external validation and 
LSS. 
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Results: In non-compartmental analysis, the mean CL/F, Vd/F and half life were 5.8 ± 5.5 L/hr, 
94.5 ± 54.9 L and 15.7 ± 7.0 hr, respectively. T1/2, Cmax, trough level, AUCo-∞, AUMCo-∞ 
and MRTo-∞ were significantly correlated with postoperative time. T1/2, λ, AUCo-∞ and CL/F 
were significantly correlated with indices of liver function (AST, total bilirubin and INR). Cmax, 
Clast, AUMCo-∞ and MRTo-∞ were significantly higher in the presence of deficient 
CYP2C19*2 alleles. There was a good correlation between AUCo-∞ and trough voriconazole 
plasma concentrations. In the population analysis, a one-compartment model with an absorption 
lag time (Tlag) adequately described the data. Population estimates of CL/F and Vd/F were 
7.92L/hr and 248L. Levels of CL/F, Vd/F and Tlag decreased with post-operative time and 
converged to stable levels in about 7 post-operative days. CL/F significantly decreased with 
increased INR. Co-administration of pantoprazole, race and ALT were also significantly 
associated with variability in pharmacokinetic parameters but ultimately excluded in the final 
model. VPC showed that most of the data fell within the 90% prediction interval and were 
symmetrically distributed around the median. Additional 52 samples from 19 patients were 
collected for external validation. MPE was 0.206ug/ml (not significantly different from zero) and 
MAPE was 0.99ug/ml. Trough levels adequately predicted voriconazole exposure in liver 
transplant patients. Compared to trough levels, LSS using two samples or one sample at a 
different time provided better MPE, MAPE and correlation (R2) between the real and LSS-
predicted AUC. 
 
Conclusions: A fixed dosing regimen of voriconazole results in a highly variable exposure of 
voriconazole in liver transplant patients. Given that trough voriconazole concentration is a good 
measure of drug exposure (AUC), voriconazole dose can be individualized based on trough 
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concentrations measurements in liver transplant patients. There is a significant association of 
voriconazole pharmacokinetics with post-operative time and liver function. Donor characteristics 
had no significant correlation with the pharmacokinetics of voriconazole. Our observations 
suggested a need for intravenous administration of voriconazole in the immediate post-operative 
period before an oral dose can be administrated in order to maintain adequate exposure of liver 
transplant patients to voriconazole. 
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3.2  Introduction 
 
Voriconazole is typically given orally for a few weeks after liver transplantation for prophylaxis 
of fungal infections at our institution. Due to hepatic surgical damage and reperfusion injury, 
liver function in liver transplant patients will be impaired and will be variable immediately after 
the transplant surgery, and will gradually improve with time. 
 
We hypothesize that use of a fixed dosing regimen will lead to a large degree of variability in the 
exposure of voriconazole in liver transplant patients due to variability in liver function after liver 
transplant surgery and due to polymorphism in CYP especially CYP2C19*2. We also 
hypothesize that voriconazole trough plasma concentration of voriconazole is a good surrogate 
marker for drug exposure (AUC). In order to test our hypothesis, we propose four specific aims: 
 
Specific aim 1 will characterize the pharmacokinetics of voriconazole, and evaluate the 
variability in the pharmacokinetics of voriconazole in adult liver transplant patients. Full 
pharmacokinetic profiles of voriconazole have been collected in thirteen liver transplant patients 
within one oral dosing interval (200mg, BID) after transplantation. Non-compartmental 
pharmacokinetic analysis and nonlinear mixed effects modeling analysis will be performed to 
estimate the pharmacokinetic parameters and to capture both inter-patient and intra-patient 
variability in the pharmacokinetic parameter estimates. We predict that the pharmacokinetic 
parameters estimated in liver transplant patients will be different from non-transplant subjects, 
there will be a large variability in the pharmacokinetic parameter estimates, and there will be a 
good correlation between voriconazole trough plasma concentration and AUC. 
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Specific aim 2 will evaluate the association of patient-specific and donor-specific variables with 
the pharmacokinetics of voriconazole in liver transplant patients. Patient-specific and donor-
specific demographic variables, liver function tests, renal function tests and CYP genotypes have 
been collected from each patient. Their association with the pharmacokinetic parameters of 
voriconazole will be evaluated using simple linear regression in non-compartmental analysis and 
evaluated as a covariate in population pharmacokinetic analysis. We predict that low CL/F will 
be associated with presence of CYP2C19*2, poor liver function. Pharmacokinetic parameters 
will change significantly with time after transplantation. 
 
Specific aim 3 will develop better doing guidelines by validating the population pharmacokinetic 
model using Bayesian forecasting. Random samples will be collected in liver transplant patients 
along with the patient-specific and donor-specific variables from the routine therapeutic 
monitoring program. Voriconazole plasma concentrations will be measured using the same 
analytical assay as used in specific aim 1. The final model built in specific aim 2 will be used to 
predict voriconazole plasma concentrations that were not used for model-building by Bayesian 
forecasting. The predictions will be compared to the actual measurements by calculating the bias 
and precision. Once the model is validated, voriconazole plasma concentrations and drug 
exposure will be simulated at different dose levels adjusted by the factors selected in the final 
model to determine the optimal dosing regimens. We predict that the bias will not be 
significantly different from zero, and new dosing regimens will depend on presence of 
CYP2C19*2 allele and liver function tests. 
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Specific aim 4 will optimize therapeutic drug monitoring by developing limited sampling 
strategies (LSS) using Bayesian approaches to predict voriconazole exposure. Maximum a 
posteriori Bayesian estimators will be used to predict voriconazole plasma concentrations (full 
profiles) using the validated final model as the a priori model, actual dosing record and covariate 
values from the patients in the model-building group without any concentrations as the input, and 
a few concentrations (limited sampling) as feedback information in the Bayesian estimation. The 
predictive performance of LSS will be evaluated by comparing true AUC0–12h and LSS-
predicted AUC0–12h. Bias and precision will be calculated. We predict that bias, precision and 
correlation between the True and LSS-predicted AUC (R2) will be improved by using a two-
sample LSS. 
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3.3 Methods 
 
3.3.1 Patients 
 
Between January 2007 and March 2007, liver transplant recipients who were initiated on a 
voriconazole prophylactic regimen (200 mg tablets twice daily orally or via a nasogastric tube) 
immediately post transplant as part of their standard clinical care and who signed informed 
consent were enrolled in this prospective study. Children under age 18, patients who were 
receiving any medications known to influence the pharmacokinetics of voriconazole and patients 
receiving voriconazole to treat an active fungal infection were excluded from this study. 
Demographic data including age, gender, height, weight, race, laboratory results and current 
medication use were recorded. All patients received tacrolimus as their primary 
immunosuppressive agent. The protocol was approved by IRB at the University of Pittsburgh. 
 
3.3.2 Blood Sample Collection 
 
Serial blood samples (3ml) were collected from each patient just prior to (0 hr) and at 0.5, 1, 1.5, 
2, 4, 6, 8 and 12 hours following administration of a minimum of 5 oral doses (range from the 5th 
to 15th dose; mean 7th dose). Blood samples were collected into heparinized Vacutainer® tubes 
and centrifuged at 3000 rpm for 10 minutes, and plasma was separated and stored at -70°C until 
analysis. 
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3.3.3 Genotyping 
 
One ml sample of whole blood was collected and immediately stored at - 80°C for genetic 
analysis. Additionally, whenever available, allograft biopsy tissue was also collected and stored 
at - 80°C for future genetic analysis. Genetic analysis was conducted through isolation of 
genomic DNA using the PureGene DNA isolation kit (Gentra Systems, Minneapolis, MN). 
Determination of a panel of CYP2C9, CYP2C19 and CYP3A4 and CYP3A5 allelic variants was 
performed by TaqMan allele discrimination analyses. The genotyping of CYP2C9*2, CYP2C9*3, 
CYP2C19*2, CYP2C19*3, CYP3A4*1B, CYP3A5*3 and CYP3A5*6 was performed in all 15 
patients (blood) and 7 donors (liver) using  the Applied Biosystems Drug Metabolism 
Genotyping Assay kits to genotype for C3608T, A42614C, G19154A, G17948A, A-392G, 
A6986G and G14690A, respectively. Positive and negative PCR controls were included with 
each amplification reaction. Blinded duplicate sample analyses were also performed for all 
genotyping assays. An additional 10% of samples are repeated to avoid further misclassification 
and verify the reproducibility of the assay. All results are interpreted independently by two 
laboratory personnel and no discordant results were obtained. 
 
3.3.4 Analytical Assay 
 
Plasma voriconazole concentrations were measured using validated HPLC method that was 
modified based on previously published assays (34, 86, 87). Sixty μl of 6% perchloric acid 
(Fisher Scientific, Fair Lawn, NJ) was added into 120 μl of plasma, vortexed, and centrifuged 
(13,000 rpm) for 4 minutes at room temperature. 50ul of supernatants were injected onto a HPLC 
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system consisting of a Waters model 510 HPLC pump, a Waters model 717 plus automatic 
sampler, and a Waters model 2487 UV tunable absorbance detector set to 255 nm. Separation 
was performed at ambient temperature on 5 µm, 4.6 × 250 mm Waters C18 Symmetry analytical 
column. The mobile phase consisted of HPLC-grade acetonitrile and water (68:32, v/v, Fisher 
Scientific, Fair Lawn, NJ). The total run time was 10 minutes at a flow rate of 0.8 ml/min. 
Chromatographic data were collected and analyzed using Empower Chromatography software 
(Waters, version 5.0). The assay precision (intraday variability) was 1.3% to 9.0% (0.2 – 9 
ug/ml), and the assay bias (interday variability) was 0.7% to 3.1% (0.5 – 9 ug/ml). The linearity 
range was 0.2 – 9 ug/ml (R2 = 0.9998). 
 
3.3.5 Non-compartmental Pharmacokinetic Analysis 
 
Various pharmacokinetic parameters were calculated using non-compartmental analysis with 
WinNonlin software (version 4.1; Pharsight Corporation, Mountainview, CA). The parameters 
calculated after enteral administration of voriconazole included terminal disposition rate constant 
(λz), terminal disposition halflife (t1/2), area under the curve (AUC), apparent systemic 
clearance over bioavailability (CL/F), apparent steady state volume of distribution over 
bioavailability (Vd/F), mean residence time (MRT), peak plasma concentrations (Cmax), time to 
reach peak concentration (Tmax), last plasma concentration at 12 hours (Clast), and area under 
moment curve (AUMC). λz and t1/2 were derived from data points during the terminal 
disposition phase only when at least three data points were available, and the AUCo-∞ and 
AUMCo-∞ specific for the dose evaluated was calculated using reverse superposition principle. 
Projected trough voriconazole plasma concentrations (Clast) was used in three patients (#11, #15 
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and #16) since Clast was missing in these three patients. Each of these parameters is presented as 
mean and standard deviation. Statistical comparison of different parameters was made using 
paired two-tailed Student t-test (SPSS software, Windows-based version 14.0, Chicago, IL). A P 
value of <0.05 was considered statistically significant. 
 
3.3.6 Statistical Analysis 
 
The relationship between various pharmacokinetic parameters and patient variables and 
biochemical indices was examined by simple linear regression analysis. A relationship was 
considered to be statistically significant at P < 0.05 for the deviation of the coefficient from zero 
in the linear regression analysis. The difference between trough concentrations (C0 and C12) was 
tested using paired two-tailed Student t-test. The effect of dichotomous variables (such as gender, 
race and concomitant medication) on various pharmacokinetic parameters of voriconazole was 
tested using unpaired two-tailed Student t-test except for the effect of CYP2C19 genotype, which 
was tested using unpaired one-tailed Student t-test since carriers of CYP2C19*2 and *3 alleles 
have been identified as poor metabolizers [25]. The effect of feeding methods on various 
pharmacokinetic parameters of voriconazole was tested using one-way ANOVA. A P value of < 
0.05 was considered to be statistically significant in all the statistical tests. The relationship 
between CL/F, Vd/F and body weight were evaluated using both simple linear model and 
allometrical model  
BWTWTAParameter )/(×= ,  
where parameter includes CL/F and Vd/F, WT denotes actual body weight, and A and B are co-
effeicients and exponents to be estimated using nonlinear regression. 
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95% confidence bands and 95% prediction bands were calculated and plotted using GraphPad 
Prism (Version 4.03, GraphPad Software, Inc.) to evaluate the precision of parameter estimation 
and predictive performance. 
 
3.3.7 Population Pharmacokinetic Analysis 
 
A nonlinear mixed-effects pharmacokinetic model (base model) was developed using NONMEM 
6.2.0 (GloboMax, Hanover, MD) using first order conditional estimation method with interaction. 
Correlations between pharmacokinetic parameters were always incorporated and estimated. One- 
and two-compartment models were tested with first/zero-order elimination and Michaelis-
Menten elimination process since nonlinear pharmacokinetics of voriconazole has been reported 
(89). Different approaches to describe the absorption phase were tested including zero-/first-
order process, an absorption lag time, Erlang distribution and Weibull distribution. Various inter-
individual variability structures were tested including: 
1. exponential model:  ijjij ePTVP
η×= )(  
2. proportional model:  )1()( ijjij PTVP η+×=  
3. additive model:   ijjij PTVP η+= )(  
4. log-additive model:  ijjij PTVLogPLog η+= ))(()(  
where Pij is the ith individual’s estimate of the jth pharmacokinetic parameter, TV(Pj) is the 
typical value of the jth pharmacokinetic parameter, and ηij is a random variable for the ith 
individual and the jth pharmacokinetic parameter distributed with mean zero and variance of ωj2. 
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Various residual variability models were tested including: 
1. additive error model:  ε+= CpredCobs  
2. proportional error model: )1( ε+×= CpredCobs  
3. combined error model: ')1( εε ++×= CpredCobs  
4. exponential error model:  εeCpredCobs ×=  
5. other error model:  θε CpredCpredCobs ×+=  
where Cobs and Cpred are the observed and predicted concentrations, respectively, and ε and ε’ 
are normal random variables with means of zero and variances of δ2 and δ’2, respectively. 
 
Covariate relationships were first visually evaluated by plotting Empirical Bayes Estimate 
against covariates. Covariate effects were then tested by incorporating covariates into the base 
model (without covariate) one at a time using at least 13 approaches to associate the covariate 
with the parameter. Different cut-off values for the covariates were also tested. A covariate was 
considered as significant and a cut-off value was considered optimal if all the following criteria 
were met: (1) a decrease in objective function value (OFV) of 6.63 for 1 degree of freedom 
(p<0.01), (2) no significant trend in Empirical Bayes Estimates vs covariate plots, (3) improved 
Goodness-of-Fit, (4) reduced inter-individual variability and (5) clinical plausibility for 
incorporating the covariate. 
 
Then using the same criteria, an intermediate model (full model) containing all selected 
covariates was built using a forward addition approach (covariate added one at a time). Then the 
 38
final model was obtained using a reverse removal approach (covariate removed one at a time 
from the full model) using the same criteria.  
 
3.3.8 Model Evaluation 
 
The adequacy of fitting was examined by plotting predicted versus observed concentrations 
(Goodness-of-Fit), concentrations versus time profiles and weighted residuals versus predicted 
concentrations. 
 
Precision of parameter estimation, stability of the final model and normality of the distribution of 
the parameter estimates was evaluated using bootstrapping (resampling repeated 2300 times) 
using Wings for NONMEM (http://wfn_sourceforge.net). Non-parametric statistics (median, 
95% confidence interval) of parameter estimates obtained from bootstrapping were compared 
with the point parameter estimates obtained from the final model. The distribution of the 
parameter estimates obtained from bootstrapping was visually inspected for normality, based on 
which standard error was calculated for each parameter estimate in the final model. 
 
To evaluate the predictive performance of the final model using visual predictive check, 1500 
data sets were simulated using the parameter estimates in the final model. The 50th percentile 
concentration (estimator of the population-predicted concentration) and the 5th and 95th percentile 
concentrations (90% prediction interval) were plotted and compared to the observed 
concentrations. 
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3.3.9 External Validation 
 
The established final model was then externally validated. Additional 52 samples were 
retrospectively collected from a separate group of 19 adult liver transplant patients in the 
therapeutic drug monitoring program at our institution who met the same criteria as patients 
included in the model-building group. Voriconazole plasma concentration in these patients was 
measured using the same assay as the model-building group. Complete dosing records and the 
same patient and donor specific factors as the model-building group were obtained. The protocol 
was approved by IRB at the University of Pittsburgh.  
 
Voriconazole plasma concentrations were predicted by fixing the parameters in the structural and 
variance model to the parameter estimates in the final model using posthoc Bayesian forecasting 
with NONMEM 6.2.0. The predicted values were compared with the corresponding observed 
values. Bias (mean prediction error, MPE) and precision (mean absolute prediction error, MAPE) 
were calculated with 95% confidence intervals using the following equations: 
N
CobsCpred
MPE ∑ −= )(  
N
CobsCpred
MAPE ∑ −=  
where Cpred and Cobs denote the predicted and observed concentrations, respectively. 
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3.3.10 Limited Sampling Strategy (LSS) 
 
The aim of developing LSS using Bayesian approaches was to explore the clinical use of the 
final model, where dosage regimens, sampling times and covariate values could change 
frequently, and to predict AUC accurately and precisely using limited number of samples. The 
validated final model and all the parameter estimates were used as the a priori model. Actual 
dosing record and covariate values from the 13 patients in the model-building group without any 
concentrations were used the input. A few concentrations (limited sampling) were input as 
feedback information in the Bayesian estimation with different combinations of 1, 2 or 3 
concentrations at 0, 0.5, 1, 1.5, 2 and 4 hours according to clinical constraints. Maximum a 
posteriori Bayesian estimators were used to predict voriconazole plasma concentrations (full 
profiles) using NONMEM. True AUC0–12h (AUCobs) and LSS-predicted AUC0–12h 
(AUCpred) was calculated using trapezoidal rules with all actual and predicted concentrations, 
respectively. The predictive performance of LSS was evaluated by comparing AUCobs and 
AUCpred. Bias (
N
AUCobs
AUCobsAUCpred
MPE
∑ ⎟⎠⎞⎜⎝⎛ ×
−
=
%100
% ) and precision 
(
N
AUCobs
AUCobsAUCpred
MAPE
∑ ×−
=
%100
% ) were calculated with 95% confidence interval. 
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3.4  Results 
 
3.4.1 Patients and Data Collection 
 
A total of 15 patients were enrolled in this study. The characteristics of the patients, including the 
primary diagnosis, days post transplantation on the day of study, methods of feeding at time of 
study, concomitant medications, MELD (Model for End-Stage Liver Disease) Score, age, gender 
and race, the characteristics of the donors, including the cold ischemic time, warm ischemic time, 
the age distribution and the type of liver donation, the laboratory biochemical and hematological 
profile of the study patients before transplantation and on the day of pharmacokinetics study, and 
the pharmacogenomic profiles of patients and donors are shown in Table 2. 
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Table 2. Characteristics of liver transplant patients and donors 
Gender (male/female) 11/4 
Diagnoses  
   Viral Hepatitis (HBV/HCV) 1/5 
   HCV + Alcohol 2 
   Non-Alcoholic Steatohepatitis 3 
   Primary Sclerosing Cholangitis  2 
   Autoimmune Hepatitis  1 
   Wilson’s Disease 1 
MELD Score 20.6 ± 11.3 (8-43) 
Patient Age (yr) 56.3 ± 10.3 (41-76) 
Weight (kg)  84.1 ± 17.7 (56-121) 
Race (Caucasian/Asian) 13/2 
Days post transplantation on the day of study 3.7 ± 1.4 (2-7) 
Feeding at time of study (tube/clear liquid/regular food) 3/11/1 
Anastomosis (T-Tube present§/T-Tube absent§/Roux-en-Y) 6/8/1 
Concomitant drug (pantoprazole)/famotidine) 10/5 
Cold Ischemic Time (min) 538.9 ± 266.6 (86-935) 
Warm Ischemic Time (min) 27.2 ± 5.1 (16.8-37.8 ) 
Donor Age (yr) 47.9 ± 21.6 (14-84) 
Cadaveric/Living (n) 13/2 
Total bilirubin (mg/dL) † 6.4 ± 5.9 (1.9-25.4) / 6.1 ± 6.4 (0.5-22.9) 
AST (aspartate aminotransferase) (U/L) † 1088.9 ±726.2 (180-2405) / 294.8 ± 204.2 (33-620) 
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Table 2. (continued) 
 
ALT (alanine aminotransferase) (U/L) † 682.6 ± 444.8 (144-1569) / 346.1 ± 263.4 (53-792) 
INR (International normalized ratio) † 1.76 ± 0.35 (1.1-2.3) / 1.3 ± 0.16 (1-1.6) 
SCr (Serum Creatinine) (mg/dL) † 1.6 ± 0.8 (0.6-2.9) / 1.7 ± 1.3 (0.5-5.2) 
Baseline plasma albumin (g/L) 3.1 ± 0.5 (2.3-4.1) 
CYP2C9*2 (C3608T) ‡ 15 : 0 : 0 (6 : 1 : 0) 
CYP2C9*3 (A42614C) ‡ 12 : 3 : 0 (5 : 2 : 0) 
CYP2C19*2 (G19154A) ‡ 12 : 3 : 0 (6 : 1 : 0) 
CYP2C19*3 (G17948A) ‡ 15 : 0 : 0 (6 : 0 : 0) 
CYP3A4*1B (A-392G) ‡ 15 : 0 : 0 (6 : 0 : 0) 
CYP3A5*3 (A6986G) ‡ 0 : 0 : 15 (7 : 0 : 0) 
CYP3A5*6 (G14690A) ‡ 15 : 0 : 0 (7 : 0 : 0) 
 
Values are all expressed as mean ± standard deviation (range) and measured in patients except specified as 
measurements in donors. 
MELD, Model for End-Stage Liver Disease, calculated using the equation MELD score = 3.78[Ln serum bilirubin 
(mg/dL)] + 11.2[Ln INR] + 9.57[Ln serum creatinine (mg/dL)] + 6.43 
§: they were both Duct-to-Duct Anastomosis, but the t-tube had been taken out in some of the patients at the time of 
study. 
† Values are displayed as baseline measurements / measurements on the day of study. 
‡ Donor genotype (liver) was displayed in parenthesis. The three values displayed represent wild type homozygous 
extensive metabolizers (-/-) : heterozygous extensive metabolizers (-/+) : poor metabolizers (+/+).  
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The mean and individual plasma concentrations of voriconazole over time after enteral 
voriconazole are shown in Figure 5. Thirty-three percent of the patients had a trough level lower 
than 1ug/ml, and the rest of the patients had a trough level between 1ug/ml and 6ug/ml. Among 
all the 15 patients that completed the study, one patient had an undetectable concentration of 
voriconazole in all of the samples and could not be evaluated (#13, no particular reason was 
identified), and three patients (#1, #3 and #7) had extremely atypical profiles with fewer than 
three data points during the terminal disposition phase, and non-compartmental pharmacokinetic 
analysis could therefore not be readily performed. 
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Figure 5. Plasma concentrations profiles of voriconazole in liver transplant patients 
 
Large inter-individual variability can be observed. Patient #1, #3, #7 and #13 had extremely atypical profiles.  
 
Upper figure: plasma concentrations of voriconazole over time during one dosing interval (all patients).  
 
Lower figure: Mean plasma concentrations of voriconazole over time during one dosing interval (mean with SD 
error bars, patient #1, #3, #7 and #13 excluded, see text). 
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3.4.2 Non-compartmental Pharmacokinetic Analysis 
 
Complete pharmacokinetic data could be calculated in 11 patients. The pharmacokinetic 
parameters of voriconazole after enteral administration of voriconazole are shown in Table 3. 
There was a wide variation in various pharmacokinetic parameters of voriconazole in liver 
transplant patients after enteral voriconazole administration. 
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Table 3. Pharmacokinetic parameters of voriconazole (non-compartmental analysis ) in liver transplant 
patients 
Patient 
ID 
λz  
(hr-) 
HL_  
λz 
 (hr) 
Tmax 
 (hr) 
Cmax  
(ug/ml) 
Clast*  
(ug/ml) 
 
AUCo-∞ 
(hr* 
ug/ml) 
AUMC 
o-∞  
(hr*hr 
*ug/ml) 
Vz/F 
_obs 
 (L) 
CL/F 
_obs  
(L/hr) 
MRT 
o-∞ 
 (hr) 
2 0.04 16.1 1.1 2.6 1.6 34.3 1662.8 81.1 3.5 48.5 
4 0.12 5.6 2.1 3.5 0.6 15.2 145.7 76.8 9.5 9.6 
5 0.07 9.5 2.0 0.9 0.4 7.2 182.9 239.1 17.5 25.4 
6 0.02 30.0 1.0 5.4 3.3 37.7 12945.6 46.0 1.1 343.5 
8 0.07 9.4 6.1 1.6 1.0 14.7 480.2 89.7 6.6 32.7 
10 0.05 14.9 2.1 4.1 2.5 38.1 2610.8 45.3 2.1 68.6 
11 0.04 17.8 0.5 3.1 1.52 27.9 2089.1 82.4 3.2 74.9 
12 0.04 15.5 1.2 4.0 1.8 34.4 1940.9 63.6 2.8 56.3 
14 0.09 7.4 1.5 1.4 0.4 9.2 135.5 165.2 15.5 14.8 
15 0.03 21.3 2.3 3.2 2.08 45.7 3826.1 65.8 2.1 83.7 
16 0.04 17.7 0.5 2.4 1.49 20.6 2113.1 84.8 3.3 102.4 
Mean 0.06 15.0 1.8 2.9 1.6 25.9 2557.5 94.5 6.1 78.2 
SD 0.03 7.0 1.5 1.3 0.9 13.1 3643.6 57.6 5.7 92.7 
CV (%) 52.69 46.6 84.8 45.4 58.3 50.7 142.5 61.0 92.6 118.6 
Median 0.04 15.5 1.5 3.1 1.7 27.9 1940.9 81.1 3.3 56.3 
95% CI 
0.04- 
0.08 
10.9- 
19.1 
0.9- 
2.74 
2.1- 
3.7 
1.0- 
2.1 
18.1- 
33.7 
404.3- 
4710.7 
60.5- 
128.6 
2.8- 
9.5 
23.4- 
133.0 
Abbreviations: Cmax, maximum concentration; Tmax, time to reach maximum concentration; Clast, concentration 
at 12 hours; λz, disposition rate constant; HL_λz, apperant half-life; AUCo-∞, area under the curve concentration; 
CL/F_obs, clearance/bioavailability; Vz/F_obs, volume of distribution/bioavailability; MRTo-∞, mean residence 
time; AUMCo-∞, area under the first moment curve 
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* Clast of patient #1, #3, #7 and #13 are 3.07 ug/ml, 1.6 ug/ml, 0.76 ug/ml and 0 ug/ml (unmeasurable). 
Projected Clast of patient #11, #15 and #16 was used (see text). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The trough concentrations prior to dosing (Co) and at 12 hours after dosing (C12) are not 
significantly different (p=0.2794), and the difference between the trough concentrations (C12-
Co)/C12 averaged 6.4%, indicating that steady state had been reached in most of the patients at 
the time of study (Figure 6).  
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Figure 6. Comparison of trough concentrations in liver transplant patients 
 
Co (left) vs C12 (right) 
 
 
 
 
 
There was a good correlation (R2=0.75) between the trough voriconazole plasma concentrations 
and the corresponding AUCo-∞ (Figure 7, n=11).  
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Figure 7. Correlation of AUCo-∞ and trough concentration in liver tranpslant patients 
 
Big figure: R2=0.745 when AUCo-∞ and trough concentrations (C12) was correlated in all the 11 patients that had 
typical profiles.  
 
Small figure: R2=0.852 when AUCo-∞ and trough concentrations (C12) was correlated in 10 patients that had 
typical profiles with patient #6 omitted. 
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There were significant correlations between various estimated pharmacokinetic parameters and 
patient variables and various biochemical indices (linear regression coefficient differs 
significantly from zero). All the correlations are summarized in Table 4 and Figure 8. The 95% 
confidence bands and 95% prediction bands were calculated and plotted (Figure 8). The 
correlation between body weight and the two independent pharmacokinetic parameters CL/F and 
Vd/F was very poor using both simple linear regression (R2=0.1345 for CL/F and 0.0308 for 
Vd/F) and the principle of allometry (R2=0.0990 for CL/F and 0.1350 for Vd/F). 
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Table 4. Correlations between patient variables and pharmacokinetic parameter estimates obtained using 
non-compartmental analysis in liver transplant patients 
 Λ T1/2 Tmax Cmax Clast AUC 
o-∞ 
Vd/F CL/F AUMC 
o-∞ 
MRT 
o-∞ 
POT *  0.7415 
(+) 
 0.6132 
(+) 
0.6256 
(+) 
0.4564 
(+) 
  0.7444 
(+) 
0.7004 
(+) 
ASTo *          0.4395 
(+) 
Bild *  0.4746 
(+) 
        
INRo * 0.6510 
(-) 
0.4214 
(+) 
     0.4490 
(-) 
  
INRd * 0.5639 
(-) 
    0.4555 
(+) 
    
RACE †   0.016 0.0402  0.0711 0.0513 0.1023   
PAN †    0.0066 0.0112 0.0939   0.0629 0.0868 
T-Tube †      0.0841     
CYP2C19 
† 
   0.0136 0.0352    0.0131 0.0154 
Abbreviation: POT, post-operative time; ASTo: baseline AST; Bild: total bilirubin on the day of study; INRo, 
baseline international normalized ratio; INRd international normalized ratio on the day of study; PAN, pantoprazole; 
T-Tube, t-tube present or absent at the time of study. CYP2C19, heterozygous extensive metabolizers 
(CYP2C19*1/*2). 
*: r-square for linear regression between the two variables is displayed in the table. Signs in the parenthesis indicate 
positive (+) or negative (-) association. 
†: p value is displayed in the table. 
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Figure 8. Correlation between post-operative time (hours post-transplantation) and trough plasma 
concentrations Clast in liver tranpslant patients 
 
Data from all the 11 patients that had typical profiles are displayed. 95% confidence bands and 95% prediction 
bands are plotted. 
 
 
 
 
Despite the small number of subjects in this study, the presence of deficient CYP2C19*2 alleles 
and race were significantly associated with some pharmacokinetic parameters of voriconazole. 
Compared to homozygous extensive metabolizers (CYP2C19*1/*1), Cmax, Clast, AUMCo-∞ 
and MRTo-∞ were significantly higher in heterozygous extensive metabolizers (CYP2C19*1/*2) 
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by 1.9-fold, 2.0-fold, 5.1-fold and 3.9-fold, respectively. Compared to Caucasian patients (n=9), 
Tmax was significantly higher (p=0.016) by 3-fold and Cmax was significantly lower (p=0.0402) 
by 2.6-fold in Asian patients (n=2) (Table 4). In addition, Vd/F was 2.1-fold higher (p=0.0513), 
CL/F was 2.5-fold higher (p=0.1023), and AUCo-∞ was 2.7-fold lower (p=0.0711) in Asian 
patients compared to Caucasian patients, although this did not reach to statistical significance. 
 
Interestingly, concomitant pantoprazole treatment with oral voriconazole was associated with a 
statistically significant decrease in voriconazole exposure. Voriconazole half-life, Cmax, Clast, 
AUCo-∞, MRTo-∞ and AUMCo-∞ were significantly lower by 37%-70% in patients receiving 
concomitant pantoprazole treatment compared to those not on pantoprazole (Table 4). CL/F was 
3.5-fold higher in patients on concomitant pantoprazole treatment compared to those not on 
pantoprazole, although this did not reach to statistical significance (p=0.0533). Feeding methods 
(regular diet, clear liquids, tube feedings) have no effect on the pharmacokinetic parameters of 
voriconazole. 
 
It is also worth mentioning that all of the donor variables including CIT (Cold Ischemic Time), 
WIT (Warm Ischemic Time), donor age and type of liver donation poorly correlated with all the 
estimated pharmacokinetic parameters (R2<0.4).  
 
3.4.3 Population Pharmacokinetic Analysis 
 
A one-compartment model with first-order absorption and elimination with an absorption lag 
time (Tlag) adequately described the data. Other elimination and absorption models tested did 
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not result in significant decrease in OFV and thus did not significantly improve the model fit. 
Inter-individual and residual variability was best described by an exponential model and a 
combined proportional and additive error model, respectively. The population estimates of CL/F, 
Vd/F, ka and Tlag, inter-individual and residual variability were summarized in Table 5. The 
additive error estimate was comparable with the lowest limit of quantification (LLOQ) of the 
assay 0.2ug/ml. Although individual predictions agreed well with observations, population 
predictions were strongly biased in the base model (Figure 9a). 
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Figure 9.  Goodness-of-Fit of base model, full model and final model in liver tranpslant patients 
 
a: Goodness-of-Fit of base model. Individual predictions (hollow circle) agreed well with observations (R2=0.87). 
Population predictions (solid square) were strongly biased (over-prediction at low concentrations and under-
prediction at high concentrations), indicated by the LOWESS smoother of population predictions (thin solid line) 
which appears to be almost horizontal. 
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b: Goodness-of-Fit of full model. Individual predictions (hollow circle) agreed well with observations (R2=0.91). 
Population predictions (solid square) were substantially improved compared to the base model. The strong bias in 
population predictions observed in the base model was basically corrected. 
 
c: Goodness-of-Fit of final model. Individual predictions (hollow circle) agreed well with observations (R2=0.89). 
Population predictions (solid square) were substantially improved compared to the base model. The LOWESS 
smoother of the population predictions (thin solid line) was close to the identity line (thick solid line), indicating that 
population predictions in the final model was not significantly biased. 
 
 
 
 
To explore covariate relationships, all the covariates were tested one at a time. The best cut-off 
value for post-operative time (POT) was found to be 168 hours (1 week) using the criteria listed 
in the METHODS section, meaning that POT was set to 168 hours for any POT greater than 168 
hours. CL/F and Vd/F significantly decreased with POT. High CL/F was significantly associated 
with low international normalized ratio (INR) or alanine aminotransferase (ALT) and with 
pantoprazole co-administration. Caucasian patients seemed to have significantly lower CL/F and 
Vd/F than Asian patients. Short Tlag was significantly associated with high INR and with 
pantoprazole co-administration. 
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Table 5. Population pharmacokinetic modeling process in liver tranpslant patients 
Parameter /  
Model 
Significant  
Covariate 
∆OFV * P value † Equation 
POT -22.10 <0.00001 
12.1
77.86
58.6/
−
⎟⎠
⎞⎜⎝
⎛×= POTFCL  
INR -24.40 <0.00001 
29.1
9.287.39/ INRFCL ×−=  
RACE -26.51 <0.00001 CAUFCL ×−= 4653/  
PANT -29.58 <0.00001 PANTFCL 3.268.4/ ×=  
CL/F ‡ 
ALT -7.21 <0.01 ⎟⎠
⎞⎜⎝
⎛ −×−=
29.246
15.33857.19.6/ ALTFCL  
POT -12.87 <0.001 ⎟⎠
⎞⎜⎝
⎛ −×−×=
71.36
77.86461.01exp106/ POTFVd  
Vd/F ‡ 
RACE -18.11 <0.0001 ( )CAUFVd ×−×= 788.011440/  
POT -12.29 <0.001 
74.8
77.86
839
−
⎟⎠
⎞⎜⎝
⎛×= POTKA  
KA ‡ 
PANT -11.13 <0.001 PANTKA 4320293.0 ×=  
PANT -11.11 <0.001 PANTTlag 005.05.0 ×=  
INR -6.78 <0.01 ⎟⎟⎠
⎞
⎜⎜⎝
⎛ ⎟⎠
⎞⎜⎝
⎛+×=
− 2.12
29.1
10.00118 INRTlag  Tlag ‡ 
POT -9.42 <0.01 ⎟⎠
⎞⎜⎝
⎛
×= 77.865.1001.0
POT
Tlag  
Full model 
POT, INR,  
RACE, PANT 
-76.54 <0.00001 Not shown 
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Table 5. (continued) 
 
Final model POT, INR -32.78 <0.00001 
51.1
77.86
) 
17.0
29.192.3(10.6  CL/F
−
⎟⎠
⎞⎜⎝
⎛×−×−= POTINR  
⎟⎠
⎞⎜⎝
⎛ ×−×=
77.86
3.1exp776Vd/F POT  
9.10
77.86
316KA ⎟⎠
⎞⎜⎝
⎛×= POT  
77.860838.0817.0 Tlag
POT
×=  
 
* ∆OFV: change in the objective function value compared to the base model 
† A decrease in OFV was referred to the chi-squared distribution to assess significance. 
‡ These are the results in the covariate relationship exploration step. All the covariates were incorporated one at a 
time into these parameters to explore the covariate relationship.  
POT: post-operative time. POT was set to a constant of 168 hours if the post-operative time was greater than 168 
hours. 
ALT: alanine aminotransferase 
INR: International normalized ratio 
CAU: 1 for Caucasian patients and 0 for Asian patients 
PANT: 1 for co-administered pantoprazole and 0 for no co-administered pantoprazole 
Tlag: absorption lag time 
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The forward addition model building step resulted in the full model containing all the covariates 
selected in the exploration process mentioned above except for ALT (Table 5). The reverse 
removal model building step resulted in the final model containing POT as a significant covariate 
on all the pharmacokinetic parameters, and INR as a significant covariate on CL/F (Table 5). 
 
Base model, full model and final model all showed adequacy of fitting. Figure 9 showed a good 
correlation (R2>0.87) between individual predictions and observations. Weighted residuals were 
approximately normally distributed and were mostly within about 2 units of the null ordinate in 
all three models. 
 
The full model and final model seemed to be superior over the base model and the covariates 
selected in the full model and final model explained a large portion of the variability in the 
population predictions in the base model. Population predictions were substantially improved in 
the full model and final model compared to the base model (Figure 9). LOWESS smoothers 
showed that the strong bias in population predictions observed in the base model was reduced in 
the full model and final model. Inter-individual variability decreased by 38.1% in CL/F and by 
64.8% in Tlag in the final model compared to the base model (Table 5). The OFV decreased by 
32.78 for 5 degree of freedom (p<0.00001) in the final model compared to the base model. 
Finally, Concentration-vs-Time plots also confirmed the superiority of the final model. 
 
According to the equations and the individual parameter estimates in the final model, CL/F, Vd/F 
and Tlag decreased rapidly and dramatically over time after the surgery and eventually reached 
stable levels at some point within 7 post-operative days. The individual CL/F, Vd/F and Tlag 
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estimates covered a wide range of values at the early period of time after the surgery. CL/F 
ranged from 102 L/hr to 383 L/hr, Vd/F ranged from 191 L to 1944 L, Tlag ranged from 0.32 
hours to 1.04 hours. However, the individual parameter estimates eventually converged to stable 
levels at some point within 7 post-operative days (Figure 10). 
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Figure 10. Covariate relationships in the final model in liver tranpslant patients 
 
a, c and d: both the population estimates of CL/F, Vd/F and Tlag according to the equations (thick dash line) and the 
individual estimates of CL/F, Vd/F and Tlag (thin solid lines) decreased rapidly and dramatically over time after the 
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surgery and eventually reached the population levels (thin horizontal dash line) at some point within 7 post-
operative days. The individual CL/F, Vd/F and Tlag estimates covered a wide range (high variability) at the early 
period of time after the surgery. CL/F ranged from 102 L/hr to 383 L/hr, Vd/F ranged from 191 L to 1944 L, Tlag 
ranged from 0.32 hours to 1.04 hours. This variability decreased over time and the individual parameter estimates 
eventually converged to the population levels at some point within 7 post-operative days. 
 
b: 3D plot of the covariate relationship between CL/F and post-operative time and INR. Individual estimates of 
CL/F (hollow circles) are symmetrically distributed around the population estimates according to the equation 
(surface). CL/F decreased with post-operative time and increased INR. 
 
 
 
 
3.4.4 Model Evaluation 
 
In the bootstrapping analysis for the final model, 1281 out of 2300 runs successfully converged 
and were incorporated into the non-parametric analysis. The point population estimates of all 
parameters were similar to the median values obtained from bootstrapping and fell within the 
95% confident intervals (Table 6), indicating precise and stable parameter estimation in the final 
model. Most of the parameter estimates seemed to be normally distributed, confirming the 
normality assumptions for model building. 
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Table 6. Comparison between population estimates in the base model and final model and comparison of population estimates in the final model and 
non-parametric statistics obtained from bootstrapping analysis of the final model in liver tranpslant patients 
Inter-individual 
variability (%) 
Residual 
 θ1 Θ2 θ3 θ4 θ5 θ6 θ7 θ8 θ9 
CL/F Vd/F KA Tlag Proportional
Additive 
(ug/ml) 
Population 
estimates 
(base model) * 
7.9 248 52.4 0.001      82.7 80.5 162.8 182.5 0.46 0.1 
Population 
estimates 
(final model) † 
10.6 776 316 0.817 -1.3 0.084
-
3.92 
-
1.51 
10.9 51.2 84 151.7 64.31 0.43 0.3 
Lower boundary 
of 95% CI ‡ 
5.24 56 5.88 0.001
-
3.37 
0.001 -5.5 
-
3.29 
3.26 5.5 42.1 51.2 30.2 0.22 0.1 
Median ‡ 9.7 327 99 0.423
-
0.62 
0.21 
-
2.41 
-
1.48 
10.4 48.4 71.3 121.2 87.3 0.37 0.28 
Upper boundary 
of 95% CI ‡ 
13 5580 105 8.152 0.94 8.03 0.02 
-
0.91 
18.6 72.3 109 209.6 165.6 0.49 0.51 
 
CI: confidence interval 
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*: In this row (base model), θ1 = CL/F, θ2 = Vd/F, θ3 = KA and θ4 = absorption lag time (Tlag) 
‡: non-parametric statistics obtained from bootstrapping analysis of the final model 
† and ‡: In these rows (final model), θ’s are numbered according to the following equations in the final model:  
8
77.86
) 
17.0
29.171(  CL/F
θ
θθ ⎟⎠
⎞⎜⎝
⎛×−×−= POTINR , ⎟⎠
⎞⎜⎝
⎛ ××=
77.86
5exp2Vd/F POTθθ , 
9
77.86
3KA 
θ
θ ⎟⎠
⎞⎜⎝
⎛×= POT , 77.8664 Tlag
POT
θθ ×=  
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In the visual predictive check, most of the data fell within the 90% prediction interval and were 
symmetrically distributed around the median (Figure 11), indicating good predictive 
performance of the final model. Figure 11 (hollow circle, observed concentrations) also 
illustrated the distribution of samples during post-operative time. 
 
 
 
 
 
 
Figure 11. Visual predictive check of the final model in liver tranpslant patients 
 
Most of the observations (hollow circles) fell within the 90% prediction interval (dash lines) and were symmetrically 
distributed around the median (solid line). 
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3.4.5 External Validation 
 
Patient characteristics did not significantly differ between the model-building and validation 
groups (Table 7).  
 
 
 
Table 7. Comparison of characteristics of liver transplant patients and donors between index group and 
validation group 
 Index group Validation group 
Number of samples/patients 117/13 52/19 
Voriconazole plasma 
concentration (ug/ml) 
2.04 ± 1.12 (0.31-5.37) 1.30 ± 1.68 (0-6) 
Gender (male/female) 10/3 16/3 
MELD Score 20.5 ± 11.7 (8-43) NA 
Patient Age (yr) 55.8 ± 10.9 (41-76) 51.5 ± 12.3 (29-66) 
Weight (kg) 83.5 ± 18.9 (56-121) 83.8 ± 24.5 (50-135) 
Height (cm) 173.1 ± 6.7 (157.5-182.9) 173.6 ± 10.5 (149.9-188) 
Race (Caucasian / Asian / 
African American) 
11/2/0 16/0/2 
Feeding at time of study 
(tube/clear liquid/regular food) 
2/10/1 NA 
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Table 7. (continued) 
Anastomosis * 6/7 NA 
Concomitant drug 
(pantoprazole/famotidine) 
8/5 NA 
Cold Ischemic Time (min) 530.8 ± 273.2 (86-935) 586.6 ± 158.5 (354-875) 
Warm Ischemic Time (min) 27.5 ± 5.4 (16.8-37.8 ) 30.1 ± 12.0 (12-57) 
Donor Age (yr) 51.4 ± 20.8 (14-84) 49.2 ± 19.0 (16-82) 
Cadaveric/Living (n) 11/2 18/1 
Total bilirubin (mg/dL) † 
6.4 ± 6.4 (1.9-25.4) / 6.4 ± 6.9 (0.5-
22.9) 
6.7 ± 4.5 (2-17.6) / 6.6 ± 7.7 (0.6-26.5) 
AST (U/L) † 
1053.3 ± 720.7 (180-2405) / 307.8 ± 
210.8 (33-620) 
1220.9 ± 732.7 (225-3007) / 51.6 ± 
58.4 (14-379) 
ALT (U/L) † 
653.7 ± 367.6 (244-1516) / 338.2 ± 
246.3 (108-792) 
615.1 ± 548.3 (118-2401) / 47.7 ±39.6 
(11-207) 
INR † 
1.78 ± 0.36 (1.1-2.3) / 1.29 ± 0.17 (1-
1.6) 
1.97 ± 0.48 (1.4-3.3) / 1.35 ± 0.16 (1-
1.6) 
SCr (mg/dL) † 1.6 ± 0.9 (0.6-2.9) / 1.8 ± 1.4 (0.5-5.2) 1.7 ±0.8 (0.7-3.1) / 1.9 ± 1.1 (0.5-7.1) 
Plasma albumin (g/L) † NA / 3.2 ± 0.5 (2.3-4.1) 2.5 ± 0.6 (1.2-3.1) / 2.8 ± 0.6 (1.4-3.9) 
Values are all expressed as mean ± standard deviation (range) except specified otherwise. Values were measured in 
patients except specified as measurements in donors. 
NA: not available 
MELD, Model for End-Stage Liver Disease, calculated using the equation MELD score = 3.78[Ln serum bilirubin 
(mg/dL)] + 11.2[Ln INR] + 9.57[Ln serum creatinine (mg/dL)] + 6.43 
AST: aspartate aminotransferase 
ALT: alanine aminotransferase 
INR: International normalized ratio 
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SCr: Serum Creatinine 
* Values are displayed as the number of patients with T-Tube present/T-Tube absent at the time of study. All the 
patients had Duct-to-Duct anastomosis, but the t-tube had been taken out in some of the patients at the time of study. 
† Values are displayed as baseline measurements / measurements on the day of study. 
‡ Donor genotype (liver) was displayed in parenthesis. The three values displayed represent wild type homozygous 
extensive metabolizers (-/-) : heterozygous extensive metabolizers (-/+) : poor metabolizers (+/+).  
 
 
 
 
In the external validation, the POT in the validation group was longer than the model-building 
group. Despite this, the bias (MPE) was only 0.206ug/ml (95% confidence interval: -1.4–
0.55ug/ml) and was not significantly different from zero (p>0.23). MPE was comparable to the 
LLOQ of the assay 0.2ug/ml and additive residual error in the final model 0.3ug/ml. The 
precision (MAPE) was 0.99ug/ml. Predicted concentrations agreed well with observed 
concentrations without significant bias. Prediction errors were symmetrically distributed around 
zero without significant patterns. 
 
3.4.6 Limited Sampling Strategy (LSS) 
 
A one-sample limited sampling strategy (LSS) using only the trough level (0 hour) did not have 
the best predictive performance. Bias, precision and correlation between True and LSS-predicted 
AUC (R2) were improved by using a sample at a different sampling time or by using an 
additional sample. R2 increased to 0.963 by using one sample at 4 hour (Figure 12a). MPE% of 
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AUC prediction (bias) decreased to -0.47% (not significant different from zero, p>0.94) by using 
one sample at 1 hour. MAPE% (precision) decreased to 8.91% by using two samples at 0.5 and 
1.5 hours. Three-sample LSS did not further improve the prediction. Examples of posterior 
individual fitting of typical and atypical pharmacokinetic profiles using two samples at 0.5 and 
1.5 hours are shown in Figure 12b and 12c, respectively. 
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Figure 12. Predictive performance of the limited sampling strategies in liver tranpslant patients 
 
a: Predictive performance of the one-sample limited sampling strategy using one sample at 4 hours. Predicted AUC 
was well correlated with observed AUC. 
 
b and c: Predictive performance of the two-sample limited sampling strategy using samples at 0.5 and 1.5 hours 
(examples of posterior individual fitting of a typical pharmacokinetic profile (b) and an atypical pharmacokinetic 
profile (c)). Black circles are samples used as feedback information (limited sampling). Grey circles are other 
observed concentrations. 
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3.5 Discussion 
 
Limited pharmacokinetic data on voriconazole in transplant patients exists in the literature. To 
date this is the first study to evaluate the pharmacokinetics of voriconazole in liver transplant 
patients. 
 
This study involved intense blood sampling (nine data points from each patient in a single dosing 
interval) in the immediate post-transplant period (within seven days) in a small group of 
relatively homogenous liver transplant patients (n = 15), which allowed accurate and precise 
parameter estimation. The pharmacokinetic profiles of voriconazole are characterized by an early 
and sharp increase of voriconazole concentration, with the peak concentration being reached 
around 1 to 2 hours after dosing. These profiles were consistent with rapid absorption of 
voriconazole. This observation is similar to what has been reported in non-transplant patients (88, 
89, 94). 
 
The additive residual was close to the LLOQ of the assay used. CL/F and V/F estimated in this 
study were similar to those in non-transplant population (89). Nonlinear pharmacokinetics was 
not observed in this study (Michaelis-Menten elimination process did not improve the fitting). 
Evaluated internally in various ways, the final model showed adequacy and good stability and 
predictive performance. 
 
Despite of the relative homogeneity of the population studied, a large inter-individual variability 
in voriconazole pharmacokinetics was demonstrated. This is in accordance with the large 
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variability in voriconazole pharmacokinetics previously reported (6, 10, 50, 63, 66, 80, 81, 96, 
109, 114, 118, 122) and the unpublished preliminary data from our research group. The large 
variability observed in liver transplant patients may be explained by variations in absorption 
(gastrointestinal function, bile flow and food effect), elimination (liver function, saturated 
metabolism and CYP2C19 polymorphism) and drug-drug interaction (CYP450 
inhibitors/inducers).  
 
It is important to identify patient factors that significantly contribute to this large inter- and intra-
individual variability by exploring the correlations between pharmacokinetic parameters 
(especially drug exposure) and patient variables. The covariates tested in this study covered a 
wide range of values within each of the categories tested. In the non-compartmental analysis, we 
have observed that patients with higher total bilirubin, international normalized ratio (INR) and 
AST, indicative of hepatic dysfunction and hepatocellulary injury, had higher voriconazole 
exposure characterized by lower λz (elimination rate constant), higher half-life, higher AUCo-∞ 
and lower CL/F. We have also identified a positive association between the post-operative time 
(POT) and voriconazole exposure characterized by increased half-life, Cmax, Clast, AUCo-∞, 
AUMCo-∞ and MRTo-∞. This suggested an increase in voriconazole exposure with increased 
time post-transplantation. 
 
In the population analysis, we have also demonstrated that the most important factor associated 
with voriconazole pharmacokinetics was POT, which is consistent with non-compartmental 
analysis. CL/F, Vd/F and Tlag decreased rapidly and dramatically over POT and eventually 
converged to stable levels at some point around 7 days. 
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The primary reason for the increase in voriconazole exposure characterized by increased Cmax, 
Clast and AUCo-∞ and the decrease of CL/F and Vd/F with POT is likely to be increased 
bioavailability (F) with POT due to improved gastrointestinal function. Gastrointestinal 
complications have been observed after transplant surgery (5, 12, 56, 141) and gastrointestinal 
function recovers gradually with POT. Results in the study of lung transplant patients showed 
that voriconazole bioavailability was as low as 10% in the early period of time after lung 
transplantation, but increased over POT. Although metabolism and clearance may be increased 
after transplantation due to recovery in improved hepatic function, recovery in gastrointestinal 
function is likely to contribute to a greater extent, resulting in decreased CL/F. Furthermore, 
improved gastrointestinal function is also likely to be the reason for the decrease of Tlag with 
POT. In addition, increased bile production and secretion may also contribute to an increased 
bioavailability and decreased Tlag over POT.  
 
The secondary reason for a decreased CL/F with POT may be a decreased unbound fraction in 
the blood (fu) caused by increased plasma protein synthesis with recovered hepatic function. 
Voriconazole is a low- to intermediate-clearance drug. Voriconazole clearance is highly variable 
in different studies from 15 to 35.25L/hr (48, 63, 88, 96, 102, 118), and oral clearance varies 
from 8.1 to 23.4L/hr (61, 95, 101). Therefore the hepatic extraction ratio should range from 0.09 
to 0.39. For a low clearance drug Clintfu ×≈apparentCl (fu denotes fraction unbound. Clint 
denotes intrinsic clearance). Therefore, a decreased fu over POT could lead to a decreased 
clearance. Considering the great extent of the change in CL/F, a decreased fu alone may not 
contribute to the change in CL/F with POT.  
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An increased plasma protein synthesis is unlikely to be responsible for a decreased Vd/F over 
POT. Voriconazole is highly lipophilic and extensively distributed into tissues (Vd=4.6L/kg), but 
is not very extensively bound to plasma proteins (fu>0.42) (94). Therefore the drug binding in 
tissues should be predominant in determining Vd rather than plasma protein binding, and 
therefore change in fu in the blood may contribute very little to a change in Vd/F. Resolution of 
ascites after the transplant surgery may be another possible explanation for decreased Vd/F over 
time. 
 
Individual parameter estimates of CL/F, Vd/F and Tlag eventually converged to stable levels at 
some point around day 7. The reason is likely that the physiological factors that determine 
voriconazole pharmacokinetics (e.g. liver function, gastrointestinal function) were highly 
variable at the early period of time after the transplant surgery, but recovered and improved with 
POT towards normal population values. 
 
Higher total bilirubin, INR, AST and ALT, indicative of hepatic dysfunction and hepatocellulary 
injury is associated with low elimination rate constant, long half life, high AUCo-∞ and low 
CL/F of voriconazole. The reason is very likely that voriconazole is extensively metabolized in 
the liver with less than 2% of the administered dose excreted unchanged in urine and faeces (89, 
94, 103). 
 
For a low clearance drug Clintfu×≈apparentCl (fu denotes fraction unbound. Clint denotes 
intrinsic clearance). Clint depends on liver function of the patient. Therefore patients with higher 
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total bilirubin, INR, AST and ALT, indicative of hepatic dysfunction and hepatocellulary injury, 
had higher voriconazole exposure and lower CL/F. 
 
The presence of CYP2C19*2 alleles resulted in higher Cmax, Clast, AUMCo-∞ and MRTo-∞. 
This observation in this study is in accordance with recently published data in healthy volunteers 
(45, 69, 132). It has been reported that voriconazole exposure (AUC) is increased by 4-fold in 
poor metabolizers compared to homozygous extensive metabolizers. Nearly 15–20% of Asians 
and 3–5% of Caucasians are poor metabolizers (88, 89, 94). There is also an average 2-fold 
increase in exposure to voriconazole in heterozygous versus homozygous extensive metabolizers 
(88, 89, 94). The presence of deficient activity CYP2C19*2 alleles resulted in higher Cmax, 
AUMCo-∞ and MRTo-∞. However, CYP2C19 genetic analysis in this study did not include the 
newly identified excessive allele *17 (ultra-rapid metabolizer) (132), and only included the 
deficient alleles *2 and *3, which account for more than 85% of defective CYP2C19 alleles in 
Caucasians (18). Therefore the existence of excessive alleles and other defective alleles and thus 
misclassification of patients can not be ruled out. 
 
The possible effect of race on voriconazole pharmacokinetics observed in this study has never 
been reported before. Asian patients seemed to have a higher CL/F and Vd/F and a slower 
absorption process than Caucasian patients characterized by higher Tmax and lower Cmax, but 
this remains to be further investigated. 
 
In addition, the possible effect of co-administered pantoprazole on the exposure of voriconazole 
might be due to decreased absorption of voriconazole caused by proton pump inhibition since it 
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has been reported that pantoprazole causes no apparent induction or inhibition of cytochrome 
P450 enzyme systems (139). Pantoprazole sodium is a proton pump inhibitor (PPI) that 
covalently binds to the (H(+), K(+))-ATPase enzyme system at the secretory surface of the 
gastric parietal cell. This action suppresses the final step in gastric acid production and leads to 
inhibition of both basal and stimulated acid secretion. Pantoprazole produces extensive and long 
lasting inhibition of gastric acid secretion. PPI agents may reduce absorption of azoles by 
increasing gastric pH. However, this explanation is also questionable because significant 
decrease in voriconazole exposure due to decreased absorption caused by proton pump inhibition 
has never been reported. By contrast, a PPI agent omeprazole has been reported to cause an 
increase in voriconazole exposure due to inhibition of metabolizing enzyme (89, 137). Therefore 
further investigation is required to make any conclusion on the effect of co-administered 
pantoprazole on the exposure of voriconazole. 
 
Donor characteristics have been shown to have no effect on voriconazole pharmacokinetics in 
this study. If this observation is unbiased, current voriconazole dosing regimen in liver transplant 
patients without consideration of donor characteristics should be an adequate dosing strategy. 
However, it is important to point out that an exclusion of a factor does not necessarily mean that 
this covariate has no significant influence on the pharmacokinetic parameters, especially in this 
study with a small homogeneous group of patients in the immediate post-transplant period. Many 
reasons can lead to an exclusion of donor characteristics as a significant factor for voriconazole 
pharmacokinetics in this study. Firstly, some of the donor characteristics are not variable in the 
population studied. Secondly, simple linear regression is not the adequate model to assess the 
correlation between donor characteristics and voriconazole pharmacokinetics. Thirdly, some of 
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the donor characteristics may only have significant effects on voriconazole pharmacokinetics 
when their values are above (or below) a certain threshold value. If the values of these donor 
characteristics in this study were all below (or above) this threshold value, these donor 
characteristics would be excluded as a significant factor influencing voriconazole 
pharmacokinetics, no matter how variable this covariate is. Finally, some of the donor 
characteristics may only have significant effects on voriconazole pharmacokinetics when 
evaluated with interaction and co-effects with other patient/donor factors together. When 
evaluated alone without interaction with other factors, a significant factor could be identified as 
insignificant, which is a limitation of this study that will be discussed in the next sections. 
Therefore, further investigation on the effects of donor characteristics on voriconazole 
pharmacokinetics is required to make a conclusion. 
 
The final model was externally validated using retrospectively collected random samples that 
were not used for model-building, which is considered to be the most rigorous validation method 
because the established model has to be able to predict completely new data. Although the 
patients in the validation group had measurements taken at longer POT, the final model was still 
able to provide accurate and precise concentration predictions, suggesting that the 
pharmacokinetic parameters remain relatively stable after 7 days post-transplant. 
 
A large variability in voriconazole exposure following a fixed doing regimen necessitates 
individualizing voriconazole dosing to maximize therapeutic efficacy and minimize toxicity in 
liver transplant patients, especially considering that 33.3% of the patients in this study had a 
trough level below 1ug/ml. As mentioned previously, there is no simple efficacy measure to 
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which patient dose can be titrated, but there is a simple HPLC/UV assay available to monitor 
voriconazole levels. Therapeutic monitoring is currently performed in the routine clinical 
monitoring program at our institution with an intention to keep the trough concentration above 
1ug/ml. However, trough plasma concentrations have never been documented as surrogate 
markers of voriconazole exposure in liver transplant recipients. 
 
The good correlation (R2=0.85) observed in this study between the trough voriconazole plasma 
concentrations and the corresponding AUCo-∞ indicates that trough voriconazole concentration 
is a good measure of voriconazole exposure (AUC) in patients. 
 
A maximum a posteriori (MAP) Bayesian estimator was developed and evaluated using the 
model-building group in this study. Interestingly, the predictive performance of two-sample LSS 
was not always superior over one-sample LSS. This suggested that one-sample LSS, which are 
clinically more applicable, efficient, convenient and economical, might be sufficient for 
reasonable AUC estimation. 
 
There are two main approaches to develop LSS: multi-covariate linear regression (MLR) and 
MAP Bayesian method that was used in this study. Compared to MLR, the LSS developed in this 
study has a number of advantages: (1) sampling times and dosage regimens are flexible as long 
as they are well recorded, which accommodates clinical constraints that dosage regimens are 
frequently changed and precisely timed sampling is difficult. (2) Covariates that significantly 
affect pharmacokinetics are included in the analysis, which is particularly important to transplant 
patients since the covariates could change dramatically from time to time. (3) The LSS can be 
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continuously updated by incorporating new data to the population parameter estimation, thus 
improving performance. (4) Bayesian forecasting allows prediction of several pharmacokinetic 
parameters simultaneously (eg. AUC, clearance, volume of distribution). (5) Full 
pharmacokinetic profiles and response can be readily simulated, which allows visual comparison, 
and doses can be calculated. (6) Atypical and typical pharmacokinetic profiles could both be 
relatively accurately and precisely predicted using the same model developed using MAP (Figure 
12b and 12c), while LSS developed using MLR may not be useful for atypical profiles. 
 
These findings are likely to be clinically relevant because it suggests that voriconazole dose 
should be relatively high immediately after transplantation, especially in patients with good liver 
function as measured by low total bilirubin, INR, ALT and AST, in order to avoid 
ineffectiveness of the prophylaxis/treatment and its consequences (fungal infections, especially 
invasive aspergillosis). Voriconazole dose should be then gradually reduced, especially in 
patients with poor liver function as defined by high AST, total bilirubin or INR, in order to avoid 
toxicity caused by high voriconazole exposure. Intravenous administration of voriconazole 
appears to provide adequate drug exposure in the study of lung transplant patients. Based on the 
simulations and observations in lung transplant patients, we recommend administration of an 
intravenous dose of 200mg during the first two days after transplant to avoid low exposure. On 
day 3, patients should receive either a high oral dose of 400mg or be continued on an intravenous 
dose of 200mg. Starting from day 4, patients should receive an oral dose of 200mg that appeared 
to be sufficient to maintain the voriconazole plasma concentrations between 1ug/ml and 6ug/ml 
due to the change of pharmacokinetic parameters with POT in order to avoid toxicity caused by 
high voriconazole exposure. However, since voriconazole is currently only given orally to liver 
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transplant patients at our institution and bioavailability was not able to be characterized in this 
study, further investigations are warranted in order to make detailed recommendation of optimal 
voriconazole dose regimen in liver transplant patients, and therapeutic drug monitoring is still 
necessary in liver transplant patients. 
 
In conclusion, this study has demonstrated that there is a large inter-individual variability in the 
pharmacokinetics of voriconazole in liver transplant patients. A fixed dosing regimen leads to 
widely variable exposure of voriconazole in liver transplant patients and therefore is not optimal 
for voriconazole therapy for prophylaxis and treatment in liver transplant patients. Donor 
characteristics seem to have no significant influence on voriconazole pharmacokinetics, but 
further investigation is required due to the small number of subjects evaluated in this study. 
Voriconazole CL/F, Vd/F and Tlag decreased rapidly and dramatically with postoperative time 
and eventually converged to stable levels at some point within 7 days. Postoperative time and 
poor liver function are positively associated with voriconazole exposure and half-life, which may 
be useful for dosage adjustment. Poor liver function is associated with low CL/F. CL/F and Vd/F 
are not correlated with body weight, which does not support weight-based dosing strategy. 
Trough concentrations (target 1ug/ml – 6ug/ml) are good measure of voriconazole exposure 
(AUCo-∞), and should be used in practice to individualize voriconazole dosage. Limited 
sampling strategies developed using Bayesian approaches in this study have shown potential to 
accurately and precisely estimate voriconazole exposure with one or two blood samples and no 
rigid sampling time or dosage regimens required, but definitely required external validation 
before used in practice to individualize voriconazole dosage. Routine therapeutic drug 
monitoring for voriconazole is warranted. This evaluation will allow for an assessment of the 
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adequacy of the prophylactic regimen in achieving therapeutic drug concentrations in all subjects, 
and could potentially help identify patients at risk for extremes in voriconazole exposure. 
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Chapter IV Pharmacokinetics of Voriconazole in Lung Transplant Patients 
 
4.1 Abstract 
 
Objectives: To characterize the pharmacokinetics and bioavailability of voriconazole in adult 
lung transplant patients during early post-operative period, identify factors significantly 
associated with various pharmacokinetic parameters, and make recommendations for adequate 
dosing regimens. 
 
Methods: Thirteen lung transplant patients received two intravenous infusions (6mg/kg, bid) 
immediately post-transplant followed by oral doses (200mg, bid) of voriconazole for prophylaxis. 
Blood samples (n=9/interval) were collected during one intravenous and one oral dosing interval 
from each patient. Voriconazole plasma concentrations were measured by HPLC. NONMEM 
was used to develop pharmacokinetic models, evaluate covariate relationships and perform 
Monte Carlo simulations. 
 
Results: There was a good correlation (R2=0.98) between AUCo-∞ and trough concentrations. A 
two-compartment model adequately described the data. Population estimates of bioavailability, 
clearance, Vc and Vp were 45.9%, 3.45L/hr, 54.7L and 143L. Cystic fibrosis (CF) patients 
exhibited a significantly lower bioavailability (23.7%, n=3) than non-CF patients (63.3%, n=10). 
Bioavailability increased with post-operative time and reached steady levels in about one week. 
Vp increased with body weight. 
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Conclusions: Bioavailability of voriconazole is substantially lower in lung transplant patients 
than non-transplant subjects, but significantly increases with post-operative time. CF patients 
exhibit significantly lower bioavailability and exposure of voriconazole, and therefore need 
higher doses. Weight-adjusted or fixed dosing regimens resulted in highly variable exposure of 
voriconazole. Voriconazole dose can be individualized based on trough concentrations as a good 
measure of drug exposure. Simulations demonstrated inadequacy of oral administration of 
voriconazole and adequacy of intravenous administration during the first post-operative day 
followed by oral doses. 
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4.2 Introduction 
 
The bioavailability of voriconazole after oral administration is 96% in non-transplant population 
(89). However, gastrointestinal complications observed after transplant surgery (5, 12, 56, 141) 
may cause clinically significant lower bioavailability of voriconazole. Our observation of a large 
portion of the samples with no measurable plasma concentration or with a plasma concentration 
of less than 1ug/ml suggested that the absorption and bioavailability may be altered in transplant 
patients. Therefore it is important to understand bioavailability of voriconazole in transplant 
patients. However, to date, the bioavailability of voriconazole in transplant patients and the 
pharmacokinetics of voriconazole in lung transplant patients have not been reported. 
 
Voriconazole is typically given as an intravenous infusion for the first day after lung 
transplantation and then given orally for prophylaxis at our institution, which provides an 
opportunity for studying the bioavailability of voriconazole in solid organ transplant patients. 
 
We hypothesize that bioavailability of voriconazole in lung transplant patients is lower than that 
reported in non-transplant population due to decreased/variable GI function during the early 
post-operative time period and will improve with time. In order to test our hypothesis, we 
propose two specific aims: 
 
Specific aim 1 will characterize bioavailability of voriconazole and evaluate the variability in 
bioavailability of voriconazole in lung transplant patients. Voriconazole plasma concentrations 
have been measured in 13 lung transplant patients within one intravenous infusion dosing 
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interval and one oral dosing interval after transplantation. Non-compartmental pharmacokinetic 
analysis and nonlinear mixed effects modeling analysis will be performed to estimate the 
bioavailability, and to capture both inter-patient and intra-patient variability in the bioavailability 
estimate. We predict that the bioavailability estimated in lung transplant patients will be lower 
than that in non-transplant subjects, and there will be a large variability in the bioavailability 
estimate. 
 
Specific aim 2 will evaluate the association of patient variables with bioavailability of 
voriconazole in lung transplant patients. Patient demographic variables have been collected for 
each patient, and their association with the bioavailability of voriconazole will be evaluated 
using simple linear regression in non-compartmental analysis and evaluated as a covariate in 
population pharmacokinetic analysis. We predict that bioavailability will be associated with post-
operative time due to gradually recovered GI function after the transplantation surgery. 
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4.3 Methods 
 
4.3.1 Patients  
 
The protocol was approved by IRB at the University of Pittsburgh. Lung transplant recipients 
who were initiated on a voriconazole prophylactic regimen immediately post transplant as part of 
their standard clinical care and who signed informed consent were enrolled in this prospective 
study. Two intravenous doses were administered first as a 2-hour intravenous infusion (6mg/kg, 
bid) followed by oral doses (200mg, bid) for a duration of 3 months post transplant. The 
exclusion criteria were: children under age 18; co-administration of medications known to 
influence voriconazole pharmacokinetics; administration of voriconazole to treat an active fungal 
infection; pre-transplant voriconazole administration; or voriconazole dosing regimens other than 
that associated with fixed oral dosage. Complete dosing history, demographic data, laboratory 
tests and current medication use were recorded. All patients received tacrolimus as their primary 
immunosuppressive agent. 
 
4.3.2 Blood Sampling and Analytical Assay 
 
Serial blood samples (7ml) were collected within one intravenous and one oral dosing interval 
from each patient. The sampling time was just prior to (0 hr) and at 0.5, 1, 1.5, 2, 4, 6, 8 and 12 
hours following the 2nd intravenous dose and following administration of a minimum of 5 oral 
doses (range from the 5th to 37th dose; mean 15th dose). Blood samples were processed and 
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analyzed for voriconazole plasma concentration using a validated HPLC method previously 
described. 
 
4.3.3 Non-compartmental Pharmacokinetic Analysis 
 
The difference between trough concentrations prior to oral dosing (Co) and at 12 hours after oral 
dosing (C12) was tested using paired two-tailed Student t-test to confirm attainment of steady 
state. Area under the plasma concentration-vs-time curve specific for the dose evaluated (AUCo-
∞) was calculated using trapezoid rule and reverse superposition principle. Time to peak 
concentration (Tmax) and peak plasma concentrations (Cmax) were directly read off the 
concentration-vs-time profiles.  
 
4.3.4 Population Pharmacokinetic Analysis 
 
A nonlinear mixed-effects pharmacokinetic model (base model) was developed using NONMEM 
6.2.0 (GloboMax, Hanover, MD) using first order conditional estimation method with interaction. 
Correlations between pharmacokinetic parameters were always incorporated and estimated. One- 
and two-compartment models were tested with first/zero-order elimination and Michaelis-
Menten elimination process since nonlinear pharmacokinetics of voriconazole has been reported 
(89). Inter-individual variability was described using exponential model ijjij ePTVP
η×= )( , 
where Pij is the ith individual’s estimate of the jth pharmacokinetic parameter, TV(Pj) is the 
typical value of the jth pharmacokinetic parameter, and ηij is a random variable for the ith 
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individual and the jth pharmacokinetic parameter distributed with mean zero and variance of ωj2. 
Residual variability was described using combined error model ')1( εε ++×= CpredCobs , 
where Cobs and Cpred are the observed and predicted concentrations, respectively, and ε and ε’ 
are normal random variables with means of zero and variances of σ2 and σ’2, respectively. The 
adequacy of fitting was examined by plotting predicted versus observed concentrations 
(Goodness-of-Fit), concentrations versus time profiles and weighted residuals versus predicted 
concentrations. 
 
4.3.5 Covariate Relationship Exploration 
 
Association between patient variables and pharmacokinetic parameters were first visually 
evaluated by plotting Empirical Bayes Estimates (EBE) against patient variables. Patient 
variables were then incorporated into the base model one at a time using at least 13 approaches 
to associate the patient variable with the parameter. A patient variable was considered as 
significant if all the following criteria were met: (1) a decrease in objective function value (OFV) 
of 6.63 for 1 degree of freedom (p<0.01), (2) no significant trend in EBE-vs-patient variables 
plots, (3) improved Goodness-of-Fit, (4) reduced inter-individual variability and (5) clinical 
plausibility for incorporating the patient variable. 
 
4.3.6 Monte Carlo Simulations 
 
 90
Voriconazole concentration-vs-time profiles in patients with and without CF (200mg, oral, BID) 
were simulated using NONMEM to illustrate that CF patients may exhibit significantly lower 
exposure of voriconazole than non-CF patients, and that CF patients may experience 
underexposure of voriconazole with trough concentrations of <1ug/ml. The simulation procedure 
is based on drawing random samples for each of the pharmacokinetic parameters from their 
statistical distributions reflecting inter-individual variability. Every random draw generates a 
parameter set that characterizes the pharmacokinetics of a “virtual” subject and is subsequently 
used to generate the concentration-vs-time profile of this “virtual” subject. A total of 1500 
“virtual” CF subjects and 1500 “virtual” non-CF subjects were simulated using this procedure. 
This simulation ensemble closely matches the original population statistics. Concentration-vs-
time profiles of the “virtual” populations were summarized and compared by their median and 
5% and 95% percentiles (90% prediction interval). The width of the 90% prediction interval 
reflects the degree of inter-individual variability in the original population. 
 
In order to illustrate voriconazole exposure under different clinical scenarios and thus make 
clinical recommendation of adequate dosing regimens, voriconazole concentration-vs-time 
profiles were simulated for five hypothetical dosing regimens (BID): oral administration only 
(200mg, 400mg, 600mg) or combined administration of two doses of a 2-hour intravenous 
infusion (6mg/kg) followed by oral administration (200mg, 400mg). 1500 “virtual” subjects 
were simulated for each regimen using the same procedure mentioned above. In addition, 
simulation of individual profiles was also performed using a fixed dose of 200mg or a body 
weight-adjusted dose of 3mg/kg, and compared with each other, in order to evaluate whether the 
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variability among the pharmacokinetic profiles was reduced by using a body weight-adjusted 
dose as compared to a fixed dose.  
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4.4 Results 
 
4.4.1 Patients 
 
A total of 13 patients were enrolled in this study. Table 8 summarizes the characteristics of the 
patients, including the primary diagnosis, age, body weight, race, gender, days post-transplant on 
the day of the oral study and laboratory biochemical profiles prior to transplant, immediately 
after transplant and on the day of the oral study. One patient did not complete the oral study. 
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Table 8. Characteristics of lung transplant patients 
Diagnoses  
         Cystic fibrosis 3 
         Emphysema 5 
         Idiopathic pulmonary fibrosis 4 
         Scleroderma 1 
Patient Age (yr) 50.9 ± 16.1 (19-70) 
Weight (kg)  68.0 ± 15.2 (46-91) 
Ideal body weight (kg)  59.6 ± 8.2 (45.5-75.3) 
Race (Caucasian/Other) 12/0 
Gender (male/female) 7/6 
Days post-transplant on the day of oral study 8.5 ± 4.4 (3-19) 
Alkaline phosphatase (U/L) * 82.4 ±31.8 (54-169) 
Alanine aminotransferase (U/L) * 30.3 ± 8.3 (22-52) 
Aaspartate aminotransferase (U/L) * 28.1 ± 14.5 (20-75) 
Gamma-glutamyl transpeptidase (U/L) * 35.1 ± 19.0 (15-71) 
Serum Creatinine (mg/dL) † 0.78 ± 0.16 (0.5-1) / 0.85 ± 0.22 (0.5-1.1) 
Creatinine Clearance (ml/min) † 85.6 ± 36.9 (55.6-177.8) / 85.7 ± 40.4 (40.5-177.8) 
Values are all expressed as mean ± standard deviation (range) except specified otherwise. 
* Values measured before the transplantation. 
† Values are displayed as measurements within one day after the transplantation / measurements on the day of the 
oral study. 
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There was a wide variation in voriconazole plasma concentrations (Figure 13). Most 
voriconazole plasma concentrations (72.5%) were maintained within 1-6ug/ml, while 17.9% and 
9.7% of voriconazole plasma concentrations were below 1ug/ml or above 6ug/ml, respectively. 
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Figure 13. Plasma concentrations-vs-time profiles of voriconazole in lung transplant patients 
 
a: individual plasma concentrations-vs-time profiles of voriconazole collected during an intravenous infusion dosing 
interval 
 
b: mean plasma concentrations-vs-time profiles of voriconazole with standard deviation error bars collected during 
an intravenous infusion dosing interval 
 
c: individual plasma concentrations-vs-time profiles of voriconazole collected during an oral dosing interval (one 
patient did not complete oral study) 
 
d: mean plasma concentrations-vs-time profiles of voriconazole with standard deviation error bars collected during 
an oral dosing interval 
 
 
 
 
4.4.2 Non-compartmental analysis 
 
Trough concentrations Co and C12 were not significantly different (p=0.82), and the difference 
between the trough concentrations (C12-Co)/C12 averaged -2.7%, indicating that steady state 
had been reached in most of the patients at the time of the oral study (Figure 14).  
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Figure 14. Comparison of trough concentrations in the oral study in lung transplant patients 
 
Co (left) vs C12 (right) 
 
 
 
 
Figure 15 illustrates a good correlation between voriconazole trough plasma concentrations and 
the corresponding AUCo-∞ both for intravenous infusion (non-steady state, R2=0.86) and oral 
dose (steady state, R2=0.98). Tmax (±SD) for oral dose was 1.9±1.3 hours. Cmax (±SD) for 
intravenous infusion and oral dose was 5.9±2.2ug/ml and 3.6±2.6ug/ml, respectively. 
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Figure 15. Correlation of AUCo-∞ with voriconazole trough plasma concentrations in lung transplant 
patients 
 
a: R2=0.83 when AUCo-∞ and trough concentrations (C12) were correlated (main figure) during an intravenous 
infusion dosing interval (non-steady state). R2=0.86 when a potential outlier is omitted (inset figure). Two patients 
have very similar C12 and AUC and therefore can not be separated in the figure. 
 
b: R2=0.98 (dash line) and R2=0.96 (solid line) when AUCo-∞ was correlated with trough concentrations Co (●) and 
C12 (□), respectively, during an oral dosing interval (steady state, one patient did not complete oral study). 
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4.4.3 Population Pharmacokinetic Analysis 
 
A two-compartment model with first-order absorption and elimination adequately described the 
data. The population estimates (inter-individual) of bioavailability, clearance, volume of 
distribution of central compartment (Vc) and peripheral compartment (Vp), inter-compartment 
clearance (Q), and absorption rate constant (ka) were 45.9% (82.9%), 3.45L/hr (107%), 54.7L 
(78.4%), 143L (88.3%), 22.6L/hr (50.1%) and 0.591hr- (115.2%). The proportional and additive 
residual variability was 0.31 and 0.49ug/ml, respectively. Individual predictions agreed well with 
observations (Figure 16). Weighted residuals were approximately normally distributed and were 
mostly within about 2 units of the null ordinate. 
 
CL/F in lung transplant (7.52L/hr) patients was similar to that in liver transplant patients (7.92 
L/hr). Vd/F in lung transplant patients (430.7 L) was significantly higher than that in liver 
transplant patients (248 L). 
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Figure 16. Goodness-of-Fit of base model in lung transplant patients 
 
Individual predictions agreed well with observations (R2=0.96). 
 
 
 
 
Based on the individual estimates obtained from the base model, mean bioavailability (±SD) was 
23.7% (±19.4%, n=3) and 63.3% (±15.2%, n=10) in CF and non-CF patients, respectively. 
Bioavailability was significantly lower in CF patients than non-CF patients (p=0.0032, two-tailed 
Student t-test). 
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4.4.4 Covariate Relationship Exploration 
 
Model 1: Cystic Fibrosis (CF) 
The most important patient variable associated with bioavailability was CF. OFV decreased by 
11.65 from -47.55 (base model) to -59.20 when CF was incorporated in bioavailability, 
indicating substantial model improvement (p=0.0006). Inter-individual variability in 
bioavailability decreased by 30.7% from 82.9% (base model) to 57.5%, while inter-individual 
variability in other pharmacokinetic parameters did not change significantly. 
 
The association between CF and bioavailability (F) was best described using the equation 
CFnonCF KFFF −×′+=  (Model 1), where FCF denotes bioavailability of CF patients, F’ denotes 
the difference in bioavailability between CF and non-CF patients, and Knon-CF=1 for non-CF 
patients and 0 for CF patients. Population estimates of FCF and F’ were 10.7% and 72%, 
respectively. Based on the model, bioavailability of voriconazole was significantly lower in CF 
patients (10.7%) than non-CF patients (82.7%) by 87%. 
 
Model 2: Post-operative Time (POT) 
Another important factor associated with bioavailability was POT. OFV decreased by 10.94 from 
-47.55 (base model) to -58.49 when POT was incorporated in bioavailability, indicating 
substantial model improvement (p=0.0009). The association between POT and bioavailability (F) 
was best described using the equation 
cFPOT
POTF
F +
×= max  (Model 2), where Fmax denotes the 
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maximal bioavailability that can be reached in the patients in this study, and Fc is a constant. 
Inter-individual variability was incorporated both in Fmax and Fc and estimated. Population 
estimates (inter-individual variability) of Fmax and Fc were 61.9% (61.5%) and 1.97 hours 
(217.3%), respectively. Even the maximal bioavailability (61.9%) in lung transplant patient 
population was still much lower than that in non-transplant subjects (96%). The small value of 
Fc indicates that bioavailability would increase rapidly with POT. 
 
According to the equation and individual parameter estimates obtained from Model 2, 
bioavailability of voriconazole significantly and rapidly increased with POT in most of the 
patients, and eventually reached maximal levels within one week post-transplant (Figure 17). 
Figure 17 also illustrates that bioavailability was significantly lower in CF patients than non-CF 
patients. The large variability demonstrated in Figure 17 is consistent with the large inter-
individual variability in Fmax and Fc. 
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Figure 17. Change of bioavailability of voriconazole over post-operative time in lung transplant patients with 
and without cystic fibrosis 
 
Individual parameter estimates of bioavailability obtained from Model 2 were plotted against post-operative time 
(POT). Bioavailability significantly and rapidly increased with POT in most of the patients, and eventually reached 
the maximal level within one week after transplant. Bioavailability was significantly lower in cystic fibrosis (CF) 
patients (dash line) than non-CF patients (solid line). Grey solid line: population estimates from Model 2. 
 
 
 
 
Model 3: Body Weight (WT) 
Vp significantly increased with WT. OFV decreased by 7.29 from -47.55 (base model) to -54.84 
when WT was incorporated in Vp, indicating substantial model improvement (p=0.0069). Inter-
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individual variability in bioavailability decreased by 31.9% from 88.3% (base model) to 61.2%, 
while inter-individual variability in other pharmacokinetic parameters did not change 
significantly. The association between Vp and WT was best described using the equation 
( )aWTWTVpTVVp ÷×= )(  (Model 3), where TV(Vp) denotes typical value of Vp in the patients 
in this study, i.e. the Vp in a patient with average body weight (68kg), and a is a constant to be 
estimated. Population estimates of TV(Vp) and a were 148L and 3.56, respectively. 
 
4.4.5 Monte Carlo Simulations 
 
Statistical distribution of pharmacokinetic parameters and inter-individual variability obtained 
from Model 1 (see above) was used to simulate CF and non-CF “virtual” subjects (Figure 18a). 
Median voriconazole plasma concentration and median AUC were 6.7 times higher in non-CF 
patients than CF patients. Furthermore, 90% prediction interval of CF patients did not include the 
median concentration-vs-time profiles of non-CF patients, and vice versa. This indicates 
significantly lower exposure of voriconazole in CF patients than non-CF patients. 
 
Ninety percent prediction interval of the entire concentration-vs-time profiles (including peak 
levels) in CF patients remain below 1ug/ml for the first three days post-transplant. 90% 
prediction interval of trough concentration remains below 1ug/ml for the first four days post-
transplant. Median concentration-vs-time profile in CF patients remains below 0.5ug/ml for the 
entire duration of study. This indicates underexposure of voriconazole in CF patients with trough 
concentration of <1ug/ml in 90% of the patients during the first four days post-transplant. In 
addition, the large inter-individual variability is confirmed by wide 90% prediction intervals. 
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Statistical distributions of pharmacokinetic parameters and inter-individual variability obtained 
from Model 2 (see above) were used to simulate different dosing regimens. Median trough 
concentrations stay above 1ug/ml since the first loading dose and are maintained between 2 and 
3ug/ml at steady state when patients receive two 2-hour intravenous infusions followed by oral 
doses (Figure 18b). In contrast, simulation with mere oral administration (BID) at 200mg, 400mg 
and 600mg results in median trough concentration below 1ug/ml for the first 3.5 days, 1.5 days 
and 1 day post-transplant, respectively. In addition, simulated individual profiles using a fixed 
dose of 200mg or a body weight-adjusted dose of 3mg/kg were compared with each other, and 
the variability among the pharmacokinetic profiles was not reduced by using a body weight-
adjusted dose as compared to a fixed dose, which confirmed the adequacy of fixed oral dosing 
regimens. 
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Figure 18. Monte Carlo simulation in lung transplant patients 
 
a: simulated voriconazole concentration-vs-time profiles during first two days post-transplant in lung transplant 
patients with and without cystic fibrosis (CF). Median of simulated voriconazole concentration in CF patients (dash 
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line) and non-CF patients (solid line) with 90% prediction intervals of CF patients ( ) and non-CF patients ( ) is 
displayed. Extension of the profiles beyond two days post-transplant is not shown. 
 
b: simulated voriconazole concentration-vs-time profiles (extended until steady state is reached) in lung transplant 
patients receiving two doses of 2-hour intravenous infusion (6mg/kg) followed by oral doses (BID). Median of 
simulated voriconazole concentration with intravenous infusion followed by oral dose of 200mg (black solid line) 
and 400mg (grey solid line) are compared. Only 90% prediction interval for intravenous infusion followed by oral 
dose of 200mg (dash line) is displayed. 
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4.5 Discussion 
 
To date this is the first evaluation of bioavailability of voriconazole in transplant patients, and the 
first pharmacokinetic study of voriconazole in lung transplant patients. 
 
Prospective intense sampling (nine samples per dosing interval) in early post-transplant period in 
a small group of relatively homogenous patients (n=13) was used in this study to provide 
accurate and precise parameter estimation. Oral pharmacokinetic profiles of voriconazole are 
characterized by an early and sharp increase of voriconazole concentration, with the peak 
concentration being reached around 2 hours after dosing. This observation is consistent with 
rapid absorption of voriconazole and similar to what has been reported in non-transplant patients 
(89). Despite the relative homogeneity of the population studied, a large inter-individual 
variability in voriconazole pharmacokinetics was demonstrated. This is consistent with previous 
reports (49, 118). Nonlinear pharmacokinetics was not observed in this study (Michaelis-Menten 
elimination process did not improve the fitting). 
 
The large inter-individual variability in voriconazole exposure has given rise to concerns about 
voriconazole dose management in transplant patients, especially when it results in underexposure. 
Preliminary data showed that nearly 15.2% of transplant patients on recommended doses have 
undetectable trough concentrations, and nearly 45% of the patients have trough concentrations of 
<1ug/ml. Drug underexposure may be caused by decreased absorption or increased elimination. 
Elimination of voriconazole is determined by liver function and Cytochrome P450 
polymorphism. Therefore elimination is unlikely to increase in lung transplant patients. 
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Therefore we hypothesized that decreased bioavailability is responsible for underexposure of 
voriconazole in transplant patients. Bioavailability of voriconazole is substantially lower in lung 
transplant patients during the early post-operative period (45.9%) in this study than that in non-
transplant subjects (96%), likely due to gastrointestinal complications observed after transplant 
surgery (5, 12, 56, 141). 
 
Furthermore, we demonstrated that bioavailability of voriconazole was significantly lower in CF 
patients than non-CF patients by 87%. It is typical that the mean bioavailability calculated using 
individual estimates of bioavailability obtained from base model (23.7% for CF patients and 
63.3% for non-CF patients) were different from the population estimates in Model 2 (10.7% for 
CF patients and 82.7% for non-CF patients). Unlike the mean, the population estimate is the 
posterior mode of the marginal likelihood distribution for that parameter value versus the 
objective function (i.e. the maximum likelihood point in the distribution).  If the distributions are 
not strictly normal (log normal is enough to skew this), the mean will not equal the mode. 
 
Low voriconazole exposure observed in patients with CF in this study agree with the 
observations reported by Berge et al. (4) that voriconazole plasma concentrations were 
<0.5ug/ml in over 30% of CF lung transplant patients, and <1.5ug/ml in nearly 70% of the 
patients. However, the authors did not perform pharmacokinetic analysis to reveal the cause of 
underexposure since only trough and peak concentrations from therapeutic drug monitoring were 
obtained. Population pharmacokinetic analysis and Monte Carlo simulation in our study 
demonstrated that the reduced bioavailability in CF patients is the potential cause of 
underexposure. 
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CF is well known to cause malabsorption and reduced bioavailability of several highly lipophilic 
compounds, such as vitamin A, D, E and K (27), cyclosporine (124) and ibuprofen (38). Due to 
its high lipophilicity and low water-solubility, absorption of voriconazole highly depends on 
digestion of fat and the subsequent formation of micelle. However, this process is severely 
impaired in CF patients for many reasons. First of all, pancreatic insufficiency in CF patients 
causes impaired digestion of fat. Obstruction in the small pancreatic ducts in CF patients leads to 
decreased secretion of pancreatic enzymes (lipase) into the intestine, resulting in impaired 
lipolysis of dietary triacylglycerols. Furthermore, decreased secretion of pancreatic bicarbonate 
causes low duodenal pH, which considerably reduces pancreatic lipase activity. Secondly, a 
diminished bile salt pool causes impaired formation and absorption of micelle (31). Bile salts 
readily precipitate at low duodenal pH, and thus the duodenal bile salt concentration may fall 
below the critical micellar concentration. Furthermore, precipitated bile salts are not reabsorbed 
for the enterohepatic circulation, and therefore lost in great amount. Finally, intestinal mucosal 
dysfunction, alterations in the intestinal mucus layer (dehydration of the luminal surface and 
altered mucus secretion with distended crypts along the mucosal surface) and accelerated 
intestinal transit time in CF patients may also contribute to malabsorption of fat and highly 
lipophilic drugs such as voriconazole (24, 124). In addition, gastric acid hypersecretion in CF 
patients (14) may further lower duodenal pH, and thus further reduce pancreatic lipase activity 
and increase precipitation and loss of bile salts. 
 
It is important to identify factors that significantly contribute to the large inter- and intra-
individual variability of voriconazole in this population by exploring associations between 
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patient variables and pharmacokinetic parameters. The eleven patient variables tested in this 
study covered a wide range of values within each of the categories tested. Bioavailability 
increased rapidly over POT and reached maximal levels within one week in most of the patients, 
likely to be due to improved gastrointestinal function over POT. CL/F and Vd/F of voriconazole 
rapidly and dramatically decrease with POT in liver transplant patients. We propose increased 
bioavailability with POT as the primary reason, which is partly supported by this study.  
 
A final model was also built as described previously (39). However, despite the statistically 
significant improvement of the final model and the covariate models (Model 1, 2 and 3) 
compared to base model, visual inspection of the Goodness-of-Fit plots of the final model and 
covariate models only showed a corrected bias of population predictions at low concentrations. 
This suggested that the patient variables tested and selected in this study (CF, POT and body 
weight) only explain part of the variability in the pharmacokinetics of voriconazole in lung 
transplant patients, while some other variables that were not collected in this study are still 
needed to account for the remaining variability. Future studies should collect more variables and 
further explore factors that are significantly associated with pharmacokinetics of voriconazole in 
lung transplant patients. 
 
Vd/F in lung transplant patients (430.7 L) was significantly higher than that in liver transplant 
patients (248 L), likely due to different study design. Voriconazole was administrated 
intravenously in this study in lung transplant patients but not in the study of liver transplant 
patients. A two-compartment model is more likely to be observed following intravenous 
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administration, resulting in larger volume of distribution as compared to a one-compartment 
model, due to the addition of the peripheral compartment. 
 
As discussed previously, the large variability in voriconazole exposure following weight-
adjusted or fixed doing regimens necessitates individualizing voriconazole dosing to maximize 
therapeutic efficacy and minimize toxicity in lung transplant patients. Therapeutic monitoring is 
currently performed in the routine clinical monitoring program at our institution with an 
intention to keep the trough concentration above 1ug/ml. However, trough concentrations have 
never been documented as surrogate markers of voriconazole exposure in lung transplant patients. 
 
The good correlation observed in this study between the voriconazole trough plasma 
concentrations and the corresponding AUCo-∞ both for intravenous infusion (non-steady state, 
R2=0.86) and oral dose (steady state, R2=0.98) indicates that trough concentration is a good 
measure of voriconazole exposure in this population. 
 
These findings are likely to be clinically relevant. Based on Monte Carlo simulations, CF 
patients are very likely to experience underexposure of voriconazole and therefore need higher 
doses. Mere oral administration of voriconazole is likely to cause underexposure of voriconazole 
in lung transplant patients in early post-transplant period, while intravenous administration 
during the first post-operative day followed by oral doses is likely to result in appropriate drug 
exposure. However, therapeutic drug monitoring of voriconazole is still necessary in lung 
transplant patients due to the large inter-individual variability. 
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In conclusion, a population pharmacokinetic model was developed for voriconazole in lung 
transplant patients in early post-operative period. Large inter-individual variability in 
voriconazole pharmacokinetics was demonstrated. Bioavailability of voriconazole is 
substantially lower in lung transplant patients (45.9%) than non-transplant subjects (96%), but 
significantly increased with post-operative time, likely due to recovery of gastrointestinal 
functions. Exposure and bioavailability of voriconazole is significantly lower in CF patients, 
likely due to impaired absorption of voriconazole caused by physiological changes associated 
with CF. We recommend intravenous infusion (6mg/kg) during the first post-operative day 
followed by oral doses (200mg or 400mg) as an adequate dosing regimen in lung transplant 
patients. Given the large variability in the pharmacokinetics and the good correlation between 
AUC and trough concentrations, trough concentrations should be used to individualize 
voriconazole dose.  
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Chapter V Double-peak profiles of voriconazole in transplant patients 
 
5.1 Abstract 
 
Objectives: To apply the two-portion absorption model to describe atypical voriconazole profiles. 
 
Methods: NONMEM (ADVAN5) was used to develop the simplified two-portion absorption 
model assuming discontinuous absorption of the available dose in two portions: F1 and F2 
(F1+F2=1). Delayed transfer of each portion from the stomach to the gut and the sequential 
absorption was described by first-order processes with lag-times (Tlag1 and Tlag2) and 
transfer/absorption rate constants (ktra1 and ktra2). Precision of parameter estimation was 
evaluated using bootstrapping. 
 
Results: Full pharmacokinetic profiles (8–9 samples/profile) with a single delayed wide peak or 
two peaks were observed in 23 transplant patients. A one-compartment model with first-order 
elimination in association with the simplified two-portion absorption model adequately described 
the data and showed superiority over one- and two-compartment models with an absorption lag 
time. The population estimates of F1, Tlag1, Tlag2, ktra1 and ktra2 were 0.27, 0.24 hours, 2.03 
hours, 0.15 hr-1 and 0.004 hr-1, respectively. Tlag1 was significantly smaller than Tlag2. 
 
Conclusions: Atypical voriconazole pharmacokinetic profiles were probably caused by impaired 
gastrointestinal functions that are common in the early post-transplant period, and could be 
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reliably described by a simplified two-portion absorption model. Twenty-seven percent of the 
available dose seemed to be rapidly absorbed immediately, with the remainder being slowly 
absorbed. This model was useful to understand the mechanisms of atypical profiles of 
voriconazole and to improve estimation of voriconazole exposure in liver, lung and small 
intestine transplant patients. 
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5.2 Introduction 
 
Double-peak phenomena of concentration-vs-time curves have been observed with a number of 
orally administered drugs, and some of them have been extensively investigated (7-9, 11, 22, 32, 
37, 41, 58-60, 65, 71-73, 76, 90-92, 104, 107, 110, 115, 128, 133, 136, 140, 142). However, to 
date there have been no reports about such observations with voriconazole. 
 
Five major physiological mechanisms have been hypothesized for double-peak profiles 
following oral administration. These include: (1) enterohepatic recirculation (84), (2) site-
specific absorption of the drug from two distinct absorption sites along the gastrointestinal tract 
that are separated by a region of relatively low absorption (53), (3) active intestinal secretion of 
the drug from the systemic circulation into the gut lumen followed by a reabsorption of the 
secreted drug (exsorption) (62), (4) progressive solubilization of the drug along the 
gastrointestinal tract and its subsequent absorption (79), and (5) gastric retention of a portion of 
the drug dose due to delayed gastric emptying and/or variable gastrointestinal motility (76). 
 
Enterohepatic recirculation and exsorption can be easily excluded as the cause of the secondary 
peak in oral voriconazole pharmacokinetic profiles since no secondary peak was observed 
following intravenous administration in lung transplant patients (10) or following oral 
administration in non-transplant populations (63, 109, 118). Furthermore, there is no evidence 
that a significant portion of an oral voriconazole dose is recovered in the bile in human subjects 
(63, 100, 109, 118). Site-specific absorption and progressive solubilization are also unlikely 
since the underlying physiological mechanisms of these two hypotheses are unlikely to differ 
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between transplant and non-transplant populations, and no secondary peak has been observed 
with the same formulation of voriconazole in non-transplant populations (63, 109, 118).  
 
In contrast, gastric retention of a portion of the drug dose is the most likely reason for the 
double-peak phenomenon with voriconazole in solid organ transplant patients since delayed 
gastric emptying and decreased/variable gastrointestinal motility has been frequently observed 
after transplant surgery (5, 12, 56, 141). One of the earliest ideas of two-portion absorption was 
proposed by Suverkrup et al. (116), and further developed by Zimmerman et al. (143), Kaniwa et 
al. (54) and Oberle et al. (76). However, these models have a large number of parameters and 
could be overparameterized if the pharmacokinetic profiles are characterized by a limited 
number of samples. Instead of applying the general two-portion absorption model, a simplified 
version may be justifiable to model voriconazole double-peak profiles. 
 
We hypothesize that the complex pharmacokinetic profiles of voriconazole with a single delayed 
wide peak or two peaks in solid organ transplant patients can be described and interpreted by 
discontinuous absorption caused by gastric retention a portion of the drug dose due to delayed 
gastric emptying and/or variable gastrointestinal motility. In order to test our hypothesis, we 
propose two specific aims: 
 
Specific aim 1 will develop a two-portion absorption model. Complex pharmacokinetic profiles 
of voriconazole will be collected from our in-house database. Each individual profile will be 
fitted using the two-portion absorption model. A population model that simultaneously fits all the 
data will also be developed. Estimated parameters will be compared with corresponding 
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physiological parameters measured in healthy population. We predict that the two-portion 
absorption model will be adequate and versatile for describing both types of complex 
voriconazole pharmacokinetic profiles with either a wide delayed peak or two peaks. There will 
be a large variability in all the parameter estimates. The lag times of the two portions will be 
significantly different. The difference between the lag times for the two portions will be similar 
as or bigger than the normal time of the gastric emptying cycle. The transfer rate constants for 
the two portions will be smaller than the normal values of the gastric emptying rate. 
 
Specific aim 2 will evaluate the superiority of the two-portion absorption model over 
conventional one- or two-compartment models with an absorption lag time. Conventional one- 
or two-compartment models with an absorption lag time will be developed to fit each individual 
profile and to simultaneously fit all the data, and their Goodness-of-Fit and adequacy will be 
compared with the two-portion absorption model. We predict that the two-portion absorption 
model will lead to a statistically significant lower objective function value (OFV) and values of 
akaike information criterion (AIC) and substantially improved Goodness-of-Fit and 
Concentration-vs-Time plots. 
 118
5.3 Methods 
 
5.3.1 Patients and Data Collection  
 
Atypical full pharmacokinetic profiles with a single delayed wide peak or two peaks were 
selected from our in-house database containing 48 patients. All patients with atypical profiles 
were chosen. All patients received voriconazole orally post transplant as part of their standard 
clinical care. All patients received no medications known to influence voriconazole 
pharmacokinetics and received tacrolimus as their primary immunosuppressive agent. Complete 
dosing record was obtained. Plasma voriconazole concentrations were measured using a 
validated HPLC method as previously described (50). 
 
5.3.2 Simplified Two-Portion Absorption Model 
 
The two-portion absorption model assumes negligible absorption from the stomach and 
discontinuous sequential absorption of the drug in two portions with the same absorption rate 
constant from the gut compartment. A fraction (F1) of the dose is transferred from the stomach 
to the gut first while the transfer of the remaining fraction (F2=1–F1) is delayed (Figure 19a). 
This delayed transfer of each portion was described by first-order processes with lag-times 
(Tlag1 and Tlag2 for each portion with Tlag1<Tlag2) and transfer rate constants (ktr1 and ktr2 
for each portion). Once transferred into the small intestine, the dose was absorbed immediately 
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without any delay, which was described by first-order processes with an absorption rate constant 
(ka). 
 
Given that voriconazole is highly lipophlic and rapidly absorbed (high ka) (63, 109, 118) while 
the gastrointestinal motility is low after transplant surgery (low ktr1 and ktr2), we assumed that 
the transfer of each portion of the drug dose from the stomach to the gut lumen is the rate 
limiting step. Under this assumption, ktr1 and ka were combined as ktra1, and ktr2 and ka were 
combined as ktra2 (Figure 19b). This simplification of the two-portion absorption model reduced 
the number of parameters to be estimated especially considering the limited number of samples 
available in this study. 
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Figure 19. Scheme of the simplified two-portion absorption model 
 
a: General two-portion absorption model. A first fraction (F1) of the dose is transferred from the stomach to the gut 
first while the transfer of the remaining fraction (F2=1–F1) is more delayed. This delayed transfer of each portion 
was described by first-order processes with transfer rate constants (ktr1 and ktr2 for each portion) and lag-times 
(Tlag1 and Tlag2 for each portion). Once transferred into the gut, the dose was absorbed immediately, which was 
described by first-order processes with an absorption rate constant (ka). 
 
b: Simplified two-portion absorption model. ktr1 and ka were combined as ktra1 and ktr2 and ka were combined as 
ktra2 (see text). Otherwise the model is exactly the same as the general two-portion absorption model. 
 
 
 
 
5.3.3 Individual Modeling 
 
One- and two-compartment models associated with the simplified two-portion absorption model 
were developed to fit each individual profile using nonlinear regression as implemented in 
NONMEM 6.2.0 (GloboMax, Hanover, MD) using ADVAN5 subroutine with the following 
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seven basic pharmacokinetic parameters: the fraction of the first portion F1, the two 
transfer/absorption rate constants ktra1 and ktra2, and the two lag-times associated with the 
transfer of each portion Tlag1 and Tlag2 and the characteristic parameters of a one-compartment 
model. The individual nonlinear regression analysis was done to serve as a comparator to the 
nonlinear mixed effects population approach as well as provide initial estimates for the models.  
This sequential process facilitated the identification of the underlying candidate structural 
models. 
 
5.3.4 Population Modeling  
 
The population approach was then applied to develop a combined population model that 
simultaneously fitted all the double-peak profiles using First-Order Conditional Estimation with 
interaction methods in NONMEM. Correlations between pharmacokinetic parameters were 
always incorporated and estimated. Various inter-individual variability structures were tested 
including: 
1. exponential model:  ijjij ePTVP
η×= )(  
2. proportional model:  )1()( ijjij PTVP η+×=  
3. additive model:   ijjij PTVP η+= )(  
4. log-additive model:  ijjij PTVLogPLog η+= ))(()(  
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where Pij is the ith individual’s estimate of the jth pharmacokinetic parameter, TV(Pj) is the 
typical value of the jth pharmacokinetic parameter, and ηij is a random variable for the ith 
individual and the jth pharmacokinetic parameter distributed with mean zero and variance of ωj2. 
Various residual variability models were tested including: 
1. additive error model:  ε+= CpredCobs  
2. proportional error model: )1( ε+×= CpredCobs  
3. combined error model: ')1( εε ++×= CpredCobs  
4. exponential error model:  εeCpredCobs ×=  
5. other error model:  θε CpredCpredCobs ×+=  
where Cobs and Cpred are the observed and predicted concentrations, respectively, and ε and ε’ 
are normal random variables with means of zero and variances of δ2 and δ’2, respectively. 
 
5.3.5 Model Evaluation 
 
The adequacy of fitting was examined by plotting predicted versus observed concentrations 
(Goodness-of-Fit), concentrations versus time and weighted residuals versus predicted 
concentrations. The simplified two-portion absorption model was compared to one- and two-
compartment model with first-order absorption and an absorption lag time to examine its 
superiority in describing the atypical profiles. The decrease in objective function values (OFV) 
was referred to the chi-squared distribution to assess significance of improvement. Akaike 
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information criterion (AIC) was calculated as OFV plus two times the number of parameters and 
compared between the models. 
 
In the population modeling process, precision of parameter estimation, stability of the final 
model and normality of the distribution of the parameter estimates was evaluated using 
bootstrapping (resampling repeated 2000 times) using Wings for NONMEM 
(http://wfn_sourceforge.net). Non-parametric statistics (median, 95% confidence interval) of 
parameter estimates obtained from bootstrapping were compared with the point parameter 
estimates obtained from the population model. The distribution of the parameter estimates 
obtained from bootstrapping was visually inspected for normality. 
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5.4 Results 
 
5.4.1 Patients and Data Collection  
 
Nine liver transplant, nine lung transplant and five small intestine transplant patients out of 48 
patients manifested atypical pharmacokinetic profiles. In each profile, nine blood samples were 
taken just prior to (0 hr) and at 0.5, 1, 1.5, 2, 4, 6, 8 and 12 hours after dosing except for 3 small 
intestine transplant patients, whose samples at 1 hour were not scheduled. Profiles with a single 
delayed wide peak were manifested in one liver transplant and one lung transplant patient 
(numbered as Liver1 and Lung1 in Table 10), while all the other patients seemed to have double-
peak profiles. 
 
5.4.2 Individual Modeling 
 
A one-compartment model associated with the simplified two-portion absorption model 
adequately described the individual profiles. In the two profiles with a single delayed wide peak, 
the estimated F1, Tlag1, Tlag2, ktra1 and ktra2 were 0, 0 hours, 5.99 hours, 1.63x1015 hr-1 and 
0.18 hr-1 for the one liver transplant patient, and 0.496, 0.0001 hours, 6.06 hours, 0.004 hr-1 and 
0.18 hr-1 for the one lung transplant patient. 
 
Table 9 summarizes individual parameter estimates of the double-peak profiles. There was large 
inter-individual variability in all the parameter estimates. The estimated Tlag1 was significantly 
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smaller than Tlag2 in all the three types of transplant populations, which confirmed the 
discontinuous absorption and suggested that the transfer of the bigger portion (F2) from the 
stomach to the gut lumen is more delayed than the smaller portion (F1). The estimated ktra1 
tended to be larger than ktra2 in all the three types of transplant, suggesting that the transfer of 
the bigger portion (F2) from the stomach to the gut lumen is slower than the smaller portion. All 
the parameter estimates were not significantly different between the three types of transplant 
populations. 
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Table 9. Summary of individual parameter estimates in patients representing voriconazole double-peak profiles using the simplified two-portion 
absorption model 
 Liver (n=8) Lung (n=8) Small Intestine (n=5) p †
F1 0.24 ± 0.20 (0.04 ~ 0.496) 0.23 ± 0.22 (0.01 ~ 0.499) 0.26 ± 0.18 (0.11 ~ 0.46) 0.9601
Tlag1 (hr) 0.31 ± 0.33 (0 ~ 0.93) 0.42 ± 0.40 (0 ~ 0.98) 0.74 ± 0.63 (0.001 ~ 1.43) 0.2564
Tlag2 (hr) 1.91 ± 1.33 (0.53 ~ 4) 3.78 ± 2.33 (0.85 ~ 7.7) 4.18 ± 3.35 (0.94 ~ 8.29) 0.1716
ktra1 (hr-1) 2.50 ± 5.32 (0.03 ~ 15.6) 2.36 ± 3.29 (0.14 ~ 8.25) 0.41 ± 0.5 (0.05 ~ 1.19) 0.5284
ktra2 (hr-1) 0.08 ± 0.06 (0.002 ~ 0.17) 0.26 ± 0.64 (0.004 ~ 1.83) 0.05 ± 0.04 (0.002 ~ 0.11) 0.5780
∆Tlag (hr) 1.29 (0.53 ~ 3.44) 3.41 (0.85 ~ 7.23) 1.36 (0.50 ~ 8.29) 0.24
p ‡ 0.0024 0.0021 0.045 
F1: the fraction of the first portion. Therefore the other portion F2=1–F1 
ktra1 and ktra2: the two transfer/absorption rate constants for each portion. 
Tlag1 and Tlag2: the two lag-times associated with the transfer of each portion. 
∆Tlag: the two-portion interval (difference between the lag times for the two portions of the oral dose). ∆Tlag=Tlag2–Tlag1. Values are displayed as median 
(range). 
†: comparison of the parameter estimates between the three types of transplant populations. P value was obtained using ANOVA. 
‡: p value that indicates whether Tlag1 is significantly larger than Tlag2 (one-tail Student t-test). 
Values are all expressed as mean ± standard deviation (range) except for ∆Tlag expressed as median (range). 
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5.4.3 Population Modeling 
 
Based on the results obtained in the individual modeling process that all the parameter estimates 
were not significantly different between the three types of transplant populations, a combined 
population model that simultaneously fitted all the double-peak profiles was developed. A one-
compartment model associated with the simplified two-portion absorption model adequately 
described all the data simultaneously. Inter-individual and residual variability was best described 
by an exponential model and a combined proportional and additive error model, respectively. 
The population estimates of F1, Tlag1, Tlag2, ktra1 and ktra2 were 0.27, 0.24 hours, 2.03 hours, 
0.15 hr-1 and 0.004 hr-1, respectively. These values were similar to that obtained during the 
individual modeling process. The large inter-individual variability agreed with that observed 
during individual modeling process. The population estimates of proportional and additive 
residual errors were 0.25 and 0.48ug/ml, respectively. 
 
5.4.4 Model Evaluation 
 
In the individual modeling process, most of the double-peak profiles were better described by the 
one-compartment model associated with the simplified two-portion absorption model compared 
to one- or two-compartment models associated with first-order absorption and an absorption lag 
time. The profiles with a single delayed wide peak were equally well described by the simplified 
two-portion absorption model and one- or two-compartment models. Compared to one- or two-
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compartment model, the simplified two-portion model led to a statistically significant lower 
objective function value (OFV, Table 10) and akaike information criterion (AIC) values in most 
of the patients (not shown) and substantially improved Goodness-of-Fit and Concentration-vs-
Time plots. Figure 20 represented typical profiles with a single delayed wide peak and two peaks 
in each type of transplant population, and showed successful prediction of the single delayed 
wide peak or the double peaks. 
 
 
 
 
Table 10. Comparison of a one-compartment model associated with the simplified two-portion absorption 
model and one- and two-compartment model associated with an absorption lag time 
 OFV Change in OFV 
Patient * 
Two-
portion 
1-CMPT 2-CMPT 
Two-potion 
vs 1-CMPT † 
Two-portion 
vs 2-CMPT ‡ 
Liver 1 ** -3.394 -3.394 -3.394 0 (p=1) 0 (p=1) 
Liver 2 -44.904 -11.177 -11.177 33.727 (p<0.000001) 33.727 (p<0.000001) 
Liver 3 -31.437 -0.747 -7.513 30.69 (p<0.000001) 23.924 (p<0.000001) 
Liver 4 -52.169 -35.527 -35.527 16.642 (p<0.0009) 16.642 (p<0.00005) 
Liver 5 -39.554 -26.001 -31.537 13.553 (p<0.0036) 8.017 (p=0.0047) 
Liver 6 -47.172 -5.778 -6.047 41.394 (p<0.000001) 41.125 (p<0.000001) 
Liver 7 -41.165 -20.563 -36.565 20.602 (p<0.0002) 4.6 (p<0.0320) 
Liver 8 -59.929 -28.415 -38.748 31.514 (p<0.000001) 21.181 (p<0.000005) 
Liver 9 -26.479 -11.746 -17.042 14.733 (p<0.0021) 9.437 (p<0.0022) 
Lung 1 ** -66.82 -62.332 -62.332 4.488 (p<0.2134) 4.488 (p<0.0342) 
Lung 2 -28.844 -9.311 -16.583 19.533 (p<0.0003) 12.261 (p<0.0005) 
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Table 10. (continued) 
 
Lung 3 -23.065 -12.565 -18.705 10.5 (p<0.0148) 4.36 (p=0.0368) 
Lung 4 -41.583 -22.454 -37.376 19.129 (p<0.0003) 4.207 (p<0.0403) 
Lung 5 -34.369 19.489 11.97 53.858 (p<0.000001) 46.339 (p<0.000001) 
Lung 6 -21.634 -17.143 -17.483 4.491 (p<0.2131) 4.151 (p<0.0417) 
Lung 7 -32.414 -14.413 -16.292 18.001 (p<0.0005) 16.122 (p<0.0001) 
Lung 8 -30.859 -13.508 -13.508 17.351 (p<0.0006) 17.351 (p<0.00005) 
Lung 9 -26.048 -15.655 -22.388 10.393 (p<0.0156) 3.66 (p<0.0558) 
SI 1 -35.472 -9.394 -14.696 26.078 (p<0.00001) 20.776 (p<0.00001) 
SI 2 -22.612 -8.384 -14.727 14.228 (p<0.0027) 7.885 (p<0.005) 
SI 3 -20.841 -11.113 -15.197 9.728 (p<0.0211) 5.644 (p<0.0176) 
SI 4 -16.939 -9.353 -5.314 7.586 (p<0.0554) 11.625 (p<0.0007) 
SI 5 -19.049 -8.844 -8.844 10.205 (p<0.0170) 10.205 (p<0.0014) 
POP § -68.792 -41.427 -55.019 27.365 (p<0.000005) 13.773 (p<0.0002) 
OFV: minimum objective function value  
Two-portion: one-compartment model associated with the simplified two-portion absorption model 
1-CMPT: one-compartment model associated with first-order absorption and an absorption lag time 
2-CMPT: two-compartment model associated with first-order absorption and an absorption lag time 
*: patient was numbered with the type of transplant. Liver: liver transplant. Lung: lung transplant. SI: small intestine 
transplant. 
**: these patients manifested profiles with a single delayed wide peak. All the other patients had double-peak 
profiles. 
†: portiontwocmpt OFVOFV −− −1 . The change in OFV was referred to chi-square distribution for 3 degrees of 
freedom to calculate p value since the simplified two-portion absorption model had seven parameters while the one-
compartment model had four. 
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‡: portiontwocmpt OFVOFV −− −2 . The change in OFV was referred to chi-square distribution for 1 degree of 
freedom to calculate p value since the simplified two-portion absorption model had seven parameters while the two-
compartment model had six. 
§: population model that simultaneously fits all the data 
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Figure 20. Typical posterior individual fittings 
 
The curves represent the individual predictions in the individual modeling process (see text). The points represent observed concentrations. 
 
a: Typical posterior individual fitting in a patient representing a profile with a single delayed wide peak 
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b: Typical posterior individual fitting in a liver transplant patient with a double-peak profile 
 
c: Typical posterior individual fitting in a lung transplant patient with a double-peak profile 
 
d: Typical posterior individual fitting in a small intestine transplant patient with a double-peak profile 
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In the population modeling process, a good correlation was observed between the individual 
predictions and the observations (R2=0.98) using the simplified two-portion absorption model 
(Figure 21). LOWESS smoother showed no apparent bias. Weighted residuals were 
approximately normally distributed and were mostly within about 3 units of the null ordinate. 
The simplified two-portion absorption model yielded an OFV of -68.792, which was 
significantly lower than the OFV yielded using a one-compartment model (-41.427, p<0.000005) 
or two-compartment model (-55.019, p<0.0002) associated with first-order absorption and an 
absorption lag time (Table 10). The AIC obtained using the simplified two-portion absorption 
model (-52.792) was substantially lower than those obtained using a one-compartment model (-
31.427) or two-compartment model (-31.019) associated with first-order absorption and an 
absorption lag time. 
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Figure 21. Goodness-of-Fit of individual predictions in population modeling process using the simplified two-
portion absorption model 
 
Individual predictions (hollow circle) agreed well with observations (R2=0.98) without obvious bias indicated by the 
LOWESS smoother. 
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All these evaluations in the individual and population modeling process showed adequacy of the 
simplified two-portion absorption model in fitting voriconazole atypical profiles and confirmed 
the superiority of the two-portion absorption model over the other two models in describing 
voriconazole double-peak profiles. 
 
In the bootstrapping analysis for the simplified two-portion absorption model, 916 runs 
successfully converged and were incorporated into the non-parametric analysis. The point 
population estimates of all parameters were similar to the median values obtained from 
bootstrapping and fell within the 95% confident intervals. The distribution of the parameter 
estimates obtained from the bootstrapping appeared to be normally distributed. 
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5.5 Discussion 
 
This study is the first report on atypical profiles with a single delayed wide peak or a secondary 
peak following oral voriconazole administration in solid organ transplant patients (liver, lung and 
small intestine), although double-peak phenomenon has been reported and investigated with a 
number of orally administered drugs, such as cimetidine (60, 71-73, 76), ranitidine (72, 73, 107, 
115, 140), cyclosporine (32, 104), alprazolam (133), talinolol (136), phenazopyridine (110), 
veralipride (91), valproate (7), celiprolol (65), furosemide (58), piroxicam (92, 128, 142), 
flurbiprofen (22), famotidine (59), furosemide (37), piretanide (8), danazol (11), acebutolol (90) 
and cephalosporins (9, 41). 
 
The simplified two-portion absorption model developed in this study seemed to be versatile for 
describing both types of atypical voriconazole pharmacokinetic profiles with either a wide 
delayed peak or a secondary peak, confirming the usefulness of this model to describe atypical 
profiles of orally administered drugs especially double-peak profiles. 
 
The underlying physiological mechanism for the two-portion absorption model is the cyclical 
and periodical nature of gastric emptying and gastrointestinal motility in the fasted state (76). 
During fasting, the upper gastrointestinal tract is cleared periodically following a cyclic pattern 
called migrating motility complex (MMC) (127, 138). The pattern is characterized by four 
phases. Phase I is a quiescent period (absence of motor activity) and lasts for 20–90 minutes. 
Phase II is an intermittent and irregular contraction process and lasts for 10–135 minutes. Then 
the strength of the contractions gradually increases, resulting in a short period of intense 
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contractions called Phase III, which is the activity phase and lasts for about 15 minutes in the 
stomach and 6 minutes in the duodenum. Then the intensity and frequency of contractions 
decreased (i.e. Phase IV), which is a transitional period from Phase III to the next Phase I, but 
Phase IV was only found occasionally. Gastric emptying is mainly associated with the active 
phase of MMC (Phase III).  
 
The situation described by the two-portion absorption model happens when the drug dose is 
partially emptied in one MMC with the remainder being emptied in another MMC. In this case, 
the two-portion interval (difference between the lag times for the two portions of the oral dose, 
∆Tlag=Tlag2–Tlag1) should be similar to MMC periodicity (interval between Phase III activity 
fronts in two successive MMC cycles ranging from 1.3–2.5 hours (21, 29, 30, 47, 57, 127)).  
 
In the double-peak profiles in this study, the two-portion interval (∆Tlag=Tlag2–Tlag1) ranged 
from 0.5–8.29 hours. The small intestine transplant patients had the largest range (0.5–8.29 
hours). This range was substantially larger than the range of MMC periodicity in healthy subjects 
(1.3–2.5 hours), suggesting more variable gastric emptying and gastrointestinal motility in solid 
organ transplant patients, especially in small intestine transplant patients. In the patients with 
moderate ∆Tlag within the range of healthy subjects (1.3–2.5 hours) in this study, the two 
portions of the dose may be transferred during two consecutive MMC cycles. In the patients with 
small ∆Tlag of less than 1.3 hours in this study, the two portions of the dose may be transferred 
within one MMC cycle instead of over two consecutive MMC cycles in these subjects. One 
portion might be emptied in phase I or phase II with the remainder being emptied in phase III. 
There may be two explanations for the patients with large ∆Tlag of greater than 2.5 hours. The 
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two portions of the dose could be transferred either during two inconsecutive MMC cycles, or 
during two consecutive MMC cycles that could be substantially longer in solid organ transplant 
patients than healthy subjects. 
 
In healthy subjects, the transfer rate constants from the stomach to the gut lumen (ktr1 and ktr2) 
should be similar to the gastric emptying rate even in the situation of discontinuous absorption 
(140). Gastric emptying of non-nutrient liquids is approximately a first-order process (29, 57) 
although it is variable (13) and may depend on volume. The half-life of liquids during gastric 
emptying is 9–40 minutes (3, 43) depending on volume (43, 70). Therefore the gastric emptying 
rate should be approximately 1.04–4.62 hr-1 in healthy subjects. 
 
In this study, the transfer/absorption rate constants ktra1 and ktra2 should be approximately 
equal to the gastric emptying rate in those patients since the gastric emptying is the rate limiting 
step as previously discussed. The values of ktra1 and ktra2 estimated in this study were basically 
smaller than the gastric emptying rate in healthy subjects (1.04–4.62 hr–). ktra1 was within this 
range only in 1 subject while ktra2 was within this range only in 4 subjects. This suggested 
decreased/variable gastric emptying and gastrointestinal motility in solid organ transplant 
patients as the cause the double-peak profiles. 
 
The five parameters in the two-portion absorption model (F1, Tlag1, Tlag2, ktra1 and ktra2) 
have different impact on the maximum concentration of each peak, appearance of the secondary 
peak and the degree of separation between the two peaks, which has been discussed in details by 
Yin et al. (140). 
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Based on the underlying physiological mechanism of the two-portion absorption model and the 
discussion above, atypical profiles of voriconazole are more likely to be observed in the early 
post-transplant period after transplant surgery since recovery of gastrointestinal function takes 
place gradually with time after transplant. In this study, the post-operative time (POT) ranged 
from 1.5 to 5 days with a median POT of 2 days in the liver transplant patients, ranged from 3 to 
18.75 days with a median POT of 7 days in lung transplant patients, and ranged from 12 to 1279 
days with a median POT of 91 days in small intestine transplant patients. This suggested that the 
frequency of atypical profiles is high in the first two weeks after transplant surgery in liver and 
lung transplant patients, but they can be observed in both early and late post-transplant periods in 
small intestine transplant patients. However, profiles from the late post-transplant period greater 
than 19 days were not available in liver and lung transplant patients in this study. Therefore the 
association between POT and the frequency of voriconazole atypical profiles should be further 
investigated. 
 
In addition to the physiological changes of gastrointestinal function in transplant patients, the 
physical properties of voriconazole could also contribute to the discontinuous absorption. The 
active substance, voriconazole, (2R,3S)-2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-
(1,2,4-triazol-1-yl)butan-2-ol (formerly known as UK-109496), is a weak base and classified as a 
low solubility, high permeability compound (25) (Class II in the Biopharmaceutical 
Classification System) with a predicted water solubility of only 98ug/ml (23). All the patients in 
this study took voriconazole tablets, which could be incompletely dissolved. The discontinuous 
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dissolution of the ingested dose could also contribute to the discontinuous absorption as liquids 
and solids have different kinetics through the gastrointestinal tract. 
 
In conclusion, the atypical profiles with a single delayed wide peak or two peaks and abnormal 
absorption of orally administered voriconazole in liver, lung and small intestine transplant 
patients were probably caused by impaired and variable gastrointestinal motility that is common 
in the early post-transplant period. These profiles were reliably described using a simplified two-
portion absorption model. Approximately 27% of the available dose seemed to be rapidly 
absorbed shortly after dosing with the remainder being slowly absorbed. Since appropriate 
pharmacokinetic models are necessary to provide physicians with convenient limited sampling 
strategies to estimate voriconazole exposure, the model developed in this study for voriconazole 
could be useful to improve estimation of voriconazole exposure and therefore contribute to 
development of limited sampling strategies in liver, lung and small intestine transplant patients. 
Future studies with a large sample size are warranted to validate the model and make the model 
clinically applicable. 
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Chapter VI Pharmacokinetics of Voriconazole in Pediatric Bone Marrow Transplant 
Patients 
 
6.1 Abstract 
 
Objectives: To characterize the pharmacokinetics of voriconazole in pediatric bone marrow 
transplant patients during pre-operative and early post-operative period and identify patient 
factors significantly associated with various pharmacokinetic parameters. 
 
Methods: Pediatric bone marrow transplant patients who received voriconazole before and 
immediately after transplant for prophylaxis were recruited. The pre-transplant dosing regimen 
consisted of oral dose only. The post-transplant dosing regimen consisted of intravenous 
infusions followed by oral dose. The initial dose was 6mg/kg twice daily and was adjusted based 
on therapeutic drug monitoring. Blood samples (n=8/interval) were collected during one pre-
transplant oral dosing interval, one post-transplant intravenous dosing interval and one post-
transplant oral dosing interval from each patient. Voriconazole plasma concentrations were 
measured by HPLC. NONMEM was used to develop pharmacokinetic models. 
 
Results: Eleven pediatric bone marrow transplant patients were recruited. A two-compartment 
model adequately described the data. There was a good correlation (R2=0.94) between AUCo-∞ 
and trough concentrations. Population estimates of bioavailability, clearance, Vc and Vp were 
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46.5%, 5.76L/hr, 19.4L and 58.8L. Clearance significantly decreased with increased indices of 
liver function tests. Volume of distribution significantly increased with body weight. 
Bioavailability significantly decreased with decreased indices of liver function tests. 
Bioavailability of voriconazole is similar between lung transplant and pediatric bone marrow 
transplant patients. Compared to liver transplant and lung transplant patients, pediatric bone 
marrow transplant patients had significantly higher apparent oral clearance and significantly 
lower volume of distribution. 
 
Conclusions: Bioavailability of voriconazole is significantly lower in pediatric bone marrow 
transplant patients than non-transplant adult subjects. Incorporation of patient variables 
associated with the pharmacokinetics of voriconazole may assist in optimizing the dosage 
regimen of voriconazole in pediatric bone marrow transplant patients. Voriconazole levels 
should be monitored and the dose can be individualized based on trough concentrations as a 
good measure of drug exposure. 
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6.2 Introduction 
 
Due to neutropenia, graft-versus host disease and chronic immunosuppression, infections are 
common life-threatening complications in bone marrow transplant (BMT) patients [14]. In 
particular invasive fungal infections [15-17], such as invasive aspergillosis can be life 
threatening [18]. As part of standard clinical care, voriconazole is administered to BMT patients 
orally for several weeks prior to the transplantation, intravenously for several weeks after the 
transplantation, and then orally for several months for prophylactic purpose at our institution. 
This provides an opportunity for studying the bioavailability of voriconazole and the impact of 
transplantation on the pharmacokinetics of voriconazole in BMT patients. 
 
We hypothesize that use of a weight-adjusted or fixed dosing regimen of voriconazole will lead 
to a large degree of variability in drug exposure among BMT patients due to variability in 
absorption and elimination caused by physiological characteristics unique to BMT patients. In 
order to test our hypothesis, we propose three specific aims: 
 
Specific aim 1 will characterize the pharmacokinetics of voriconazole, evaluate the variability in 
the pharmacokinetics of voriconazole and compare the pharmacokinetics of voriconazole of 
pediatric BMT patients with non-transplant adult subjects. Voriconazole plasma concentrations 
was measured in 11 BMT patients following administration of one oral dose prior to the 
transplantation, and one intravenous dose and one oral dose after transplantation. Non-
compartmental pharmacokinetic analysis and nonlinear mixed-effects modeling analysis was 
performed to estimate the pharmacokinetic parameters, and to capture both inter-patient and 
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intra-patient variability in the pharmacokinetic parameter estimates. We predict that the 
pharmacokinetic parameters estimated in BMT patients will be different from non-transplant 
adult subjects, especially the bioavailability will be lower and there will be a large variability in 
the pharmacokinetic parameter estimates. 
 
Specific aim 2 will evaluate the association of patient variables with the pharmacokinetics of 
voriconazole in BMT patients. Patient-specific demographic variables, liver and renal function 
tests and blood counts will be collected from each patient, and their association with the 
pharmacokinetic parameters of voriconazole will be evaluated as a covariate in population 
pharmacokinetic analysis. We predict that low clearance or CL/F will be associated with poor 
liver function, and volume of distribution will be associated with body weight.  
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6.3 Methods 
 
6.3.1 Patients 
 
The protocol was approved by IRB at the University of Pittsburgh. Pediatric bone marrow 
transplant recipients who were initiated on a voriconazole prophylactic regimen several weeks 
prior to the transplantation and immediately post transplant as part of their standard clinical care 
and who signed informed consent were enrolled in this prospective study. The pre-transplant 
dosing regimen consisted of oral dose only. The post-transplant dosing regimen consisted of 
intravenous infusions followed by oral dose for several months. The initial dose was 6mg/kg 
twice daily and adjusted based on therapeutic drug monitoring. The exclusion criteria were co-
administration of medications known to influence voriconazole pharmacokinetics or 
administration of voriconazole to treat an active fungal infection. Complete dosing history, 
demographic data, laboratory tests and current medication use were recorded. All patients 
received tacrolimus or cyclosporine as their primary immunosuppressive agent. 
 
6.3.2 Blood Sampling and Analytical Assay 
 
Serial blood samples (1.2ml) were collected from each patient just prior to (0 hr) and at 0.5, 1, 
1.5, 2, 4, 6 and 12 hours after the dose of voriconazole on three separate phases (Figure 22 and 
Table 11). The first phase was performed approximately within a month pre transplant. The 
second phase was anticipated within the first few days after transplant when the subject appears 
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to be clinically stable and is on intravenous voriconazole. The third phase was anticipated to be 
within a few days after the second phase, when the patient is on oral therapy. Blood samples 
were processed and analyzed for voriconazole plasma concentration using a validated HPLC 
method previously described (51). The assay precision (intraday variability) was 1.3% to 9.0% 
(0.2 – 9 ug/ml), and the assay bias (interday variability) was 0.7% to 3.1% (0.5 – 9 ug/ml). The 
linearity range was 0.2 – 9 ug/ml (R2 = 0.9998). 
 
 
 
 
 
 
Figure 22. Study design and sampling scheme of the pharmacokinetic study of voriconazole in pediatric bone 
marrow transplant patients 
 
VOR: voriconazole, IV: intravenous, PO: oral, PK: pharmacokinetic 
 
Phase 1 
Full PK 
profile 1 
PO VOR 
prophylaxis 
IV VOR 
prophylaxis 
PO VOR prophylaxis 
Routine therapeutic monitoring 
Several weeks A few days Months to years 
Bone Marrow 
Transplant 
Phase 2 
Full PK 
profile 2 
Phase 3 
Full PK 
profile 3 
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Table 11. Study design and sampling scheme of the pharmacokinetic study of voriconazole in pediatric bone 
marrow transplant patients 
 Phase 1 Phase 2 Phase 3 
Route Intravenous Intravenous Oral 
Before/after 
transplant 
Before transplant After transplant 
Ideal time 
After several doses, 
or as late as 
possible 
As late as possible 
during the intravenous 
dosing period 
As soon as possible after 
change from intravenous 
dosing to oral dosing 
Justification of 
the ideal time 
To make sure the 
steady state is 
reached 
To minimize confounding between occasion 2 and 3 so 
that bioavailability can be adequately calculated 
Blood sampling 
8 samples (total 9.6 
ml blood) 
8 samples (total 9.6 ml 
blood) 
8 samples (total 9.6 ml 
blood) 
 
 
 
 
6.3.3 Non-compartmental Pharmacokinetic Analysis 
 
The difference between trough concentrations prior to dosing (Co) and at 12 hours after dosing 
(C12) was tested using paired two-tailed Student t-test to confirm attainment of steady state in 
 148
each phase. Time to peak concentration (Tmax) and peak plasma concentrations (Cmax) were 
directly read off the concentration-vs-time profiles. Various pharmacokinetic parameters were 
calculated using non-compartmental analysis with WinNonlin software (version 4.1; Pharsight 
Corporation, Mountainview, CA). The parameters calculated included terminal disposition rate 
constant (λz), terminal disposition halflife (t1/2), area under the plasma concentration-vs-time 
curve (AUC), apparent systemic clearance over bioavailability (CL/F), apparent steady state 
volume of distribution over bioavailability (Vd/F), and time to reach peak concentration (Tmax). 
λz and t1/2 were derived from data points during the terminal disposition phase only when at 
least three data points were available, and the AUCo-∞ specific for the dose evaluated was 
calculated using trapezoid rule and reverse superposition principle. Projected trough 
voriconazole plasma concentrations (Clast) was used if the first plasma concentration at 0 hours 
(Co) were not taken within 5 minutes before dosing or the last plasma concentration at 12 hours 
(Clast) were not taken at exactly 12 hours. Each of these parameters is presented as mean and 
standard deviation. Statistical comparison of different parameters was made using paired two-
tailed Student t-test (SPSS software, Windows-based version 14.0, Chicago, IL). A P value of 
<0.05 was considered statistically significant. 
 
6.3.4 Population Pharmacokinetic Analysis 
 
A nonlinear mixed-effects pharmacokinetic model (base model) was developed using NONMEM 
7.1.0 (GloboMax, Hanover, MD) using first order conditional estimation method with interaction. 
Correlations between pharmacokinetic parameters were always incorporated and estimated. One- 
and two-compartment models were tested with first/zero-order elimination and Michaelis-
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Menten elimination process since nonlinear pharmacokinetics of voriconazole has been reported 
(88, 89). Inter-individual variability was described using exponential model ijjij ePTVP
η×= )( , 
where Pij is the ith individual’s estimate of the jth pharmacokinetic parameter, TV(Pj) is the 
typical value of the jth pharmacokinetic parameter, and ηij is a random variable for the ith 
individual and the jth pharmacokinetic parameter distributed with mean zero and variance of ωj2. 
Residual variability was described using combined error model ')1( εε ++×= CpredCobs , 
where Cobs and Cpred are the observed and predicted concentrations, respectively, and ε and ε’ 
are normal random variables with means of zero and variances of σ2 and σ’2, respectively. The 
adequacy of fitting was examined by plotting predicted versus observed concentrations 
(Goodness-of-Fit), concentrations versus time profiles and weighted residuals versus predicted 
concentrations. 
 
6.3.5 Covariate Relationship Exploration 
 
Association between patient variables and pharmacokinetic parameters were first visually 
evaluated by plotting Empirical Bayes Estimates (EBE) against patient variables. Patient 
variables were then incorporated into the base model one at a time using at least 13 approaches 
to associate the patient variable with the parameter. A patient variable was considered as 
significant if all the following criteria were met: (1) a decrease in objective function value (OFV) 
of 6.63 for 1 degree of freedom (p<0.01), (2) no significant trend in EBE-vs-patient variables 
plots, (3) improved Goodness-of-Fit, (4) reduced inter-individual variability and (5) clinical 
plausibility for incorporating the patient variable. 
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6.4 Results 
 
6.4.1 Patients 
 
A total of 11 patients were enrolled in this study. Table 12 summarizes the characteristics of the 
patients including age, gender and days post-transplant on the day of the study in each phase. 
Table 13 summarizes the conditioning regimens of the patients. Three patients did not complete 
the phase 2 intravenous study, and two patients did not complete the phase 3 oral study. Graft-
versus-host was diagnosed in three patients. Figure 23 (a – r) summarizes the characteristics of 
the patients over the period of time from the initiation of voriconazole administration until the 
time of discharge. These characteristics included body weight, laboratory biochemical profiles 
and voriconazole dose. The dash lines in the figures represent the normal range of these indices. 
A large degree of inter-individual and intra-individual variability was observed in these 
characteristics of the patients. Most of these characteristics of the patients varied substantially 
over time and were out of normal range. 
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Table 12. Characteristics of patients in the pharmacokinetic study of bone marrow transplant patients 
Patient 
ID 
Age Gender 
Phase 1  
Oral 
Pre-transplant 
Phase 2  
Intravenous 
Post-transplant 
Phase 3 
Oral 
Post-transplant 
#1 16 Female -3 10  
#2 5 Female -4 8 41 
#3 22 Male -5  110 
#4 5 Female -6  43 
#5 2 Female -8 16 104 
#6 3 Male -7 *  68 
#7 0.6 Female -1 22 33 
#8 15 Female -7 7 83 
#9 7 Male -10 10 72 
#10 16 Female -1 6 31 
#11 1.9 Male -7 19 53 
Mean 8.5  -5.4 12.3 63.8 
SD 7.4  2.9 6.0 28.5 
Median 5.0  -6.0 10.0 60.5 
CV 86.6%  53.6% 48.7% 44.6% 
Min 0.6  -10 6 31 
Max 22  -1 22 110 
* Voriconazole was administrated intravenously (clinical decision). 
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Table 13.  Conditioning regimens of patients in the pharmacokinetic study of bone marrow transplant 
patients 
Patient 
ID 
Drug / Irradiation 
Days before 
Transplant 
Dose Frequency Total Dose
ATGAM 4 15 mg/kg/dose q12h x 6 doses 3600 mg 
Cyclophosphamide 5 50 mg/kg/dose once a day x 4 8000 mg 1 
Busulfex 9 0.8 mg/kg/dose q6h x 4 days 572 mg 
TBI 3 1.8 Gy/fraction 7 fraction over 4 days 12.6 Gy 
2 
Cyclophosphamide 5 60 mg/kg/dose once a day x 2 2040 mg 
ATGAM 4 15 mg/kg/dose q12h x 6 doses 6750 mg 
TBI 4 1.8 Gy/fraction 7 fraction over 4 days 12.6 Gy 3 
Cyclophosphamide 6 60 mg/kg/dose once a day x 2 9000 mg 
Cyclophosphamide 5 50mg/kg/dose daily for 4 days 3660 mg 
4 
Busulfex 9 1.1mg/kg/dose q6h x 4 days 280 mg 
ATGAM 4 15mg/kg/dose q12h x 6 doses 1140 mg 
Cyclophosphamide 5 50mg/kg/dose daily for 4 days 2500 mg 
Busulfex 9 1.1mg/kg/dose q6h x 4 days 210 mg 
5 
ATGAM 32 15mg/kg/dose q12h x 6 doses 1650 mg 
Cyclophosphamide 5 50mg/kg/dose daily for 4 days 2920 mg 
6 
Busulfex 9 0.8mg/kg/dose q6h x 4 days 207 mg 
Melphalan 2 140mg/m2 once 50 mg 
Fludarabine 7 1mg/kg/dose daily for 5 days 35 mg 7 
Alemtuzumab 8 0.2mg/kg/dose daily for 5 days 7.5 mg 
TBI 4 1.8 Gy/fraction 7 fraction over 4 days 12.6 Gy 
8 
Cyclophosphamide 7 60mg/kg/dose once a day x 2 7200 mg 
9 Cyclophosphamide 8 50mg/kg/dose daily for 4 days 4980 mg 
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Table 13. (continured) 
 
 Busulfex 12 1.1mg/kg/dose q6h x 4 days 420 mg 
TBI 4 1.8 Gy/fraction 7 fraction over 4 days 12.6 Gy 
10 
Cyclophosphamide 27 60mg/kg/dose once a day x 2 7850 mg 
ATGAM 4 15mg/kg/dose q12h x 6 doses 1200 mg 
Cyclophosphamide 5 50 mg/kg/dose daily for 4 days 2740 mg 11 
Busulfex 9 1.1mg/kg/dose q6h x 4 days 194 mg 
 TBI: total body irradiation 
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Figure 23. Characteristics of patients in the pharmacokinetic study of bone marrow transplant patients 
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Figure 23. (continued) 
c) Body Mass Index (kg/m2) 
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d) Serum Creatinine (mg/dL) 
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Figure 23. (continued) 
e) Albumin (g/dL) 
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f) Total Bilirubin (mg/dL) 
0
1
2
3
4
5
-20 0 20 40 60 80 100 120 140
Days Post-Transplant
To
ta
l B
ili
ru
bi
n 
(m
g/
dL
)
 
 
 157
Figure 23. (continued) 
g) Alanine aminotransferase / ALT / SGPT (IU/L) 
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h) Aspartate aminotransferase AST / SGOT (IU/L) 
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Figure 23. (continued) 
i) Alkaline Phosphatase / ALP (IU/L) 
0
100
200
300
400
500
-20 0 20 40 60 80 100 120 140
Days Post-Transplant
A
lk
al
in
e 
P
ho
sp
ha
ta
se
 / 
A
LP
 (I
U
/L
)
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Figure 23. (continued) 
k) Mycophenolic acid plasma concentration (mg/ml) 
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l) White blood cell count / WBC (X10E+09/L) 
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Figure 23. (continued) 
m) Red blood cell count / RBC (X10E+12/L) 
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Figure 23. (continued) 
o) Hematocrit / HCT 
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Figure 23. (continued) 
q) Cyclosporine whole blood concentration (ng/ml) 
0
500
1000
1500
2000
2500
-20 0 20 40 60 80 100 120 140
Days Post-Transplant
C
yc
lo
sp
or
in
e 
(n
g/
m
l)
 
 
r) Voriconazole Dose (mg) 
0
50
100
150
200
250
300
350
400
450
-20 0 20 40 60 80 100 120 140
Days Post-Transplant
V
or
ic
on
az
ol
e 
D
os
e 
(m
g)
 
  
 163
 
Figure 24 illustrated the time post-transplant when each pharmacokinetic profile was collected 
and the range of the voriconazole plasma concentrations of each profile. Figure 25 and 26 
summarized individual pharmacokinetic profiles in each study phase. There was a wide variation 
in voriconazole plasma concentrations. Among the total of 228 blood samples collected, less 
than half of the voriconazole plasma concentrations (45.4%) were maintained within 1-6ug/ml. 
Underexposure appeared to be predominant with 46.2% and 8.4% of voriconazole plasma 
concentrations below 1ug/ml or above 6ug/ml, respectively. This percentage was similar to the 
preliminary data as mentioned previously. 
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Figure 24. Collection time (post-transplant) and the range of the voriconazole plasma concentrations of each 
pharmacokinetic profile in the pharmacokinetic study of voriconazole in pediatric bone marrow transplant 
patients 
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Figure 25. Individual pharmacokinetic profiles of voriconazole in the pharmacokinetic study of voriconazole 
in pediatric bone marrow transplant patients 
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Figure 26. Individual dose-normalized pharmacokinetic profiles of voriconazole in the pharmacokinetic study 
of voriconazole in pediatric bone marrow transplant patients 
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6.4.2 Non-compartmental analysis 
 
Figure 27 illustrated that the trough concentrations Co and C12 were not significantly different in 
phase 1 (p= 0.2161), phase 2 (p=0.0867) or phase 3 (p=0.6087), indicating that steady state had 
been reached in most of the patients at the time of study in each phase. 
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Figure 27. Comparison of trough concentrations in pharmacokinetic study of voriconazole in pediatric bone 
marrow transplant patients 
Hollow circle: individual levels. Bold bar: average levels. 
 
 169
 
Figure 28 illustrates a good correlation between voriconazole trough plasma concentrations and 
the corresponding AUCo-∞ at steady state (R2=0.94). 
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Figure 28. Correlation of AUCo-∞ with voriconazole trough plasma concentrations in pediatric bone marrow 
transplant patients 
 
Left figure: correlation of AUCo-∞ with voriconazole trough plasma concentrations in pediatric bone marrow 
transplant patients with all data points. 
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Right figure: Correlation of AUCo-∞ with voriconazole trough plasma concentrations in pediatric bone marrow 
transplant patients with the point of the highest concentration omitted. 
 
 
 
 
 
 
 
 
 
The pharmacokinetic parameters of voriconazole estimated using non-compartmental analysis 
are shown in Table 14 – 22. There was a wide variation in various pharmacokinetic parameters 
of voriconazole in pediatric bone marrow transplant patients after oral and intravenous 
voriconazole administration. 
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Table 14. Dose of voriconazole (mg) in pediatric bone marrow transplant patients 
Patient ID 
Phase 1 
Oral, Pre-transplant
Phase 2 
Intravenous, Post-transplant
Phase 3 
Oral, Post-transplant
#1 200 150  
#2 120 120 140 
#3 200  200 
#4 130  140 
#5 90 150 60 
#6  100 * 100 
#7 50 80 80 
#8 200 375 300 
#9 175 275 250 
#10 200 250 200 
#11 100 125  
Mean 146.50 180.56 163.33 
SD 55.68 97.96 80.31 
Median 152.5 150 140 
CV 38.0% 54.3% 49.2% 
Max 200 375 300 
Min 50 80 60 
* Voriconazole was administrated prior to the transplant (clinical decision). 
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Table 15. Tmax (hour) of voriconazole in pediatric bone marrow transplant patients 
Patient ID 
Phase 1 
Oral, Pre-transplant
Phase 2 
Intravenous, Post-transplant
Phase 3 
Oral, Post-transplant
#1 4.0 1.0  
#2 0.5 1.0 1.1 
#3 1.1   
#4 0.6  1.0 
#5 1.6 1.0 2.0 
#6  0.9 * 1.1 
#7 0.5 2.0 1.0 
#8 1.0 1.5 2 
#9 0.5 1.0 0.5 
#10 2.0 1.0 4.0 
#11 1.5 3.5  
Mean 1.3 1.4 1.6 
SD 1.1 0.9 1.1 
Median 1.04 1.03 1.11 
CV 81.1% 59.1% 69.3% 
Max 4.0 3.5 4.0 
Min 0.5 0.9 0.5 
* Voriconazole was administrated prior to the transplant (clinical decision). 
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Table 16. Cmax (ug/ml) of voriconazole in pediatric bone marrow transplant patients 
Patient ID 
Phase 1 
Oral, Pre-transplant
Phase 2 
Intravenous, Post-transplant
Phase 3 
Oral, Post-transplant
#1 4.96 8.81  
#2 1.42 9.99 2.22 
#3 0.78   
#4 4.83  4.66 
#5 1.23 8.44 0.67 
#6  5.01 * 6.17 
#7 1.11 4.09 5.5 
#8 1.19 8.57 2.99 
#9 2.17 7.12 8.52 
#10 1.61 15.4 1.87 
#11 1.94 2.94  
Mean 2.12 7.82 4.08 
SD 1.52 3.71 2.61 
Median 1.52 8.44 3.83 
CV 71.3% 47.5% 64.0% 
Max 4.96 15.40 8.52 
Min 0.78 2.94 0.67 
* Voriconazole was administrated prior to the transplant (clinical decision). 
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Table 17. Dose normalized AUC (ug*hr/ml) and bioavailability of voriconazole in pediatric bone marrow 
transplant patients 
Patient ID 
Phase 1 
Oral, Pre-transplant 
Phase 2 
Intravenous, Post-transplant
Phase 3 
Oral, Post-transplant 
Bioavailability
#1 0.184 0.122   
#2 0.025 0.226 0.130 58% 
#3 0.013    
#4 0.139  0.165  
#5 0.098 0.099 0.039 39% 
#6  0.371 * 0.241  
#7 0.044 0.153 0.176 115% 
#8 0.046 0.073 0.051 70% 
#9 0.046 0.131 0.043 33% 
#10 0.029 0.140 0.042 30% 
#11 0.103 0.070   
Mean 0.073 0.154 0.111 58% 
SD 0.056 0.094 0.078 32% 
Median 0.05 0.13 0.09 48% 
CV 77.0% 61.0% 70.2% 55.9% 
Max 0.184 0.371 0.241 115% 
Min 0.013 0.070 0.039 30% 
* Voriconazole was administrated prior to the transplant (clinical decision). 
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Table 18. Half life (hour) of voriconazole in pediatric bone marrow transplant patients 
Patient ID 
Phase 1 
Oral, Pre-transplant
Phase 2 
Intravenous, Post-transplant
Phase 3 
Oral, Post-transplant
#1 8.87 5.06  
#2 1.45 3.42 6.99 
#3 2.70   
#4 3.32  3.73 
#5 3.51 1.26 1.52 
#6  5.45 * 5.01 
#7 1.53 3.87 1.96 
#8 7.17 4.07 3.33 
#9 2.58 1.77 4.15 
#10 7.63 4.91 3.50 
#11 1.99 2.64  
Mean 4.07 3.61 3.77 
SD 2.75 1.47 1.72 
Median 3.01 3.87 3.61 
CV 67.4% 40.9% 45.5% 
Max 8.87 5.45 6.99 
Min 1.45 1.26 1.52 
P ** 0.0539 0.0011 0.008 
* Voriconazole was administrated prior to the transplant (clinical decision). 
** P: the significance of comparison between the half life of voriconazole in pediatric bone marrow transplant 
patients and that in healthy subjects (6 hours) using two-tailed t-test. 
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Table 19. Clearance (L/hr) of voriconazole in pediatric bone marrow transplant patients 
Patient ID 
Phase 1 
Oral, Pre-transplant
Phase 2 
Intravenous, Post-transplant
Phase 3 
Oral, Post-transplant
#1 5.42 8.17  
#2 40.21 4.43 7.68 
#3 74.53   
#4 7.19  6.07 
#5 10.24 10.10 25.79 
#6  2.70 * 4.15 
#7 22.50 6.55 5.67 
#8 21.57 13.74 19.61 
#9 21.96 7.64 23.03 
#10 33.92 7.13 23.57 
#11 9.70 14.22  
Mean 24.72 8.30 14.45 
SD 20.93 3.86 9.34 
Median 21.76 7.64 13.64 
CV 84.7% 46.5% 64.7% 
Max 74.53 14.22 25.79 
Min 5.42 2.70 4.15 
* Voriconazole was administrated prior to the transplant (clinical decision). 
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Table 20. Clearance normalized to body weight (L/kg) of voriconazole in pediatric bone marrow transplant 
patients 
Patient ID 
Phase 1 
Oral, Pre-transplant
Phase 2 
Intravenous, Post-transplant
Phase 3 
Oral, Post-transplant
#1 0.14 0.20  
#2 2.47 0.28 0.44 
#3 0.90   
#4 0.40  0.34 
#5 0.83 0.82 2.15 
#6  0.18 * 0.30 
#7 3.05 0.86 0.77 
#8 0.35 0.22 0.30 
#9 0.87 0.32 0.82 
#10 0.51 0.11 0.37 
#11 0.74 1.01  
Mean 1.03 0.45 0.69 
SD 0.96 0.35 0.63 
Median 0.78 0.28 0.40 
CV 93.4% 78.1% 91.5% 
Max 3.05 1.01 2.15 
Min 0.14 0.11 0.30 
* Voriconazole was administrated prior to the transplant (clinical decision). 
 
 178
 
 
Table 21. Volume of distribution (L) of voriconazole in pediatric bone marrow transplant patients 
Patient ID 
Phase 1 
Oral, Pre-transplant
Phase 2 
Intravenous, Post-transplant
Phase 3 
Oral, Post-transplant
#1 69.38 59.73  
#2 84.20 21.84 77.39 
#3 290.41   
#4 34.47  32.67 
#5 51.81 18.36 56.52 
#6  21.22 * 30.01 
#7 49.52 36.57 16.06 
#8 223.09 80.68 94.23 
#9 81.81 19.47 137.83 
#10 373.44 50.52 118.90 
#11 27.82 54.14  
Mean 128.60 40.28 70.45 
SD 121.97 22.19 44.27 
Median 75.60 36.57 66.96 
CV 94.8% 55.1% 62.8% 
Max 373.44 80.68 137.83 
Min 27.82 18.36 16.06 
* Voriconazole was administrated prior to the transplant (clinical decision). 
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Table 22. Volume of distribution normalized to body weight (L/kg) of voriconazole in pediatric bone marrow 
transplant patients 
Patient ID 
Phase 1 
Oral, Pre-transplant
Phase 2 
Intravenous, Post-transplant
Phase 3 
Oral, Post-transplant
#1 1.77 1.49  
#2 5.17 1.36 4.42 
#3 3.51   
#4 1.90  1.80 
#5 4.18 1.50 4.71 
#6  1.43 * 2.14 
#7 6.72 4.83 2.17 
#8 3.59 1.32 1.47 
#9 3.25 0.82 4.92 
#10 5.61 0.77 1.85 
#11 2.12 3.83  
Mean 3.78 1.93 2.94 
SD 1.66 1.41 1.47 
Median 3.55 1.43 2.16 
CV 43.9% 73.3% 50.1% 
Max 6.72 4.83 4.92 
Min 1.77 0.77 1.47 
* Voriconazole was administrated prior to the transplant (clinical decision). 
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The half life of voriconazole appeared to be significantly smaller than that in healthy adult 
subjects (6 hours) following intravenous and oral voriconazole administration in the post-
transplant period (3.61±1.47 hours and 3.77±1.72 hours), and appeared to be smaller than that in 
healthy subjects (6 hours) following oral voriconazole administration in the pre-transplant period 
(4.07±2.75 hours). However, the half life of voriconazole appeared to be similar following oral 
and intravenous voriconazole administration in the pre- and post-transplant period. 
 
The half life of voriconazole in pediatric bone marrow transplant patients (3.61 ~ 4.07 hours) 
was comparable with the value reported in previously published pediatric studies, such as that in 
children below age of 12 (3.58 hours) as reported by Karlsson et al. (55), that reported by Neely 
et al. (5.63 hours for children under 12 years of age and 3.47 hours for children above 12 years of 
age) (74), and that in immunocompromised children under 11 years of age (4.33 hours) as 
reported by Walsh et al. (130). However, the half life of voriconazole in pediatric bone marrow 
patients appeared to be significantly lower than that in immunocompromised children under 11 
years of age (7.66 hours) as reported by Michael et al. (68). 
 
The post-transplant bioavailability of voriconazole in pediatric bone marrow patients (58%±32%) 
was significantly lower than that in healthy adult subjects (96%) with a p value of 0.0167. The 
post-transplant bioavailability of voriconazole in pediatric bone marrow patients (58%±32%) 
was comparable with the value reported in previously published pediatric studies, such as that in 
immunocompromised children (65%) as reported by Walsh et al. (129), that in children below 
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age of 12 (44.6%) as reported by Karlsson et al. (55), and that reported by Neely et al. (75% for 
children under 12 years of age and 81% for children above 12 years of age) (74). 
 
The oral clearance of voriconazole in pediatric bone marrow patients was similar before and after 
transplant. However, the clearance of voriconazole following oral voriconazole administration 
was significantly lower compared to that following intravenous voriconazole administration in 
pediatric bone marrow patients in the post-transplant period (p=0.0288). 
 
The oral clearance of voriconazole appeared to be similar to the lower range of clearance of 
voriconazole reported in healthy adult subjects (13 – 36 L/hr) in both pre-transplant 
(24.72±20.93 L/hr) and post-transplant (14.45±9.34 L/hr) period. However, the clearance of 
voriconazole following intravenous voriconazole administration in the post-transplant period 
(8.30±3.86 L/hr) appeared to be significantly lower than the lowest clearance reported in healthy 
subjects (13 L/hr) with a p value of 0.0137. 
 
The weight-normalized clearance of voriconazole following intravenous administration after 
transplant in pediatric bone marrow patients (0.45 L/hr/kg) was comparable with the value 
reported in previously published pediatric studies, such as that in children below age of 12 (0.58 
L/hr/kg) as reported by Karlsson et al. (55), that reported by Neely et al. (0.32 L/hr/kg for 
children under 12 years of age and 0.2 L/hr/kg for children above 12 years of age) (74), that in 
immunocompromised children under 11 years of age (0.19 L/hr/kg) as reported by Michael et al. 
(68), and that in immunocompromised children under 11 years of age (0.4 L/hr/kg) as reported 
by Walsh et al. (130). 
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The weight-normalized volume of distribution of voriconazole in pediatric bone marrow patients 
appeared to be similar to the lower range of volume of distribution of voriconazole reported in 
healthy adult subjects (2 – 4.6 L/kg). The weight-normalized volume of distribution of 
voriconazole following intravenous administration in pediatric bone marrow patients after 
transplant (1.93 L/kg) was comparable with the value reported in previously published pediatric 
studies, such as that in children below age of 12 (3.0 L/kg) as reported by Karlsson et al. (55), 
that reported by Neely et al. (2.6 L/kg for children under 12 years of age and 1.0 L/kg for 
children above 12 years of age) (74), that in immunocompromised children under 11 years of age 
(2.1 L/kg) as reported by Michael et al. (68), and that in immunocompromised children under 11 
years of age (2.5 L/kg) as reported by Walsh et al. (130). 
 
There appeared to be no significant difference in pharmacokinetic parameters between phase 1 
(pre-transplant oral administration) and phase 3 (post-transplant oral administration). Half life 
and Tmax of voriconazole was similar between phase 2 (post-transplant intravenous 
administration) and phase 3 (post-transplant oral administration), while Cmax, dose-normalized 
AUC, clearance and volume of distribution were significantly lower in phase 3 as compared to 
phase 1 due to low bioavailability. 
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Table 23. Comparison of pharmacokinetic parameters estimated in this study with previously reported values 
 
 
T1/2 F CL/WT Vd/WT 
 
Walsh et al. (129) 
 
 65%   
 
Karlsson et al. (55) 
 
3.58 44.6% 
 
0.58 
 
3 
Neely et al. (74), (<12 years old) 5.63 75% 
 
0.32 
 
2.6 
 
Neely et al. (74), (>12 years old) 
 
3.47 81% 0.2 1 
 
Michael et al. (68) 
 
7.66  0.19 2.1 
 
Walsh et al. (130) 
 
4.33  0.4 2.5 
 
This study (non-compartment analysis) 
 
3.61 ~ 4.07 58% 0.45 1.93 
 
This study (population analysis) 
 
 46.5% 0.18 2.45 
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6.4.3 Population Pharmacokinetic Analysis 
 
A two-compartment model with first-order absorption and elimination adequately described the 
data. The population estimates (inter-individual) of bioavailability, clearance, volume of 
distribution of central compartment (Vc) and peripheral compartment (Vp), inter-compartment 
clearance (Q), and absorption rate constant (ka) were 46.5% (104.4%), 5.76L/hr (62.0%), 19.4L 
(62.0%), 58.8L (122.3%), 6.94L/hr (84.3%) and 0.98hr-1 (118.5%). The proportional and 
additive residual variability was 0.65 and 0.31ug/ml, respectively. Individual predictions agreed 
well with observations (Figure 29). There is no significant bias in population predictions (Figure 
30a). Weighted residuals were approximately normally distributed and were mostly within about 
4 units of the null ordinate (Figure 31). 
 
Bioavailability of voriconazole is similar between lung transplant (45.9%) and pediatric bone 
marrow transplant patients (46.5%). CL/F in pediatric bone marrow transplant patients 
(12.39L/hr) was significantly higher as compared to liver transplant (7.92 L/hr) and lung 
transplant (7.52L/hr) patients. Vd/F in pediatric bone marrow transplant patients (168.2 L) was 
significantly lower as compared to liver transplant (248 L) and lung transplant (430.7 L) patients. 
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Figure 29. Goodness-of-Fit of base model in pediatric bone marrow transplant patients 
Individual predictions agreed well with observations (R2=0.85). 
 
 186
 
a       b 
Base Model
Predicted vs Observed
0
2
4
6
8
10
12
14
16
0 5 10 15
Observed Cp (ug/ml)
Pr
ed
ic
te
d 
C
p 
(u
g/
m
l)
 
Final Model
Predicted vs Observed
0
2
4
6
8
10
12
14
16
0 5 10 15
Observed Cp (ug/ml)
Pr
ed
ic
te
d 
C
p 
(u
g/
m
l)
 
 
Individual Prediction
Population Prediction
Unit
LOWESS smoother for individual predictions
LOWESS smoother for population predictions  
 
Figure 30. Goodness-of-Fit of base model in pediatric bone marrow transplant patients 
 
a: Goodness-of-Fit of base model. Individual predictions agreed well with observations (R2=0.85). Population 
predictions were biased (R2=0.4969) with over-prediction at low concentrations and under-prediction at high 
concentrations, indicated by the LOWESS smoother of population predictions. 
 
b: Goodness-of-Fit of final model. Individual predictions agreed well with observations (R2=0.86). Population 
predictions were substantially improved compared to the base model (R2=0.6217), especially at low concentrations, 
indicated by the LOWESS smoother of population predictions. 
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Figure 31. Weighted residual of base model in pediatric bone marrow transplant patients 
Weighted residuals were approximately normally distributed and were mostly within about 4 units of the null 
ordinate. 
 
 
 
 
To explore covariate relationships, all the covariates were tested one at a time (Table 24). CL 
significantly decreased with body weight as opposite to allometric principles. CL significantly 
increased with albumin levels. Furthermore, low CL was significantly associated with bad liver 
function as indicated by high levels of ALT, AST and GGTP. In addition, low CL was 
significantly associated with high blood count as indicated by high levels of WBC, HGB, HCT 
and RBC. 
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Volume of distribution in the central (V2) and peripheral (V3) compartment significantly 
increased with body weight. V2 significantly increased with albumin levels and blood count as 
indicated by WBC and RBC. However, V3 significantly decreased with albumin levels and 
blood count as indicated by WBC, HGB, HCT and RBC. 
 
Bioavailability significantly decreased with body weight, age and albumin levels. Furthermore, 
high bioavailability was significantly associated with bad liver function as indicated by high 
levels of total bilirubin, ALT, AST and GGTP. In addition, high bioavailability was significantly 
associated with high blood count as indicated by high levels of WBC, HGB, HCT and RBC. 
 
A final model was developed using forward addition and reverse removal approach as described 
previously:  
( )( )9.2900478.0exp53.5 −×−×= ASTCL  
( )9.2901.1%6.32 −×= ASTF  
 
Increased AST level was significantly associated with decreased clearance and increased 
bioavailability of voriconazole in pediatric bone marrow transplant patients. The final model 
resulted in an OFV of 38.394 with a decrease of 50.534 compared to the base model, indicating 
that the final model was substantially improved compared to the base model (p<0.00001). The 
Goodness-of-Fit of the final model was demonstrated in Figure 30b. Individual predictions 
agreed well with observations (R2=0.86). Population predictions were substantially improved 
(R2=0.6217) compared to the base model (R2=4969), especially at low concentrations. 
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Table 24. Exploration of covariate relationships in pediatric bone marrow tranpslant patients 
Parameter 
Significant  
Covariate 
∆OFV * P value † Equation 
WT -19.99 <0.00001 ( )( )31.90021.0exp77.4 −×−×= WTCL  
ALB -22.53 <0.00001 ( )( )27.32.0exp25.5 −××= ALBCL  
ALT -30.35 <0.00001 ( )( )64.190093.0exp98.5 −×−×= ALTCL  
AST -45.17 <0.00001 ( )( )9.290248.0exp51.4 −×−×= ASTCL  
GGTP -26.44 <0.00001 ( )( )3.220024.0exp58.5 −×−×= GGTPCL  
WBC -21.90 <0.00001 ( )11.6986.077.4 −×= WBCCL  
HGB -25.29 <0.00001 ( )( )92.80171.0exp15.5 −×−×= HGBCL  
HCT -25.88 <0.00001 ( )258.00023.075.4 −×= HCTCL  
CL ‡ 
RBC -20.21 <0.00001 ( )96.2825.022.5 −×= RBCCL  
WT -21.31 <0.00001 ( )31.90287.06.212 −×+= WTV  
ALB -25.12 <0.00001 ( )27.308.92.252 −×+= ALBV  
WBC -22.40 <0.00001 ( )11.645.07.222 −×+= WBCV  V2 ‡ 
RBC -21.44 <0.00001 ( )96.234.27.212 −×+= RBCV  
WT -21.67 <0.00001 ( )31.9244.01023 −×+= WTV  
ALB -22.78 <0.00001 ( )( )27.3893.0exp1203 −×−×= ALBV  
WBC -29.69 <0.00001 ( )11.6786.04.303 −×= WBCV  
HGB -26.21 <0.00001 ( )( )92.898.1exp2553 −×−×= HGBV  
HCT -17.80 <0.00005 ( )( )258.09.60exp5.823 −×−×= HCTV  
V3 ‡ 
RBC -23.48 <0.00001 ( )( )96.277.5exp2783 −×−×= RBCV  
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Table 24. (continued) 
 
WT -21.28 <0.00001 ( )( )31.90211.0exp%7.56 −×−×= WTF  
AGE -29.72 <0.00001 ( )( )3.90809.0exp%7.45 −×−×= AGEF  
ALB -24.35 <0.00001 ( )27.3148.0%5.42 −×−= ALBF  
BIL -21.63 <0.00001 ( )7.00182.0%5.42 −×+= BILF  
ALT -37.01 <0.00001 ( )64.1901.1%3.36 −×= ALTF  
AST -46.86 <0.00001 ( )9.2902.1%6.33 −×= ASTF  
GGTP -28.62 <0.00001 ( )3.220012.0%1.39 −×+= GGTPF  
WBC -21.28 <0.00001 ( )11.60019.0%6.42 −×+= WBCF  
HGB -32.01 <0.00001 ( )92.8122.0%9.46 −×+= HGBF  
HCT -32.65 <0.00001 ( )258.004.4%2.48 −×+= HCTF  
F ‡ 
RBC -26.94 <0.00001 ( )96.2197.0%7.47 −×+= RBCF  
 
* ∆OFV: change in the objective function value compared to the base model 
† A decrease in OFV was referred to the chi-squared distribution to assess significance. 
‡ These are the results in the covariate relationship exploration step. All the covariates were incorporated one at a 
time into these parameters to explore the covariate relationship.  
CL: clearance 
V2: volume of distribution of central compartment 
V3: volume of distribution of peripheral compartment 
F: bioavailability 
WT: body weight 
BIL: total bilirubin 
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ALT: alanine aminotransferase 
AST: aspartate aminotransferase 
ALP: Alkaline phosphatase 
GGTP: Gamma glutamyl transpeptidase 
ALB: albumin 
WBC: white blood cell count 
HGB: hemoglobin 
HCT: hematocrit 
RBC: red blood cell count 
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6.5 Discussion 
 
To date this is the first evaluation of bioavailability and pharmacokinetics of voriconazole in 
pediatric bone marrow transplant patients. 
 
This study involved intense blood sampling (eight data points from each patient in a single 
dosing interval) in a small group of relatively homogenous pediatric bone marrow transplant 
patients (n = 11), which allowed accurate and precise parameter estimation. The pharmacokinetic 
profiles of voriconazole are characterized by an early and sharp increase of voriconazole 
concentration, with the peak concentration being reached around 1 to 2 hours after dosing. These 
profiles were consistent with rapid absorption of voriconazole. This observation is similar to 
what has been reported in non-transplant adult patients (88, 89, 94). 
 
Pharmacokinetics of voriconazole was studied both in the pre-transplant and post-transplant 
period. No significant difference in CL/F or Vd/F was observed between these time periods. 
However, this did not exclude the possibility that CL, Vd and F were all changed after transplant, 
resulting in unchanged CL/F and Vd/F. Therefore further investigation is warranted to study the 
change in pharmacokinetics of voriconazole after transplant. 
 
Despite of the relative homogeneity of the population studied, a large inter-individual variability 
in voriconazole pharmacokinetics was demonstrated. This is in accordance with the large 
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variability in voriconazole pharmacokinetics previously reported (6, 10, 50, 63, 66, 80, 81, 96, 
109, 114, 118, 122) and the unpublished preliminary data from our research group. 
 
It is important to identify patient factors that significantly contribute to this large inter- and intra-
individual variability by exploring the correlations between pharmacokinetic parameters 
(especially drug exposure) and patient variables. The covariates tested in this study covered a 
wide range of values within each of the categories tested. We have demonstrated that the most 
important factors associated with voriconazole pharmacokinetics were body weight and indices 
of liver function tests. 
 
Clearance of voriconazole significantly decreased with increased indices of liver function tests in 
pediatric bone marrow transplant patients. The reason is very likely that voriconazole is 
extensively metabolized in the liver with less than 2% of the administered dose excreted 
unchanged in urine and faeces (89, 94, 103). For a low clearance drug Clintfu ×≈apparentCl (fu 
denotes fraction unbound. Clint denotes intrinsic clearance). Clint depends on liver function of 
the patient. Therefore patients with higher indices of liver function tests, indicative of hepatic 
dysfunction and hepatocellulary injury, had lower CL/F of voriconazole. Clearance of 
voriconazole also significantly decreased with body weight in pediatric bone marrow transplant 
patients, which is opposite to the allometric principles. The reason is very likely that body weight 
is correlated with age of children, and it is well known that younger children have a higher rate 
of metabolism. 
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Bioavailability of voriconazole significantly decreased with decreased indices of liver function 
tests. The primary reason is likely to be the positive correlation between gastrointestinal function 
with liver function. The secondary reason could be increased first-pass metabolism due to 
increased liver function indicated by decreased indices of liver function tests. 
 
CL/F in pediatric bone marrow transplant patients (12.39L/hr) was significantly higher as 
compared to liver transplant (7.92 L/hr) and lung transplant (7.52L/hr) patients, likely due to 
higher rate of metabolism in children as compared to adults. Vd/F in pediatric bone marrow 
transplant patients (168.2 L) was significantly lower as compared to liver transplant (248 L) and 
lung transplant (430.7 L) patients, likely due to lower body size of children as compared to adults. 
 
Despite the statistically significant improvement of the final model and the covariate models 
compared to base model, visual inspection of the Goodness-of-Fit plots of the final model and 
covariate models only showed a corrected bias of population predictions at low concentrations. 
This suggested that the patient variables tested and selected in this study only explain part of the 
variability in the pharmacokinetics of voriconazole in pediatric bone marrow transplant patients, 
while some other variables that were not collected in this study are still needed to account for the 
remaining variability. Future studies should collect more variables and further explore factors 
that are significantly associated with pharmacokinetics of voriconazole in pediatric bone marrow 
transplant patients. 
 
As discussed previously, the large variability in voriconazole exposure following weight-
adjusted or fixed doing regimens necessitates individualizing voriconazole dosing to maximize 
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therapeutic efficacy and minimize toxicity in pediatric bone marrow transplant patients. 
Therapeutic monitoring is currently performed in the routine clinical monitoring program at our 
institution with an intention to keep the trough concentration above 1ug/ml. However, trough 
concentrations have never been documented as surrogate markers of voriconazole exposure in 
pediatric bone marrow transplant patients. 
 
The good correlation observed in this study between the voriconazole trough plasma 
concentrations and the corresponding AUCo-∞ at steady state (R2=0.94) indicates that trough 
concentration is a good measure of voriconazole exposure in this population. 
 
These findings are likely to be clinically relevant because it suggests that voriconazole dose 
should be relatively higher in pediatric bone marrow transplant patients due to significantly 
reduced bioavailability, especially in patients with good liver function as measured by low total 
bilirubin, ALT and AST, in order to avoid ineffectiveness of the prophylaxis/treatment and its 
consequences (fungal infections, especially invasive aspergillosis). However, therapeutic drug 
monitoring is still necessary in pediatric bone marrow transplant patients. 
 
In conclusion, this study has demonstrated that there is a large inter-individual variability in the 
pharmacokinetics of voriconazole in pediatric bone marrow transplant patients. A weight-
adjusted and fixed dosing regimen leads to widely variable exposure of voriconazole in pediatric 
bone marrow transplant patients. A population pharmacokinetic model was developed for 
voriconazole in pediatric bone marrow transplant patients in pre-transplant and early post-
transplant period. Bioavailability of voriconazole is substantially lower in pediatric bone marrow 
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transplant patients (46.5%) than non-transplant adult subjects (96%), and significantly decreased 
with decreased indices of liver function tests. Clearance of voriconazole significantly decreased 
with increased indices of liver function tests. Given the large variability in the pharmacokinetics 
and the good correlation between AUC and trough concentrations, trough concentrations should 
be used to individualize voriconazole dose. 
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Chapter VII Conclusions and Future Directions 
 
7.1 Discussion and Summary 
 
The objective of the work carried out in this dissertation was to characterize the 
pharmacokinetics of voriconazole in transplant patients, to identify factors that are associated 
with the variability in the pharmacokinetics using population pharmacokinetic modeling, and to 
apply the finding for developing adequate dosing guidelines for transplant patients. 
 
In this research work, we studied the pharmacokinetics of voriconazole in liver transplant, lung 
transplant and pediatric bone marrow transplant patients. Multiple blood samples were collected 
within one dosing interval. Voriconazole plasma concentrations were measured using HPLC. 
Non-compartmental analysis was performed using WinNonlin. Nonlinear mixed-effects 
pharmacokinetic models were developed using NONMEM. The association between 
pharmacokinetic parameters and patient- and donor-specific variables was evaluated. Several key 
findings were generated in this work, which are summarized in the following section. 
 
In the first part of the study, we studied the pharmacokinetics of voriconazole in liver transplant 
patients. We characterized the pharmacokinetics of voriconazole in liver transplant patients, 
evaluated the potential correlations between pharmacokinetic parameters and patient variables, 
externally validated the model, and explore limited sampling strategies (LSS) using Bayesian 
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approaches. We demonstrated that there was a good correlation between AUCo-∞ and trough 
voriconazole plasma concentrations. T1/2, Cmax, trough level, AUCo-∞, AUMCo-∞ and 
MRTo-∞ were significantly correlated with postoperative time. T1/2, λ, AUCo-∞ and CL/F were 
significantly correlated with indices of liver function (AST, total bilirubin and INR). Cmax, Clast, 
AUMCo-∞ and MRTo-∞ are significantly lower in the presence of deficient CYP2C19*2 alleles. 
In the population analysis, a one-compartment model with an absorption lag time (Tlag) 
adequately described the data. Population estimates of CL/F and Vd/F were 7.92L/hr and 248L. 
Levels of CL/F, Vd/F and Tlag decreased with post-operative time and converged to stable levels 
in about 7 post-operative days. CL/F significantly decreased with increased INR. Co-
administration of pantoprazole, race and ALT were also significantly associated with 
pharmacokinetic parameters but ultimately excluded in the final model. VPC showed that most 
of the data fell within the 90% prediction interval and were symmetrically distributed around the 
median. Additional 52 samples from 19 patients were collected for external validation. MPE was 
0.206ug/ml (not significantly different from zero) and MAPE was 0.99ug/ml. Compared to 
trough levels, LSS using two samples or one sample at a different time provided better MPE, 
MAPE and correlation (R2) between the real and LSS-predicted AUC. These findings suggested 
that a fixed dosing regimen of voriconazole results in a highly variable exposure of voriconazole 
in liver transplant patients. Given that trough voriconazole concentration is a good measure of 
drug exposure (AUC), voriconazole dose can be individualized based on trough concentrations 
measurements in liver transplant patients. There is a significant association of voriconazole 
pharmacokinetics with post-operative time and liver function. Donor characteristics had no 
significant correlation with the pharmacokinetics of voriconazole. Our observations also 
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suggested a need for intravenous administration of voriconazole in the immediate post-operative 
period before an oral dose can be administrated. 
 
In the second part of the study, we studied the pharmacokinetics of voriconazole in lung 
transplant patients. We characterized the pharmacokinetics and bioavailability of voriconazole in 
adult lung transplant patients during early post-operative period, identified factors significantly 
associated with various pharmacokinetic parameters, and made recommendations for adequate 
dosing regimens. We demonstrated that there was a good correlation (R2=0.98) between AUCo-
∞ and trough concentrations. A two-compartment model adequately described the data. 
Population estimates of bioavailability, clearance, Vc and Vp were 45.9%, 3.45L/hr, 54.7L and 
143L. Cystic fibrosis (CF) patients exhibited a significantly lower bioavailability (23.7%, n=3) 
than non-CF patients (63.3%, n=10). Bioavailability increased with post-operative time and 
reached steady levels in about one week. Vp increased with body weight. These findings 
suggested that bioavailability of voriconazole is substantially lower in lung transplant patients 
than non-transplant subjects, but significantly increases with post-operative time. CF patients 
exhibit significantly lower bioavailability and exposure of voriconazole, and therefore need 
higher doses. Weight-adjusted or fixed dosing regimens resulted in highly variable exposure of 
voriconazole. Voriconazole dose can be individualized based on trough concentrations as a good 
measure of drug exposure. Simulations demonstrated inadequacy of oral administration of 
voriconazole and adequacy of intravenous administration during the first post-operative day 
followed by oral doses. 
 
 200
In the third part of the study, we applied the two-portion absorption model to describe atypical 
voriconazole profiles. The simplified two-portion absorption model assumes discontinuous 
absorption of the available dose in two portions: F1 and F2 (F1+F2=1). Delayed transfer of each 
portion from the stomach to the gut and the sequential absorption was described by first-order 
processes with lag-times (Tlag1 and Tlag2) and transfer/absorption rate constants (ktra1 and 
ktra2). We demonstrated that a one-compartment model with first-order elimination in 
association with the simplified two-portion absorption model adequately described the data and 
showed superiority over one- and two-compartment models with an absorption lag time. The 
population estimates of F1, Tlag1, Tlag2, ktra1 and ktra2 were 0.27, 0.24 hours, 2.03 hours, 0.15 
hr-1 and 0.004 hr-1, respectively. Tlag1 was significantly smaller than Tlag2. These findings 
suggested that atypical voriconazole pharmacokinetic profiles were probably caused by impaired 
gastrointestinal functions that are common in the early post-transplant period, and could be 
reliably described by a simplified two-portion absorption model. Twenty-seven percent of the 
available dose seemed to be rapidly absorbed immediately, with the remainder being slowly 
absorbed. This model could be useful to understand the mechanisms of voriconazole atypical 
profiles and to improve estimation of voriconazole exposure in liver, lung and small intestine 
transplant patients. 
 
In the final part of the study, we studied the pharmacokinetics of voriconazole in pediatric bone 
marrow transplant patients. We characterized the pharmacokinetics of voriconazole in pediatric 
bone marrow transplant patients during pre-operative and early post-operative period and 
identify factors significantly associated with various pharmacokinetic parameters. We 
demonstrated that there was a good correlation (R2=0.94) between AUCo-∞ and trough 
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concentrations. A two-compartment model adequately described the data. Population estimates 
of bioavailability, clearance, Vc and Vp were 46.5%, 5.76L/hr, 19.4L and 58.8L. Clearance 
significantly decreased with increased indices of liver function tests. Volume of distribution 
significantly increased with body weight. Bioavailability significantly decreased with decreased 
indices of liver function tests. These findings suggested that bioavailability of voriconazole is 
significantly lower in pediatric bone marrow transplant patients than non-transplant adult 
subjects. Incorporation of patient variables associated with the pharmacokinetics of voriconazole 
may assist in optimizing the dosage regimen of voriconazole in pediatric bone marrow transplant 
patients. Voriconazole levels should be monitored and the dose can be individualized based on 
trough concentrations as a good measure of drug exposure. 
 
7.2 Clinical implications 
 
1. Both fixed and weight-adjusted dosing regimens of voriconazole resulted in a highly 
variable exposure of voriconazole, and therefore routine therapeutic drug monitoring of 
voriconazole trough plasma concentration is necessary in transplant patients. 
2. Voriconazole dose can be individualized based on trough concentrations as a good 
measure of drug exposure in transplant patients given that there was a good correlation 
between AUCo-∞ and trough voriconazole plasma concentrations in transplant patients.  
3. Oral administration only of voriconazole is inadequate in transplant patients. 
Voriconazole should be administrated intravenously during the early period of time after 
transplant followed by oral doses in transplant patients. 
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4. For liver transplant and lung transplant patients, the pharmacokinetics of voriconazole 
changed significantly with post-operative time, and eventually reached a steady level in 
about one week. Levels of CL/F, Vd/F and Tlag in liver transplant patients decreased 
with post-operative time and reached steady levels in about one week. Bioavailability of 
voriconazole is substantially lower in lung transplant patients than non-transplant subjects, 
but significantly increased with post-operative time and reached a steady level in about 
one week. Therefore voriconazole dose for liver transplant and lung transplant patients 
should be low during the early period of time after transplant and then gradually 
increased with time. 
5. Cystic fibrosis patients exhibited significantly lower bioavailability and exposure of 
voriconazole, as indicated by significantly reduced trough levels and AUC of 
voriconazole, and therefore need higher voriconazole doses. 
6. For pediatric bone marrow transplant patients, higher oral dose should be administrated 
due to reduced bioavailability. 
 
7.3 Limitations and Future Directions 
 
1. These studies involved intense blood sampling in a single dosing interval in a small group 
of relatively homogenous transplant patients due to clinical constraints of the standard 
patient care. The small sample size may reduce the power of the statistical analysis and 
conclusions. 
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2. These studies were conducted in a certain pre-transplant or post-transplant period due to 
clinical constraints of the standard patient care. The homogeneity of the subjects may 
limit the applicability of the conclusions to the entire population. 
3. Pharmacodynamic modeling was not applied in these studied. The first reason was that 
simple efficacy measure for molds are not quite available yet. So far there have only been 
data in animals for Candida showing a predictive pharmacodynamic parameter 
(AUC/MIC) and a potential target value (2) with no equivalent data for molds. The 
second reason was that all the transplant patients in our institution who receive 
voriconazole for prophylaxis go through routine clinical therapeutic monitoring program, 
based on which the dose of voriconazole is constantly adjusted to avoid infections and 
toxicity. Therefore pharmacodynamic endpoints such as infections and toxicity were not 
available. 
4. A potentially significant reduction in the exposure of voriconazole has been observed in 
patients receiving concomitant pantoprazole, as indicated by significantly reduced trough 
levels, Cmax, AUC and AUMC of voriconazole. In vivo and in vitro studies are 
warranted to illustrate the effects of pantoprazole on the pharmacokinetics of 
voriconazole, especially its effects on the absorption of voriconazole, and to explore the 
underlying mechanisms of these effects. 
5. Limited sampling strategies developed using Bayesian approaches in this study have 
shown potential to accurately and precisely estimate voriconazole exposure with one or 
two blood samples and no rigid sampling time or dosage regimens required, but definitely 
required external validation before used in practice to individualize voriconazole dosage.  
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6. A definitely significant reduction in bioavailability and exposure of voriconazole has 
been observed in cystic fibrosis patients, as indicated by significantly reduced trough 
levels and AUC of voriconazole. In vivo and in vitro studies are warranted to illustrate the 
effects of cystic fibrosis on the pharmacokinetics of voriconazole, especially its effects on 
the absorption of voriconazole, and to explore the underlying mechanisms of these effects. 
7. Due to clinical constraints, bioavailability of voriconazole was only assessed once in each 
patient in all the studies in this dissertation, which limited the comparison of 
bioavailability of voriconazole before and after transplant and limited the demonstration 
of the change in bioavailability of voriconazole with post-operative time. Future studies 
should assess bioavailability of voriconazole at multiple times in each patients in order to 
compare bioavailability of voriconazole before and after transplant and to demonstrate 
the change in bioavailability of voriconazole with post-operative time 
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